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2Abstract
Huntington’s Disease (HD) is caused by an expansion in the CAG repeats of the 
huntingtin gene. This thesis describes an Ecdysone cell model which expressed inducible 
wild type (WT) and mutant (MT) N-terminal huntingtin (htt) in HEK 293 cells and 
constitutive EYFP full length (FL) htt in SH-SY5Y cells. 
WT and MT EYFP FL htt was diffusely localised to the cytoplasm whereas endogenous 
FL htt and N-terminal htt localised to the nucleus and cytoplasm suggesting that htt has a 
role both in the nucleus and cytoplasm and EYFP inhibited nuclear translocation. N-
terminal htt partially colocalised with vesicular and mitochondrial markers suggesting 
that N-terminal htt may be involved in vesicle trafficking and mitochondrial function. 
The decrease in mitochondrial complex IV activity in MT FL htt cells supported previous 
reports that a complex IV defect is an early event in the pathogenesis of HD. Normal 
mitochondrial respiratory chain activities in cells expressing N-terminal htt contrasted 
with some cells models demonstrating a complex II/III defect when highly expanded 
CAG repeats were expressed. This suggested that a detectable complex II/III defect is not 
an early feature in the pathogenesis of HD.
Muscle biopsies from HD patients revealed a relationship between clinical progression, 
CAGs and a decrease in complex II/III:CS ratio, consistent with the defect in HD brains 
and cell models and suggested that muscle may be a useful tissue to study the disease. 
3Decreased aconitase activity with MT FL htt expression and increased sensitivity to 
paraquat with MT N-terminal htt expression demonstrated that MT htt was associated 
with increased oxidative stress or compromised antioxidant defences. 
There was evidence of proteasomal dysfunction in the MT FL htt clones and inhibition of 
the proteosome by lactacystin caused the formation of perinuclear "aggresome-like" 
inclusions in both WT and MT FL htt clones. These inclusions contained FL htt which 
suggested that the proteasome was necessary for processing of FL WT and MT htt. 
Under normal conditions there was no evidence of cleavage of WT or MT FL htt, 
however following treatment with lactacystin, an additional 11 kDa N-terminal htt 
fragment was present in most MT FL htt clones representing a novel mutation-specific 
cleavage product which may play an important role in the toxicity of MT htt. 
This thesis has demonstrated several defects in cellular function in the absence of gross 
cell death and htt inclusion formation. These findings expand on previous hypotheses in 
the   pathogenesis   of   HD   involving   abnormal   MT   htt   cleavage,   oxidative   stress, 
mitochondrial dysfunction and proteasomal inhibition.
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Introduction
181.1. A brief history and future of Huntington’s disease
In 1872 George Huntington described a movement disorder clinically characterised by 
early personality changes, chorea and dementia (Huntington 1872) and the disorder 
subsequently took his name, Huntington’s disease (HD). Huntington documented HD as 
an autosomal dominant condition with complete penetrance and many of the clinical 
features. It was not until 1993 that a collaborative effort by the international scientific 
community resulted in the discovery of the causative gene, huntingtin (Huntington’s 
Disease Collaborative Research Group, 1993). A cure for HD still remains elusive, but 
the molecular mechanisms that connect the mutant gene to the clinical phenotype are 
currently been described and enabling work to be extrapolated to the study of other 
neurodegenerative diseases. Treatment options for HD are close to clinical translation and 
the near future promises to herald the onset of a new generation of therapeutics in clinical 
neurosciences.
1.2. Clinical features
HD has an estimated prevalence in North America and Europe of 4-10 per 100,000 
(Quarrell et al. 1988). The first clinical symptoms of HD are personality changes, mood 
disturbances and other psychiatric abnormalities. Involuntary choreiform movements 
develop in the fourth or fifth decades as part of a complex movement disorder. The 
choreiform movements can occur early or late in the disease and can affect the limbs, 
trunk, face, neck, and respiratory muscles. Parkinsonian features, in the form of 
bradykinesia and dystonia, become more prominent as the disease progresses. The 
associated eye movement disorder is often typical and includes slow and hypometric 
saccades, convergence paresis, and gaze impersistence. Orolingual dyspraxia is common. 
19The disease progresses over 10-20 years and is associated with cognitive decline and 
eventually dementia. Death usually occurs due to the complications of immobility and 
suicide is more common than in the general population (Kremer 2002).
A minority of cases present in childhood or adolescence (“juvenile” HD) with an akinetic-
rigid  form  of  the disease or  “Westphal variant”,  which is  associated  with early 
parkinsonism, seizures and a shorter life-expectancy (Bruyn 1968).
There is no treatment for the progressive neurodegenerative process underlying HD and 
management includes pharmacological symptomatic control of the movement disorder 
and psychiatric features, as well as non-pharmacological treatments, such as parenteral 
feeding and therapy services (Haskins et al. 2000).
1.3. Genetics of HD
The HD gene was discovered in 1993 by the Huntington’s Disease Collaborative 
Research Group (Huntington’s Disease Collaborative Research Group, 1993). The exon 
amplification   of   cosmids   in   the  chromosome  4p16.3   interval   yielded   “interesting 
transcript 15” or “IT15” from a novel gene in which an expanded CAG repeat size within 
the predicted open reading frame was associated with HD. The gene was called HD and 
protein product were called “huntingtin” (htt) or HD. HD is a true autosomal dominant 
condition with homozygotes presenting with the same phenotype as heterozygotes 
(Wexler et al. 1987). However, more recent clinical and molecular studies have suggested 
that although homozygosity for the HD mutation does not influence the age of onset of 
symptoms, homozygosity is associated with a more aggressive disease course (Squitieri et 
al 2003, Maglione et al 2006). The HD gene lacks homology with any other known gene 
20apart from the CAG repeat tract in exon 1. There is significant sequence homology of htt 
across a wide variety of mammalian species suggesting a fundamental cellular function. 
The gene spans 180kb and contains 67 exons. The predicted open reading frame yields a 
protein containing 3144 amino acids with a predicted molecular mass of 348 kDa 
(Huntington’s Disease Collaborative Research Group, 1993).
The normal htt CAG repeat length within exon 1 has been demonstrated to be between 9 
and 35 although most normal individuals have between 17-20 repeats (Myers et al. 2004). 
Repeat lengths between 27 and 35 are uncommon and are not associated with HD but are 
meiotically unstable and can expand into the disease range of 36 and above especially 
when transmitted paternally. Most HD patients have between 40-50 repeats. In a study by 
Rubinsztein et al. (1996) of 178 HD patients world-wide, there were no HD patients with 
less than 36 repeats. Patients with between 36 and 39 repeats have an increasing risk of 
developing the disease with increased repeat length. The overlap suggests that there are 
other factors influencing phenotype expression other than CAG repeat length.
The CAG sequence is inherently unstable between generations causing a tendency for 
repeat lengths to increase. This underlies the phenomenon of genetic anticipation (Harper 
2002 for a review). When inherited from the mother, the repeat increases or decreases by 
approximately 4 CAG repeats with a tendency for a slight increase to occur. When 
inherited from the father, there are much larger expansions, up to double the original size, 
and expansions occur more frequently than contractions. The molecular basis of this sex-
difference is still uncertain but is postulated to derive from the large number of cell cycles 
the gametes undergo in men versus women.
The CAG repeat size correlates inversely with the age of onset and directly with the 
21severity of the phenotype and the neuropathological severity (Ross et al 1995, Brinkman 
et al 1997, Penney et al. 1997). However, within each individual the CAG repeat length 
poorly predicts the age of onset and only 70% of the variance in the age of onset in HD 
can be accounted for by the CAG repeat length (Imarisio et al. 2008). In spite of this 
variation, most patients with greater than 50 repeats develop the disease before the age of 
30 and often present with the “Westphal variant” described above.
1.4. Neuropathology of HD
In the early stages of the disease, the brain can be macroscopically normal. As the clinical 
phenotype progresses, characteristic neuropathological features develop. There is a direct 
correlation between disease duration and brain weight (Vonsattel et al. 1985). The brain 
volume loss is severe in the basal ganglia with up to 60% reduction in mass in the 
caudate, putamen and globus pallidus. The neuronal loss and gliosis is most severe in the 
caudate nucleus with the medium γ-aminobutyric acid (GABA)ergic spiny neurons being 
the most affected within the caudate. These neurons project to the globus pallidus and 
receive glutaminergic input from the cortex and dopaminergic input from the substantia 
nigra. The larger cholinergic and aspiny NADPH-diaphorase interneurons are relatively 
spared. The putamen and cerebral cortex also demonstrate neuronal loss and gliosis and 
are less severely affected compared to the caudate nucleus. The cerebellum is only mildly 
affected (Vonsattel et al. 1998). The cause of such specific regional and sub-population 
neuronal loss and the absence of cell loss in other tissues remain uncertain. The 
formation, location and putative role of aggregates will be discussed in Section 1.7 and 
the location of htt in Section 1.5.
1.5. Huntingtin transcription, translation, functions and protein interactions
221.5.1. Htt transcription 
In situ hybridization studies have demonstrated that htt mRNA is expressed widely in 
neuronal and non-neuronal tissues. Expression is highest in neurons, testes, ovaries and 
lung (Li, S-H et al 1993, Strong et al. 1993, Sharp et al. 1995 and Sapp et al. 1997). These 
studies demonstrated no qualitative difference in mRNA expression between different 
brain regions and neuronal subtypes. There was no correlation between transcript 
expression levels and neuropathology. There are two expressed mRNAs at 10kb and 
13kb. The larger form appears to be expressed more in brain than the smaller form, 
although it is unclear whether this is responsible for the greater protein expression in 
brain. The expression of huntingtin mRNA is much lower in glia than neurons. (Dure et. 
al. 1994). 
1.5.2. Htt translation
The levels of htt protein expression have been reported using a panel of antibodies, which 
have been developed to internal sequences of htt in order to delineate the location of 
various   htt   fragments.   Immunocytochemical   studies   in   post-mortem   tissue   have 
demonstrated that htt is widely expressed in neurons throughout the normal brain 
(Gutekunst et al. 1995; DiFiglia et al. 1995) with the highest levels in the cortical 
pyramidal cells, striatal cells and cerebellar Purkinje cells.
The expression of htt is heterogeneous within each region of the brain. In the striatum, the 
neurons with the highest expression have been found in one study to be the same as those 
that are most vulnerable to neurodegeneration, whilst the relatively-spared interneurons 
express low levels of htt (Ferrante et al. 1997). A study in rats also found higher levels of 
23htt expression in cells of the striatum that would be most vulnerable in humans (Kosinski 
et al. 1997). These findings may partly explain the selective neuronal vulnerability within 
the striatum, although many neurons that express high levels in other brain regions e.g. 
cerebellum (Gutekunst et al. 1995) do not degenerate and so levels of htt expression 
represents only one factor contributing to selective regional cell death.
1.5.3. Subcellular localisation and physiological function of htt 
Full-length (FL) wild-type (WT) htt has been consistently found in the cytoplasm 
(Difiglia et al. 1995, Gutekunst et al. 1995) but there are several reports of FL WT htt in 
the nucleus (Bessert et al. 1995, De Rooij et al. 1996, Sapp et al. 1997 and Kegel et al. 
2002) and in a perinuclear location (Sapp et al. 1997, Strehlow et al. 2007). Bessert et al. 
(1995) found nuclear and cytoplasmic localisation of WT htt in HEK 293 cells (one of the 
cell types used in this thesis).  Htt is associated with various organelles within the 
cytoplasm including the nucleus, endocytic vesicles (clathrin–coated and non-coated), 
autophagic vesicles, mitochondria, endoplasmic reticulum and Golgi complex in the cell 
body, neurites, axons and synapses (DiFiglia et al. 1995, Velier et al. 1998, Hilditch-
Maguire et al. 2000, Hoffner et al. 2002, Kegel et al. 2002, Panov et al. 2002, Li et al 
2003, Choo et al. 2004, Caviston et al 2007, Strehlow et al. 2007, Rockabrand et al. 2007, 
and Atwal et al. 2007). The widespread subcellular localisation of htt throughout the cell 
has not facilitated a specific understanding of the function of htt although it does suggest 
that htt has a widespread cellular function.
Htt is a soluble protein of 3,144 amino acids and has many potential domains whose 
boundaries and activities are not fully understood. The primary amino acid sequence of 
htt also reveals little about its function, as there are only a few known sequence motifs 
24and no structural domains with defined functions. A diagramatic representation of htt and 
the main functional regions are shown in Fig. 1.1. The first 17 aa of htt, prior to the 
polyglutamine stretch, have been associated with the nuclear pore protein “translocated 
promotor region “ (TPR). The removal of these 17aa results in accumulation of the 
protein in the nucleus (Cornett et al. 2005) suggesting that the first 17aa. are a nuclear 
export sequence (NES). Atwal et al. (2007) have suggested that the first 17aa. in htt are an 
ampipathic alpha helical membrane binding domain that is involved in tagetting htt from 
the nucleus to the endoplasmic reticulum. A single point mutation in the first 17aa of htt, 
caused nuclear accumulation and increased cell death in a mouse striatal cell model of HD 
(N171-Q138). Several lysine residues within the first 17aa sequence compete for 
SUMOylation and ubiquitination which are post-translational modifications that could 
regulate the half-life, localisation and nuclear export of WT htt, as well as modifying the 
toxicity of MT htt (Kalchman et al 1996, Dohmen et al 2003 and Steffan et al 2004).
One of the most important parts of htt is the polyglutamine (polyQ) region which begins 
at the eighteenth amino acid. It is possible that the polyglutamine stretch is not essential 
for physiological function (Harjes et al 2003, Li, S.H. et al 2004 and Clabough et al 
2006). A polyQ region is also present in many transcription factors (Yu et al 2002), which 
may represent one mechanism by which MT htt impairs transcriptional activity. Perutz et 
al. (1994) demonstrated that the polyQ region may form a polar zipper structure and 
suggested that its physiological function was to bind transcription factors that contain a 
polyQ (Perutz et al 1994). It has been shown that WT htt interacts with
Fig 1.1
25several polyQ-containing proteins and that the polyQ tract is a key regulator of this 
interaction (Harjes et al. 2003, Goehler et al. 2004 and Li S.H et al. 2004). 
In higher vertebrates, the polyQ region is followed by a polyproline (polyP) stretch, 
26which may keep htt in solution (Steffan et al. 2004). Downstream of the polyP region is a 
HEAT (huntingtin, elongation factor 3, the PR65/A subunit of protein phosphatase 2A 
and the lipid kinase Tor) repeat sequence. HEAT repeats are approximately 50aa long 
sequences that occur multiple times within a given protein and are involved in protein–
protein interactions (Andrade et al. 1995, Neuwald et al 2000). HEAT repeat sequences 
are   found   in   proteins   that   often   play   roles   in   intracellular   transport   (including 
nucleocytoplasmic   shuttling),   microtubule   dynamics   and   chromosome   segregation. 
Bioinformatics analysis has found 37 putative HEAT repeats in htt (MacDonald 2003). 
The number of functionally active HEAT repeats remains uncertain (Takano et al 2002), 
although there are probably three main clusters (Fig. 1.1.) (Andrade et al 1995).
Htt contains a functionally active C-terminal nuclear export signal (NES) sequence (Fig. 
1.1.) which may also suggest that the protein is involved in transporting molecules from 
the nucleus to the cytoplasm (Xia et al. 2003). Hoffner et al (2002) demonstrated that htt 
associates with β-tubulin in a perinuclear and centrosomal distribution and the authors 
suggested that htt may regulate entry of proteins into the nucleus. The role of nuclear 
translocation of htt in HD is discussed further in Section 6.9.3.
Htt contains three protease cleavage consensus sites (Goldberg et al., 1996, Gafni et al. 
2002 and 2004, Wellington 1998 and 2000, Lunkes et al 2002) (Fig. 1.1). Cleavage at 
these sites leads to fragments of WT and MT htt, although MT htt is more susceptible to 
proteolysis (Davies et al 1997, DiFiglia et al 1997, Kim 2001, Lunkes et al. 2002 and 
Wellington et al. 2002, Mende-Mueller et al. 2001). The processing of htt is discussed in 
more detail in Section 1.6.
Htt can undergo four types of post-translational modification. The N-terminal lysines K6, 
27K9 and K15 compete for sumoylation and ubiquitination (Steffan et al. 2004, Kalchman 
et al. 1996) and these post-translational modifications could regulate the half-life, 
localisation and nuclear export of WT htt as well as modifying the toxicity of the MT 
protein (Dohmen et al 2004, Steffan et al. 2004, Kalchman et al. 1996). Phosphorylation 
at serines 421 and 434 influences cleavage and toxicity, and is reduced in HD (Humbert 
et al. 2002, Warby et al. 2005, Luo et al. 2005). Htt is palmitoylated by its co-partner, 
huntingtin-interacting protein 14 (Hip-14, a palmitoyl transferase) at cysteine 214. Hip-14 
regulates trafficking and function of htt as well as several other neuronal proteins 
(DiFiglia et al 1995, Huang et al. 2004, Yanai et al 2006). Htt containing expanded polyQ 
has been found to be a poorer Hip-14 substrate compared with WT htt and therefore 
differential palmitoylation may represent one mechanism by which MT htt is toxic (Yanai 
et al 2006).
Htt is phylogenetically conserved which suggests that it is an essential protein for cellular 
function. WT and MT htt are expressed during development (Ambrose et al. 1994) 
although expression in non-neuronal tissues is relatively down-regulated (Schmitt et al. 
1995). The htt knock-out mouse model was generated independently and simultaneously 
by three groups (Duyao et al. 1995, Nasir et al. 1995, Zeitlin et al. 1995). All three models 
demonstrated that nullizygous mice die at embryonic days 6-10 suggesting that htt is vital 
for embryonic survival, although all three have different phenotypes. Nullizygous mice 
embryos can be rescued from lethality by WT extra-embryonic tissues suggesting that htt 
has a role in the development of extra-embryonic tissues (Dragatsis et al. 1998). Embryos 
with less than 50% normal htt die by E18.5 with extensive mid and hind-brain 
abnormalities suggesting that htt also has a role in gastrulation and neurogenesis (White et 
al. 1997). A chimeric study has demonstrated that following the injection of nullizygous 
embryonic stem (ES) cells into WT blastocysts, viable nullizygous neurons were found in 
28the brain although they were sparse in the cortex and striatum. This suggests that 
expression of htt is critical for region-specific survival and differentiation of neurons 
(Reiner et al. 2001 and 2003). However, the absence of htt does not kill cells in culture, 
suggesting that htt is not critical for post-embryonic cell survival (Metzler et al. 1999).
The cellular roles of htt remain poorly defined. This is mainly due to the large size of the 
protein, making it difficult to isolate and analyse, the lack of sequence homology with 
other proteins of known function, its ubiquitous localisation within the body and the cell, 
and its interactions with over 200 other proteins (see Harjes et al 2003 for review). In 
general, most evidence to date suggests that htt is a scaffold protein within the cell 
involved   in   controlling   intracellular   trafficking   and   signalling   pathways.   More 
specifically, it has anti-apoptotic effects (Rigamonti et al 2001), it is involved in 
transcriptional   regulation,   possibly   involving   its   HEAT   domain   regions   and 
nucleocytoplasmic shuttling of transcriptional regulatory proteins (Boutell et al. 1999, 
Truant et al 2007 and Section 1.8), and it may have a role in vesicle trafficking and axonal 
transport through its association with endosomal vesicles and trafficking proteins such as 
Hip1 and Hap1 (Li et al. 1995, DiFiglia et al. 1995, Gutekunst et al. 1995, Sharp et al. 
1995, Colomer et al. 1997, Engelender et al. 1997, Velier et al. 1998, Hattula and Peranen 
2000, Harjes et al 2003 and Section 1.9). Htt may also have a role in iron homeostasis 
(Hilditch-Maguire et al. 2000).
There is growing evidence that a reduction in WT htt may have a role in the pathogenesis 
of HD. Van Raamsdonk et al. (2005) generated a mouse model that expressed FL human 
htt with CAG repeats up to 128, with and without endogenous mouse htt. The authors 
found a slightly worse phenotype with worse motor dysfunction, hyperkinesia, testicular 
atrophy and slightly reduced lifespan in the mice lacking endogenous mouse htt but there 
29were no gross neuropathological differences. This suggested that replacement of WT htt 
will not be sufficient to treat HD and that MT htt can maintain its physiological function 
even with highly expanded CAG repeats.
1.5.4. Protein interactions with htt
Many protein/htt interactions have been described and most of these interactions are CAG 
repeat length-dependent. CREB-binding protein (CBP) is involved in transcriptional 
regulation and binds htt strongly in a direct repeat length-dependent manner (Kazantsev et 
al. 1999 and Section 1.8.1.). Huntingtin associated protein 1 (Hap-1) was one of the first 
proteins to be found to interact with htt and may also be involved in cellular trafficking in 
a repeat length-dependent manner (Li, X.J. et al. 1995 and Section 1.9.). Huntingtin 
interacting protein 1 (Hip-1) is involved in endocytosis and intracellular vesicular 
transport and binds htt in an inverse length-dependent manner (Kalchman et al. 1997, 
Wanker et al. 1997 and section 1.9.). Hip-1 has been demonstrated to have pro-apoptotic 
activity which can be modulated by htt (Hackam et al. 2000). The strength of the 
interaction  between  htt  and Hip-1  is inversely  proportional to  the length of the 
polyglutamine repeat. It is postulated that sequestration of pro-apoptotic Hip-1 by WT htt 
prevents apoptosis that could occur when Hip-1 is released by MT htt (Hackam et al. 
2000). Huntingtin interacting protein 2 (Hip-2) is a ubiquitin conjugating enzyme which 
ubiquitinates proteins for degradation by the 26S proteasome (Kalchman et al. 1996) 
although abnormal interactions between MT htt and Hip-2 have not been investigated. 
Gusella and MacDonald (1998), using a yeast two-hybrid interactor screen, identified 13 
protein interactions with htt and three of these were WW domain proteins (HYP A,B and 
C). WW domains are 38-40 amino acid sequences involved in protein-protein interactions 
through the binding of polyproline regions such as the rgion following the polyQs in htt. 
301.6. The molecular pathogenesis of HD: Processing of huntingtin
1.6.1. Processing of WT and MT htt in humans and cell and mouse models
There is compelling evidence that the first step in the pathogenesis of HD is the 
processing of FL htt to generate toxic N-terminal htt fragments, which accumulate not 
only in the nucleus but also in the cytoplasm, axons, dendrites and synapses. The selective 
neuronal loss in post-mortem HD brain and in HD mice may partially be explained by 
variations in regional processing, since N-terminal MT htt expressing transgenic and 
knock-in mouse models demonstrate more widespread aggregates than FL models 
(Davies et al. 1997, Schilling et al 1999 and Becher et al 1998). Transgenic or knock-in 
HD mice that express FL htt with expanded CAG repeats develop inclusions formed by N 
terminal fragments of MT htt (Reddy et al. 1998, Hodgson et al. 1999 and Wheeler 2000). 
Aggregates in HD post-mortem brains and in animal models contain epitopes for N-
terminal (1-549 amino acids) but not internal or C-terminal antibodies (DiFiglia et al. 
1997; Gutekunst et al. 1999; Sapp et al 1997 and Sieradzan et al. 1999) suggesting that 
processing occurs prior to aggregation. N-terminal fragments of MT htt have been 
detected in immunoblots of homogenates from HD brains (DiFiglia et al. 1997) and from 
transgenic mouse models expressing FL MT htt (Zhou et al. 2003 and Tanaka et al. 
2006). N-terminal fragments of approximately 40kDa in length have been described in 
Western blots of the nuclear fraction of striatal lysates of post-mortem juvenile HD brain 
(DiFiglia et al. 1997). Similar fragments have been described in the nuclear fractions of 
striatal lysates of MT FL htt knock-in mice by Li, H. et al. (2000). Lunkes et al (2002) 
demonstrated that the pathologic htt fragments terminated between the polyglutamine 
domain (beginning at amino acid 19) and amino acids 115-129 in HD post-mortem brain 
31and HD cell models (all amino acid numbers, unless otherwise stated, are based on WT 
htt with 23Q/21CAGs). Sieradzan et al (1999) demonstrated that an antibody to an htt 
peptide encompassing amino acids 80-113 recognized nuclear and cytoplasmic aggregates 
of MT htt in human HD brain, localising the C terminus of the putative N-terminal htt 
fragment to this 33-amino acid region of htt. A recent study has demonstrated that 
pathologic inclusions in the brains of HD patients, the N171-82Q mouse model of HD 
and a HEK 293 transiently transfected N233-78Q cell model are composed of N-terminal 
fragments of htt that terminate at an epitope between amino acids 81-90 and 115-129 
(Schilling et al 2007). This would produce a fragment containing the polyproline region, 
and would be N-terminal to the caspase/calpain cleavage sites (Fig 1.1). The authors also 
demonstrated that a transiently transfected HEK 293 cell model expressing an N-terminal 
WT htt fragment (N171-18Q) formed a fragment approximately 10kDa smaller than the 
MT construct fragment suggesting that WT htt may also be processed to N-terminal 
fragments. There is evidence suggesting WT htt processing may also follow an ischaemic 
insult to brain (Kim et al. 2003). In contrast to MT N-terminal htt fragments, which are 
considered to have a key role in the pathogenesis of HD, the role of potential WT htt 
processing remains to be elucidated.
In summary there is evidence of multiple potential cleavage sites in htt which could lead 
to the formation of an N-terminal htt fragment, but the precise size of the toxic N-terminal 
fragment has not consistently been described.
1.6.2. Htt processing by caspases and calpains
Caspases have an important role in apoptosis and some have a greater role in initiation 
and regulation of apoptosis e.g. caspases 8, 9 and 10, whereas others are involved in the 
molecular dismantling of cells e.g. 3, 6 and 7 (Vila et al. 2003 for review of apoptosis in 
32the context of neurodegeneration). Caspase cleavage sites in htt have been described for 
caspases 2, 3 and 6 (Wellington et al. 1998, 2000, 2002, Goldberg et al. 1996, Sun et al 
2002). The caspase cleavage sites were located at amino acids 513 (caspase 3), 552 
(caspase 3 and 2) and 586 (caspase 6) in htt (Fig. 1.1) and produced N-terminal htt 
fragments of 70, 75 and 80 kDa respectively. Caspase 3 can cleave both WT and MT htt 
and site-directed mutagenesis abolishes the cleavage (Wellington et al 2000). Caspase 3 is 
only expressed in cells already undergoing apoptosis and therefore cleavage of htt by 
caspase 3 is unlikely to be an initiating event in cell death in HD.
Calpains are a ubiquitously expressed family of calcium-dependent non-lysosomal 
cysteine proteases. Ischaemic brain injury caused increased calpain processing of WT htt 
into 55kDa fragments (Kim et al. 2003). Gafni et al. (2002) found that calpain-mediated 
cleavage of htt produced three N-terminal products of 62, 67 and 72 kDa. Subsequently, 
Gafni et al. (2004) described two putative calpain-cleavage sites in htt at amino acid 
residues 469 (corresponding to the 67kDa fragment) and 536 (corresponding to the 72kDa 
fragment) and preferential accumulation of these fragments in the nucleus (Fig. 1.1). The 
mutation of these cleavage sites produced less proteolysis, less aggregates and less 
toxicity in a cell culture model (Gafni et al. 2004) which suggested that calpain cleavage 
was an important event in the pathogenesis of HD. 
1.6.3. Ubiquitin proteasome system (UPS) inhibition by htt
The ability of the proteosome to degrade htt and the failure of molecular chaperones to 
maintain the molecular conformation of htt are potentially important events in the 
molecular pathogenesis of HD (Gusella and MacDonald 1998, Bence et al. 2001, Jana et 
33al. 2001). Proteasomes are large protein complexes located in the nucleus and the 
cytoplasm of all eukaryotic cells (Voges et al. 1999). The main function of proteasomes is 
to regulate the concentration of proteins and degrade misfolded proteins by proteolytic 
degradation which yields peptides of seven to eight amino acids. Proteins are tagged for 
degradation by ubiquitin. The tagging reaction is catalyzed by ubiquitin ligases. Once a 
protein is tagged with a single ubiquitin molecule, this signals other ligases to attach 
additional ubiquitin molecules. The result is a polyubiquitin chain that is recognised and 
bound by the proteasome, allowing it to degrade the tagged protein (Ciechanover et al. 
2000 and 2006 for review).
Several proteasome inhibitors have been described. Lactacystin was the first natural 
proteasomal inhibitor identified from Streptomyces and it inhibits the chymotryptic and 
tryptic activities of the proteasome by covalently binding to the N-terminal Thr1 of the β5 
proteasome subunit in the 20S catalytic core (Fenteany et al 1995; Groll et al 1997). 
Lactacystin inhibits the proteasome specifically without inhibiting other proteases  in 
vitro, and it does not inhibit
 lysosomal protein degradation (Fenteany et al. 1998). 
Seo, H. et al (2004) described a reduction in peptidyl-glutamyl peptide-hydrolyzing 
(PGPH) and chymotrypsin-like activities of the UPS in early and late-grade post-mortem 
HD   cerebellum,   cortex,   substantia   nigra   and   caudate/putamen.   HD  patient’s   skin 
fibroblasts demonstrated similar reductions in the UPS suggesting that MT htt caused a 
widespread inhibition of the UPS and that additional factors must be responsible for 
selective neuronal cell death. The authors found a specific increase in ubiquitin in late-
grade caudate/putamen and a reduction in caudate/putamen BDNF levels and complex 
II/III activity. It was suggested that a composite of several metabolic abnormalities could 
explain the regional specific loss in HD. Subsequently, the same authors described a 
34reduction in all three proteasomal activities in primary striatal cells from an HD mouse 
model. These activities were significantly improved with transfection of a lentiviral 
vector expressing the proteasome activator subunit PA28γ which also partially protected 
the cells from a proteasomal inhibitor (MG132), and quinolinic acid (an excitotoxic) but 
not a complex II mitochondrial inhibitor (3-NP) (Seo, H et al. 2007). Bence et al. (2001) 
demonstrated a failure of degradation of GFP in cells expressing N-terminal MT htt 
suggesting proteasomal inhibition by N-terminal htt. Jana et al. (2001) demonstrated that 
expanded   polyglutamines,   in   an   N-terminal   htt   inducible   cell   model,   inhibited 
chymotrypsin-like activity in the cytosolic fractions. This was associated with reduced 
degradation of p53 and a transfer of proteasomal activity to aggregate-containing 
precipitated fractions. Bennet et al (2005) described inhibition of the UPS in cells co-
expressing ubiquitin tagged with GFP and MT htt exon 1 in the absence of visible 
aggregates. Isolated polyglutamine aggregates in vitro do not inhibit the proteasome 
(Bennett et al 2005) but fibrillar species of MT htt purified from HD transgenic mice and 
HD post-mortem brain can decrease proteasome function (Diaz-Hernandez et al. 2006).
The 20S proteasomal subunit is sequestrated in htt inclusions in the R6/1 mouse model, 
N-terminal htt expressing cell cultures (Cummings et al 1998, Jana et al. 2001, Waelter et 
al. 2001a, Wyttenbach et al. 2000) and post-mortem HD brain (DiFiglia et al 1997), 
which may underlie UPS inhibition and htt aggregate toxicity (Section 1.7).
SH-SY5Y cells stably expressing polyQ (19, 56, or 80Q) within GFP did not lead to 
proteasomal impairment (Ding et al 2002) and there was no evidence of decreased UPS 
activity in a knock-in mouse cell model of SCA7 (Bowman et al. 2005). These studies 
suggest that the protein context of the polyglutamine repeats may be important in 
polyglutamine-mediated UPS inhibition.
35In contrast to decreased UPS function in HD, Diaz-Hernandez et al. (2003) found an 
increase in the chymotrypsin and trypsin activities of the proteasome in striatal and 
cortical, but not cerebellar, lysates from a conditional HD mouse model expressing exon 
with 1-94Q. This was attributed to an increase in the levels of the proteasome subunits 
LMP2 and LMP7 and the induction of the immunoproteasome. Increased proteasomal 
chymotrypsin-like activity has also been observed in brain lysates from the R6/2 model of 
HD compared with non-transgenic littermates (Bett et al 2006). However, this study 
found no change in overall 26S proteasome activity and showed that the nuclear 
proteasome activator PA28 was not involved in polyglutamine pathology. This is in 
contrast with data demonstrating the reversal of proteasome dysfunction in MT htt-
expressing striatal neurons and rescue of cell death by PA28 overexpression (Seo et al 
2007).
In conclusion, there is contrasting evidence relating the influence of MT htt upon UPS 
function in HD. This may in part be due to the different model systems (stable, inducible 
and transient cell models, transgenic mice and post-mortem HD brain), the variation in 
the sizes of the htt fragments used in the studies (isolated polyQ, compared to N-terminal 
and FL htt) and the different methodologies used to assess UPS function. Therefore, 
conclusive proof of UPS dysfunction in HD has yet to be verified.
1.6.4. UPS and degradation of htt
Htt aggregates are ubiquitinated in human post-mortem brain (DiFiglia 1997) and in HD 
transgenic mice (Mangiarini et al 1997) which suggests that they have been targeted for 
degradation by the proteasome. The ubiquitin-conjugating enzyme, E2 or huntingtin 
interacting protein-2 (Hip-2), has been found to equally bind to, and ubiquitinate, MT and 
36WT htt (Kalchman et al. 1996). This suggested that preferential labeling of MT htt for the 
proteasome was not a potential mechanism for the selective toxicity of MT compared to 
WT htt in this system. Parkin, an E3-ubiquitin ligase, co-localises with htt aggregates in 
HD mouse and human brains and overexpression of parkin enhances the clearance of the 
MT protein (Tsai et al 2003). These data suggest that htt may be a proteasome substrate. 
The HD94 conditional mouse model (Yamamoto et al. 2000), demonstrated that by 
switching   off   the   MT   htt   transgene,   there   was   reversal   of   neuropathology   and 
neurological phenotype in the mice (Section 1.7.4 for further description). Martin-
Aparicio et al. (2001) subsequently demonstrated the conditional formation of htt 
aggregates in a striatal culture model of HD94, and that the loss of aggregates on 
switching off the transgene was inhibited by lactacystin, suggesting that removal of htt 
aggregates   is   proteasome-dependent.   Proteasome  inhibition   also   increases   MT  htt 
aggregation and toxicity in other HD cell models (Wyttenbach et al 2000, Jana et al 2001, 
Waelter et al 2001a, Ravikumar et al. 2002). 
Venkatraman et al. (2004) and Holmberg et al (2004) have demonstrated that eukaryotic 
proteasomes are incapable of digesting proteins of between 9 and 29 polyglutamine 
repeats and therefore these must be released from the proteasome for further hydrolysis. 
Bhutani et al (2007) described the very slow and inefficient degradation of polyglutamine 
tracts released from the proteasome by a puromycin-sensitive aminopeptidase. It is 
therefore unclear whether enhancing proteasome function to remove toxic MT htt species 
may actually increase the amount of polyglutamine tracts without a protein background 
which could potentially  be more toxic. There is therefore no direct evidence of 
proteasome processing of htt.
1.6.5. Protein folding and htt
37The folding of newly synthesized proteins and the refolding of misfolded proteins is 
performed by the sequential actions of several molecular chaperones. If the molecular 
chaperones fail, then the misfolded protein is often degraded by the proteasome (Fink 
1999). Heat shock protein 40 and 70 (HSP 40 and 70) are the two main classes of 
molecular chaperones that coordinate folding and maintenance of proteins into a soluble 
conformation (Hartl and Hayer-Hartl 2002). If misfolded proteins are not degraded, this 
results in the accumulation of insoluble protein and aggregation can occur.
Following the generation of N-terminal htt fragments from FL MT htt, as described in 
Section 1.6.1., it is postulated that MT N-terminal htt misfolds and forms oligomers and 
subsequently aggregates. This is not a feature of WT htt. Htt interacts with both HSP 40 
and 70 families of molecular chaperones, with both co-localising with aggregates in HD 
tissue and animal and cellular models (Sakahira et al. 2002). This sequestration may lead 
to an increase in protein misfolding and lead to a cascade of molecular events culminating 
in cell death (Hay et al. 2004). This may be a feature of other CAG repeat disease as the 
overexpression of HSP 40 and 70 in a Drosophila model of spinocerebellar ataxia type 3, 
rescued cells expressing truncated protein with 78 CAGs (Bonini 2002).
1.6.6. Autophagy and htt
Autophagy is a process involving the formation of double-membrane structures, called 
autophagosomes, around a portion of cytoplasm. These autophagosomes ultimately fuse 
with lysosomes, where their contents are degraded. MT htt has been shown to be 
degraded by autophagy (Ravikumar et al 2002). The strategy of up-regulating autophagy 
to increase clearance of MT protein has shown promise in cell, Drosophila and mouse 
38models of HD where the increase in clearance shows a preference for the MT form of the 
protein (Ravikumar et al 2004). Drugs which can be used to up-regulate autophagy, such 
as rapamycin, carbamazepine, sodium valproate, have been shown to work in animal and 
cell models expressing other aggregate-prone proteins that lead to human disease, 
including tau and MT α-synuclein (Berger et al 2006). Pharmacological enhancement of 
the autophagosome may represent a possible method of removal of aggregate-prone 
mutant proteins in several neurodegenerative diseases.
1.7. The molecular pathogenesis of HD: Aggregate formation
The formation of cytoplasmic and nuclear protein inclusions is a striking histological 
feature of HD post-mortem brains and all other known polyglutamine diseases, most HD 
transgenic mice and some HD cell models (DiFiglia et al 1997 Becher et al 1998, Davies 
et al 1997 Lunkes et al 1998 and Section 1.11).
1.7.1. Distribution of aggregates in HD brain
N-terminal htt aggregates, with detectable epitopes between amino acids 1-549 (DiFiglia 
et al. 1997), are heterogeneously distributed throughout the HD brain. Aggregates are 
mostly found in the layers V and VI of the cerebral cortical grey matter. The insular and 
cingular cortices contain more inclusions than the prefrontal, temporal association and 
pre-motor cortices (Gutekunst et al. 1999). The aggregates are uncommon and scattered 
widely in the striatum where neurodegeneration is most prominent, in contrast to the R6/2 
mouse model (Sections 1.7.3 and 1.10.7.). Aggregates are rarely seen in the globus 
pallidus, hippocampus and cerebellum, but may be found in the thalamus, brainstem 
nuclei and substantia nigra (pars compacta) (Gutekunst et al. 1999).
39At a subcellular level, the aggregates form in the nucleus, perikaryon and neuropil. 
Neuropil aggregates are the most common form (Gutekunst et al. 1999). They can be 
small round structures or long tubular forms that fill the axons for hundreds of microns 
(DiFiglia et al. 1997, Becher et al. 1998, Gutekunst et al. 1999). The nuclear aggregates 
are round to oval and are between 3-5µm in diameter. There is usually only one or 
occasionally two per nucleus. The perikaryal aggregates are smaller in size (0.3-1.5µm). 
Ultrastructural studies have suggested that the aggregates are not membrane-bound but 
are made up of granular and filamentous material. The filaments have a width of 
approximately 10nm (DiFiglia et al. 1997, Gutekunst et al. 1999). The first possible 
description of aggregates probably came from an ultrastructural study of the neuronal 
nuclei in HD brains in 1979 but the significance of these filamentous inclusions was not 
fully appreciated at the time (Roizin et al. 1979).
1.7.2. Aggregates in early HD 
There have been relatively few studies which have examined the distribution of 
aggregates in early HD (DiFiglia et al. 1997; Gutekunst et al. 1999). These studies 
demonstrated that there were neuropil aggregates in two presymptomatic HD patients in 
the cortex, especially in cortical layers V and VI. Aggregates in the dorsal striatum, where 
the earliest neurodegeneration occurs, were rare, apart from one report of aggregates in 
the tail of the caudate in a presymptomatic patient (Gomez-Tortosa et al. 2001). 
`
1.7.3. Aggregates in mouse models
40Neuronal nuclear aggregates were first described in the R6/2 mouse model (Davies et al. 
1997). Aggregates have subsequently been described in many HD mouse models. 
Aggregate formation is most extensive in models which express truncated htt which 
contain highly expanded CAG repeats. The R6/2 model is a good example of this, where 
the transgene htt background consists of only exon 1 (90aa.) containing 148 CAG repeats. 
In the R6/2 mouse, by 8 weeks, most groups of neurons contain aggregates, but there is a 
sequence of progression of aggregate formation e.g. cortex and hippocampus before 
striatum in the R6/2 mouse (Morton et al. 2000). Aggregates have also been described in 
organs outside of the CNS including skeletal muscle, heart, liver, pancreas, kidneys, 
stomach, and adrenal glands (Sathasivam et al 1999, Orth et al 2003). The mice tend to 
develop striatal nuclear aggregates in contrast to the human disease where striatal 
aggregates are relatively sparse and more frequent in the cerebral cortex (Li et al. 2000). 
There appears to be a consistent sequence of events in the formation of nuclear inclusions 
in   the   mouse   models.   At   first,   using   the   EM48   antibody   to   detect   expanded 
polyglutamines, there was diffuse nuclear staining followed by intense nuclear staining 
and the development of small puncta in the nucleus. The puncta then coalesce to form a 
single inclusion and the diffuse nuclear staining disappears. It is postulated that the early 
diffuse staining represents translocation of an N-terminal fragment of htt into the nucleus 
or even retention of FL htt and truncation to an N-terminal fragment within the nucleus.
At an ultrastructural level, the inclusions are granular and fibrillar structures which are 
not membrane-bound and they are similar to nuclear inclusions described in post-mortem 
HD brain (Roizin et al. 1979, Davies et al. 1997). The aggregates are associated with 
changes in the nuclear membrane and pores (Davies et al. 1997). The nuclear aggregates 
are   ubiquitinated   and   are   associated   with   a   number   of   other   proteins   including, 
components of the proteasome, heat shock proteins (Jana et al. 2000), transcription 
41factors, e.g.CREB-binding protein (CBP) (Nucifora et al. 2001), Sin3b, and complexin II 
(Morton and Edwardson 2001).
There is evidence from a conditional transgenic model of HD that aggregates are involved 
in a dynamic process of formation and breakdown (Yamamoto et al. 2000). Turning off 
the transgene, resulted in not only resolution of the aggregates but  also a dramatic 
improvement in the neurological phenotype, demonstrating that the aggregates are in a 
dynamic cycle of deposition and removal. Progression of the disease also required that the 
MT transgene was continuously expressed. These findings suggest that HD therapeutics 
may be able to benefit patients who already have developed an HD phenotype. 
1.7.4. Mechanism of aggregate formation
Perutz et al. (1994) proposed that elongated polyglutamine chains can form stable hair-
pins when the number of polyglutamines exceeds 37 and that the hairpins associate to 
form aggregates. This was termed the “polar zipper” model of aggregation because 
antiparallel β-strands of polyglutamine were proposed to link together by hydrogen 
bonds. Subsequently, in vitro studies have confirmed that MT N-terminal htt can form 
fibrils (Georgalis et al. 1998). These in vitro htt fibrils, and htt aggregates in HD post-
mortem brain, stain with Congo red and demonstrate green birefringence when examined 
under polarized light, suggesting that the fibrils/aggregates contain amyloid with a β-
pleated sheet structure (Huang et al. 1998). Fig. 1.2. summarises the proposed mechanism 
of self-assembly of MT htt into aggregates. In vitro and transgenic studies have 
demonstrated that the more truncated the N-terminal fragment and the longer the CAG 
repeats, the faster aggregation occurs and the more widespread are the inclusions, 
although aggregation only occurs when there are greater than 37 glutamines (Cooper et al. 
421998, Hackam et al. 1998, Kazantsev et al. 1999, Kim et al. 1999, Lunkes and Mandel 
1998, Marsh et al. 2000, Martindale et al. 1998, Peters et al 1999).
Transglutaminases are a family of calcium-dependent enzymes that catalyse the formation 
of covalent ε-(γ-glutamyl)-lysine isopeptide bonds, resulting in the formation of insoluble 
cross-linked proteins (Greenberg et al. 1991). Aggregation of htt has also been proposed 
to occur by cross-linking of MT htt to itself or other lysyl residues by transglutaminases 
(Kahlem et al. 1996, 1998, Karpuj et al. 1999). Cystamine is primarily an inhibitor of the 
enzyme transglutaminase and several studies have variably demonstrated significant 
clinical   and   neuropathological   improvements   in   the   phenotype   of   mouse   models 
following administration of cystamine (Karpuj et al. 2002, Dedeoglu et al. 2002, Lesort et 
al. 2003, Wang et al. 2005). These studies have contrasting results in that Karpuj et al 
(2002) and Lesort et al (2003) did not find a dramatic effect on aggregates in spite of 
clinical improvement and suggested that this may be due to an anti-caspase 3 effect of 
cystamine (Lesort et al 2003). In contrast, Dedeoglu et al (2002) Fig 1.2.
43and Wang et al. (2005) found a reduction in aggregate formation which may have been 
due to the administration of cystamine in utero (Dedeoglu et al 2002).
1.7.5. Toxicity of aggregates
One of the biggest controversies in HD biology is the role of the htt aggregates in the 
pathogenesis of the disease. In HD post-mortem brains, the density of the inclusions in 
the cerebral cortex correlates with repeat length (Becher et al. 1997), although there is 
little correlation between inclusion burden and the areas of the brain most affected by 
neurodegeneration in HD (Gutekunst et al 1999). There are several in vitro cell models 
that have associated toxicity with N-terminal MT htt expression and aggregate formation 
(Carmichael et al. 2000, Lunkes 1998, Hackam et al. 1999 Waelter et al. 2001a) and there 
44is a strong correlation between the appearance of inclusions with cell dysfunction and 
death (Hackam 1998 and Lunkes et al 1998). 
Several putative mechanisms of polyglutamine aggregate toxicity have been proposed. 
These mechanisms can be summarised as aggregates causing sequestration of vital 
cellular  proteins (Table 1.1.)  or direct aggregate cellular  toxicity by non-specific 
interference in cellular trafficking (Section 1.9) or by obstruction of the ubiquitin-
proteasomal system as has been demonstrated (Bence et al. 2001 and section 1.6.3.). 
These findings are in contrast to several in vitro cell models which have found that cell 
death and aggregate formation are independent processes and that aggregates may be 
protective (Kim et al. 1999 and Saudou et al. 1998). Bodner et al (2006) demonstrated 
decreased proteasome dysfunction and cell death in a cell model of HD following 
treatment with a small molecule, in spite of greater inclusion formation. In cell culture, 
MT htt expression was more protective in cells demonstrating aggregate formation than
Transcription factors (TBP/TFIID, CBP)
Steffan et al. 2000, Nucifora et al. 2001, 
Suhr et al 2001
Caspases (caspase 8) Sanchez et al. 1999
Protein kinases (MEKK1) Meriin et al. 2001
Components of the UPS (ubiquitin, 20S, 
19S and 11S proteasome)
Cummings et al. 1998, Waelter et al. 2001a, 
Suhr et al 2001
α-synuclein Charles et al. 2000, Waelter et al. 2001a
Components of the nuclear pore complex Suhr et al. 2001
Cell cycle proteins (p53, mdm-2) Suhr et al. 2001
Cytoskeletal proteins (actin) Suhr et al. 2001
Molecular chaperones (HSP70 and 40, BiP/
GRP78)
Waelter et al. 2001a
RNA binding proteins (TIA-1) Waelter et al. 2001a
Table 1.1. Proteins sequestered in htt inclusions
cells that did not form aggregates (Arrasate et al (2004). Saudou et al. (1998) transiently 
45transfected rat striatal and hippocampal neurons with plasmids expressing N-terminal 
human htt of 171 or 480aa. in length containing either 17Q or 68Q. They found that 
inclusions formed maximally in the striatal cultures at day 6 but significant apoptosis did 
not occur until day 9. Hippocampal neurons also formed inclusions but did not undergo 
apoptosis suggesting that MT htt induced-apoptosis was dependent on the cell type. AC-
DEVD-CHO (a caspase inhibitor), growth factors (BDNF and CNTF) and the anti-
apoptotic protein, BclXL  all rescued cells from apoptosis but did not prevent nuclear 
inclusion formation. This in itself did not prove that inclusions are protective, as apoptosis 
may have been activated by the inclusions and subsequently these agents rescued the cells 
by interfering with downstream execution of apoptosis. The authors then demonstrated 
the level of apoptosis was not related to the length of the htt construct. A dominant 
negative mutation in the ubiquitin-conjugating enzyme hCdc34p(CL→S) was expressed 
in the model and inhibited nuclear inclusion formation but produced greater cell death at 
day 6 compared to day 9 in the cells containing inclusions without the dominant negative 
mutation. These  results suggested that nuclear localisation of htt is important in htt-
induced cell death but that aggregate formation may be independent and possibly 
protective of cell death. 
The overexpression of CA150, a transcription factor, in HD transgenic rats and knock-in 
mice rescued neuronal toxicity whilst increasing neuritic aggregates and had no effect on 
nuclear inclusions (Arango et al 2006). These findings suggested against htt aggregate-
induced toxicity.
In summary, at the very least, the presence of htt inclusions demonstrates that there is 
abnormal processing or misfolding of the MT htt protein. The presence of nuclear and 
non-nuclear inclusions of various types in a wide range of neurodegenerative diseases 
46(Trojanowski and Lee 2000) suggests that insoluble protein deposits are a pivotal feature 
of neurodegeneration and that these diseases may have a common underlying pathogenic 
mechanism. The demonstration of inclusions in the brain of a mouse model with ectopic 
expression of polyglutamine in the hypoxanthine ribosyl transferase gene (hprt) and the 
subsequent development of a neurological phenotype (Ordway et al. 1997) further 
highlights the link between inclusions, neurodegeneration and polyglutamine repeats. 
However, based on current evidence, it is not certain whether inclusions are pathological, 
protective or an epiphenomenon.
1.8. The molecular pathogenesis of HD: Transcriptional regulation
An early observation in HD biology was that WT FL htt was mainly found in the 
cytoplasm, and only truncated MT N-terminal htt was found in the nucleus (Martindale et 
al 1998). This early observation suggested that the nucleus may be an important site of 
MT htt toxicity. Nuclear localisation of MT htt enhanced toxicity in HD cell models and 
transgenic mice (Saudou et al. 1998, Ross et al 2004 and Schilling et al. 2004). A number 
of   transcriptional   regulators   contain   glutamine-rich   activating   domains,   which   are 
important for the interaction between transcription factors and transcription regulators. 
Therefore, proteins containing polyglutamines may influence transcription factors and 
alter transcription (Perutz et al 1994, Gerber et al 1994).
In support of transcriptional dysregulation as an important mechanism in HD, in situ 
hybridization studies have demonstrated downregulation of several genes in HD post-
mortem striatum, including substance P, enkephalin and D1 and 2 dopamine receptor 
mRNA (Augood et al. 1996, 1997), as well as cannabinoid receptors and NR1 and NR2B 
subunits of the NMDA receptor (Arzberger et al. 1997 and Richfield and Herkenham 
471994). In situ hybridization studies in R6/2 transgenic mouse striatum have revealed that 
the D1 dopamine receptor, metabotropic glutamate receptor and A2a adenosine receptor 
mRNA were decreased by four weeks of age before neuronal loss was observed (Cha et 
al.   1998   and   1999).   PET   studies   in   asymptomatic   HD   mutation   carriers   have 
demonstrated decreased D1 and D2 receptor activities, and these abnormalities correlated 
with subtle cognitive deficits (Backman et al. 1997, Lawrence et al. 1998). This suggested 
that these changes may account for some of the early cognitive features observed in HD 
patients and that functional neuronal changes may occur before gross cell death and 
inclusion formation.
Changes in at least six transcriptional systems have been described in HD. These include 
the CREB system (Li and Li for a review 2004, Steffan JS. et al. 2000, Steffan et al. 2001 
and Hockly et al. 2003), SP-1 (Dunah et al. 2002), TATA-binding protein (TBP) 
(Stevanin et al. 2003), repressor complexes containing nuclear corepressor protein and 
Sin3a (Boutell et al. 1999), neuron-restrictive silencer elements (NRSEs) (Zuccato et al. 
2003) and PGC-1α (Cui et al. 2006). These will be discussed below.
1.8.1. The cAMP-responsive element binding protein (CREB) 
CREB proteins are transcription factors which bind to DNA sequences called cAMP 
response elements (CRE) (Mantamadiotis et al. 2002). The disruption of the CREB 
system   in   mice   leads   to   an   HD-like   phenotype   in   which   there   is   progressive 
neurodegeneration in the hippocampus and striatum (Mantamadiotis et al. 2002). The 
downregulation of CREB-regulated genes has also been detected in HD patients (Glass et 
al. 2000). The CREB-binding protein (CBP) is involved in controlling the activity of 
CREB proteins and has been found to be sequestered into aggregates in HD as well as 
other   polyglutamine   diseases   (Li   and   Li   2004).   Htt   interacts   with   CBP   via   its 
48polyglutamine and acetyltransferase domains, which may explain why there is a reduction 
in CREB-mediated transcription and acetyltransferase activity in models of HD (Steffan 
et al. 2000). In cellular, fly and mouse models of HD, neurodegeneration can be partly 
ameliorated   through   the  administration   of   histone  deacetylase  inhibitors   which   is 
associated with a reversal in the reduction of acetyltransferase activity (McCampbell et al. 
2001, Steffan et al. 2001 and Hockly et al. 2003). Further data has challenged some of 
these findings. A double-transgenic mouse model of MT htt overexpression and the CRE-
β galactosidase reporter construct suggested that CREB-regulated transcription was 
upregulated (Obrietan and Hoyt 2004). 
1.8.2. Specificity protein-1 (Sp1)
MT htt has also been demonstrated to sequester another transcriptional regulator, Sp1, 
into aggregates and therefore disrupt Sp1-mediated transcription. MT htt also disrupts the 
specific interaction of Sp1 with co-activator TAFII130. Of particular importance, an 
enhanced association between Sp1 and MT htt has been described in presymptomatic HD 
patients and the association of Sp1 with TAFII130 was reduced in HD brain (Dunah et al. 
2002). The interaction between Sp1 and htt also blocks the binding of Sp1 to its promoter 
region. The overexpression of both Sp1 and TAFII130 has been demonstrated to overcome 
the inhibition of D2 receptor gene expression by MT htt (Dunah et al. 2002). In contrast, 
more recent studies by Qui et al. (2006) demonstrated an increase in Sp1 expression 
levels in different experimental models of HD, suggesting that suppression of Sp1 could 
be beneficial for HD pathology, while an increase in Sp1 levels may enhance MT htt 
toxicity.
1.8.3. TATA-binding protein (TBP)
49TBP has also been found to localise to htt nuclear inclusions. Sp1 binds to and regulates 
molecules of the transcription machinery, such as transcription factor IID (TFIID) which 
is a multi-protein complex and contains TBP and multiple TAFIIS. An expansion of the 
polyglutamine region of TBP causes SCA17 which is an autosomal dominant ataxia with 
overlapping clinical features of HD (Stevanin et al. 2003). 
1.8.4. Nuclear co-repressor protein and mSin3a
Yeast two-hybrid analysis has demonstrated that htt may also disrupt transcriptional 
repressors   as   well   as   promoters.   Htt   directly   interacts   with   repressor   complexes 
containing nuclear corepressor protein and mSin3a in a polyglutamine-dependent manner 
(Boutell et al. 1999). These are involved in repressing the transcriptional activation of 
nuclear receptors such as retinoic acid. One quarter of the genes with altered transcription 
in the R6/2 mouse were found to be under the control of retinoic acid (Luthi-Carter et al. 
2000). 
1.8.5. NRSE-regulated pathways
WT htt has been found to regulate the activity of genes that contain neuron-restrictive 
silencer elements (NRSEs) (Zuccato et al. 2003). Brain-derived neurotrophic factor 
(BDNF) is regulated by NRSE and WT htt binds cytosolic REST/NRSF complex, the 
transcription factor that binds to the NRSE in the promotor of BDNF, preventing it from 
entering   the   nucleus   and   inhibiting   BDNF   transcription.   MT   htt   does   not   bind 
REST/NRSF effectively, which enables REST/NRSF to enter the nucleus and switch off 
BDNF transcription. BDNF has been found to be an important pro-survival factor of 
striatal neurons, which may explain not only the mechanism of cell death induced by MT 
50htt but also the regional specificity due to the loss of BDNF in the striatum from cortical 
neurons (Zuccato et al. 2001).
1.8.6. PGC-1α
Transgenic mice lacking PGC-1α, a transcriptional coactivator that regulates several 
genes involved in mitochondrial biogenesis and respiration, show defects in brown 
adipose tissue as well as a pattern of neurodegeneration similar to HD (Lin et al 2002, 
Leone et al 2005). MT htt may cause disruption of mitochondrial function by inhibiting 
expression of PGC-1α and over expression of PGC-1α reverses the effects of MT htt in 
cell models and HD transgenic mice (Cui et al. 2006). This suggests that inhibition of 
mitochondrial function by htt may occur at an early biosynthetic level.
1.9. The molecular pathogenesis of HD: Cellular transport
Htt purifies with vesicle fractions from human and rat brain (DiFiglia et al. 1995, 
Gutekunst et al. 1995, Sharp et al. 1995, Velier et al. 1998, Wood et al. 1996). Htt also 
associates with microtubules (Bhide et al. 1996, DiFiglia et al. 1995, Gutekunst et al 
1995, Tukamoto et al 1997) and interacts with several proteins involved in retrograde 
transport (Colomer et al. 1997, Engelender et al. 1997, Hattula and Peranen 2000, Velier 
et al 1998). Polyglutamine tracts interact with neurofilament proteins (Nagai et al 1999). 
Following a crush injury to rat sciatic nerve, the accumulation of N-terminal and FL htt 
was demonstrated either side of the injury (Block-Galarza et al. 1997). These findings 
suggest that htt is involved in axonal transport and vesicle trafficking.
The role of htt in vesicle trafficking was therefore originally proposed on the basis of its 
51localisation to endocytic/endosomal vesicles in axons and synaptic terminals and from its 
interaction with a number of endocytic/trafficking proteins, including α-adaptin, Hip1, 
Hip14, Hap (huntingtin-associated protein) 1, Hap40, PACSIN1 (protein kinase C and 
casein kinase substrate in neurons-1) and SH3GL3 [SH3 (Src homology 3)-domain Grb2-
like 3] (endophilin 3) (Harjes et al. 2003, Li and Li 2004). 
The endocytic proteins, clathrin and dynamin have been found to colocalise with htt 
(Velier et al 1998, Kaltenbach et al 2007). Mutations in the huntingtin-interacting protein 
1 (Hip-1) yeast homologue (S1a2p) have been associated with disrupted endocytosis 
(Raths et al. 1993). Hip-1 has been found to bind to clathrin, is localised to clathrin-
coated vesicles and is probably involved in receptor-mediated endocytosis (Metzler et al. 
2001, Waelter et al. 2001b). Hip-1 also directly interacts with Hap-1(Waelter et al. 
2001b). Htt interacts with SH3GL3, the human homologue of the mouse endophilin 3 
gene which may be involved in endocytosis (Sittler et al. 1998). In spite of the 
associations with htt described above, a direct role of htt in endocytosis is still uncertain, 
as the effect of reducing htt levels on endocytosis has yet to be shown. There is some 
evidence that MT htt disrupts synaptic vesicular function. MT N-terminal htt binds 
synaptic vesicles and inhibits glutamate uptake in vitro (Li et al. 2000). Sun et al. (2001) 
described a reduced association between MT htt and post-synaptic density protein 95 
(PSD-95). PSD-95 is involved in regulating the NMDA receptor and the GluR6 subunit 
of the kainate receptor. The weakening of the huntingtin/PSD-95 interaction may result in 
increased NMDA receptor signaling and excitotoxicity. It is also possible that this effect 
may underlie the association between a polymorphic marker in the GluR6 gene and the 
age of onset in HD (Rubinsztein et al.1997).
The role of htt in axonal transport has been documented more extensively than 
52endocytosis, although the role of MT htt interrupting this process also remains unclear. 
Hap-1 was the first protein found to interact with htt (Li et al 1995). Hap-1 interacts with 
the p150 subunit of dynactin, and htt, p150 and Hap-1 all co-immunoprecipitate from rat 
brain homogenates (Engelender et al. 1997, Li et al. 1998). Dynactin interacts with the 
protein dynein and these are involved in the movement of vesicles along microtubules 
(Allan 1996). It has been proposed that Hap-1 and htt are involved in the formation of the 
dynein/dynactin complex during fast axonal transport. A reduction in endogenous htt or 
expression of MT htt inhibits movement of vesicles and mitochondria along neuronal 
projections (Trushina et al 2004, Caviston et al 2007) Defective retrograde transport can 
result in dystrophic neurite formation similar to those observed in HD brains (Sapp et al. 
1999).
Vesicle associated membrane protein (VAMP)  or  synaptobrevin  is a small integral 
membrane protein of secretory vesicles. VAMP is one of the SNARE proteins involved in 
formation of the SNARE complexes (see Duman et al 2003 for review of SNARE 
proteins). SNARE proteins are the key components of the molecular machinery that 
drives fusion of membranes in exocytosis and VAMP has been linked to neurite 
outgrowth (Martinez-Arca, et al 2000). Synaptophysin is a synaptic vesicle glycoprotein 
and is present in most neurons in the brain and spinal cord that participate in synaptic 
transmission. The precise function of the protein is unknown, although it interacts with 
VAMP (Gincel et al 2002). Direct evidence for the involvement of MT htt in disrupting 
axonal transport in vitro and in vivo, including mitochondrial trafficking, has been 
described by Trushina et al (2004). 
1.10. The molecular pathogenesis of HD: Energetic defects in HD
531.10.1. The spectrum of mitochondrial function
Mitochondria are subcellular organelles in eukaryotic cells which have several roles in 
maintaining cellular homeostasis such as transient storage of intracellular calcium, fatty 
acid oxidation, the Kreb’s cycle and iron metabolism (McBride et al. 2006 for review). 
Mitochondria also have a key role in the regulation of apoptosis (Wang 2001 for review). 
Pro-apoptotic proteins cause mitochondrial swelling, through the formation of membrane 
pores, or by directly increasing the permeability of the mitochondrial membrane. This 
results in the release of apoptotic effector proteins, and the induction of apoptosis. 
Mitochondrial proteins known as SMACs (second mitochondria-derived activator of 
caspases) are released into the cytosol following an increase in mitochondrial membrane 
permeability. SMAC binds to inhibitor of apoptosis proteins (IAPs) and deactivates them, 
preventing the IAPs from inhibiting caspases. Cytochrome c is also released from 
mitochondria following the formation of the mitochondrial apoptosis–induced channel 
(MAC), in the outer mitochondrial membrane (Dejean et al 2006 for review).
  Once 
cytochrome c is released, it binds with Apaf-1 and ATP, which then bind to pro-caspase-9 
to create a protein complex known as an “apoptosome”. The apoptosome cleaves the pro-
caspase 9, to its active form, caspase-9, which in turn activates the effector caspase-3 
leading to cell death by apoptosis. One of the most important roles of mitochondria is to 
catalyse the phosphorylation of the majority of cellular adenosine diphosphate (ADP) to 
adenosine triphosphate (ATP). ATP is generated by oxidation of intermediates, such as 
NADH and FADH2, via the process of oxidative phosphorylation (OXPHOS) within 
mitochondria (Fig. 1.3).
1.10.2. The mitochondrial respiratory chain
54The mitochondrial respiratory chain consists of five multi-subunit protein complexes, 
which are located in the inner mitochondrial membrane, and two mobile electron carriers, 
cytochrome c and ubiquinone (Fig. 1.3). The respiratory chain generates a proton gradient 
across the inner mitochondrial membrane which drives ADP 
Fig. 1.3.
55phosphorylation by ATP synthase or complex V. The proton gradient is produced by the 
release of protons from complexes I, III and IV into the intermembranous space. The 
energy for this process is yielded from the transfer of electrons from NADH/FADH2 
through the protein complexes to the final electron acceptor, oxygen. Complex V couples 
the re-entry of protons into the mitochondrial matrix with the phosphorylation of ADP.
1.10.3. The mitochondrial hypothesis in neurodegeneration
Neurons require a high level of ATP production to maintain ionic homeostasis following 
the controlled flux of ions across the cell membrane during electrical signaling. Most of 
the ATP, utilised by Na
+/K
+ ATPase and Ca
2+ ATPase in maintaining ionic homeostasis, 
is   generated   in   mitochondria.   The   mitochondrial   hypothesis   in   neurodegeneration 
postulates that defects in mitochondrial metabolism may lead to chronic mitochondrial 
dysfunction and eventually to depletion of cellular ATP. The entry into apoptosis may be 
linked to the competence of mitochondria to produce ATP and provide a mechanism by 
which chronic mitochondrial dysfunction could lead to neurodegeneration.
Mitochondrial dysfunction may be precipitated by exogenous and endogenous oxidative 
phosphorylation (OXPHOS) inhibitors or by mutations in nuclear or mitochondrial DNA-
encoded   proteins   involved   in   OXPHOS   or   non-OXPHOS   mitochondrial   function 
56(Leonard et al. 2000a and b). This hypothesis is supported by evidence that disorders of 
mitochondrial function caused by mutations in mitochondrial proteins or the presence of 
mitochondrial inhibitors have a role in several neurodegenerative diseases.
1.10.4. Imaging energetic defects
PET studies are consistent with a defect in energy utilisation in HD striatum and cortex. 
Studies using 
18F-deoxyglucose positron emission tomography (PET) have demonstrated 
reductions in striatal and cortical but not thalamic or cerebellar regional utilisation of 
glucose in symptomatic HD patients (Kuhl et al. 1982, Leenders et al. 1986, Kuwert et al. 
1990, Martin et al. 1992). Striatal reductions in utilisation of glucose have also been 
described in pre-symptomatic/chorea-free/”at risk” patients (Mazziotta et al. 1987, 
Grafton et al. 1990, Grafton et al. 1992, Kuwert et al. 1993). 
Subsequently,  nuclear  magnetic  resonance (NMR) spectroscopy has  enabled more 
accurate determination of perfusion and metabolite changes in HD brains.  
1H NMR 
spectroscopy demonstrated elevated lactate levels in the occipital cortex (Jenkins et al. 
1993), frontal cortex of symptomatic and some pre-symptomatic HD patients (Harms et 
al.1997) and in the striatum of symptomatic and some pre-symptomatic HD patients 
(Jenkins et al. 1998). The levels of lactate correlated with the length of the CAG repeats 
and disease duration. The striatal levels of N-acetyl aspartate (NAA), a putative neuronal 
marker, was also reduced and choline (Ch), a putative glial marker, was elevated. This 
suggested that there was striatal neurodegeneration and gliosis in regions of elevated 
lactate formation and therefore a greater dependence on anaerobic metabolism (Jenkins et 
al. 1993, Davie et al. 1994, Martin et al 1996, Sanchez-Pernaute, 1999). The absence of a 
reduction in the NAA/Ch ratio in pre-symptomatic HD patients in spite of an elevation in 
57lactate levels, suggested that defects in energy metabolism occured before gross neuronal 
loss and before phenotypic expression (Harms et al. 1997). A widespread defect in energy 
metabolism in HD that is not confined to the nervous system has been demonstrated by a 
significant decrease in the phosphocreatine to inorganic phosphate ratio in symptomatic 
HD patient’s skeletal muscle (Koroshetz et al. 1997, Lodi et al. 2000). Muscle ATP/(PCr 
+ inorganic P) was significantly reduced in both symptomatic and pre-symptomatic HD 
patients. During recovery from exercise the maximum rate of ATP production (Vmax) in 
HD skeletal muscle was also reduced. The Vmax deficit divided by age also correlated with 
CAG repeat length. These results suggest that 
31P MRS of HD muscle may be utilised as a 
surrogate marker to study disease progression and response to therapy (Lodi et al. 2000). 
1H NMR spectroscopy of R6/2 mice brains has demonstrated a large reduction in NAA 
levels commencing at 6 weeks of age coincident with the onset of symptoms and the 
presence of intranuclear inclusions but in the absence of neuronal death (Jenkins et al. 
2000). Further studies using the R6/2 mouse demonstrated that dietary supplementation 
with creatine enhanced brain creatine levels and reduced the reduction in NAA with time 
(Ferrante et al. 2000). Chronic systemic administration of 3-nitropropionic acid (3-NP), 
an irreversible inhibitor of succinate dehydrogenase (SDH) or complex II, reproduces 
most of the motor, cognitive and histopathological features of HD in primates, rodents 
and humans (Chyi et al 1999). Serial 
1H-NMR spectroscopy in 3-NP treated baboons 
(Dautry et al 1999) demonstrated a region-selective increase in lactate and progressive 
decrease in NAA, creatine and choline in the striatum in association with the formation of 
a lesion in the dorsolateral putamen on T2-weighted MRI. The selective decrease in NAA 
and creatine in the striatum suggested that there was preferential vulnerability of the 
striatum to impairment of mitochondrial function by 3-NP. It is postulated that the 
impairment of mitochondrial function in HD, especially complex II, may therefore cause 
selective neuronal loss within the basal ganglia in HD patients.
581.10.5. Mitochondrial respiratory chain function in HD tissues
The major studies of oxidative phosphorylation in HD are shown in Table 1.2. The more 
recent studies have demonstrated a consistent defect in mitochondrial complex II/III 
activity and to a lesser extent complex IV activity in regions associated with significant 
neurodegeneration. The abnormalities found in HD lymphoblasts and muscle suggested 
that a widespread peripheral, as well as CNS, mitochondrial respiratory chain defect 
occurs in HD.
Respiratory chain defect Authors
↓ complex II Stahl et al. 1974, Butterworth, 1975
↓ caudate cytochrome oxidase (COX) and 
cytochrome aa3 (complex IV subunit)
Brennan et al. 1985
↓ caudate complex II/III Mann et al. 1990
↓ complex I in platelet mitochondria Parker et al. 1990
↓ caudate complex II/III and IV Gu et al. 1996, Tabrizi et al. 1999
↓ caudate and putamen complex II/III and 
putamen complex IV
Browne et al. 1997
↓ skeletal muscle complex I Arenas et al. 1998
↑ apoptosis with cyanide (complex IV 
inhibitor) in HD lymphoblasts
Sawa et al. 1999
Table 1.2. The major studies of oxidative phosphorylation in HD
1.10.6. 3-nitropropionic acid (3-NP) and malonate: mitochondrial inhibitors
3-NP is a widely distributed plant and fungal neurotoxin that causes damage to the basal 
ganglia, hippocampus, spinal tracts and peripheral nerves in animals (Alexi et al. 1998). 
Reports from Northern China have suggested that 3-NP caused putaminal necrosis and 
delayed dystonia in children who have eaten mildewed sugar cane (Ludolph et al. 1991). 
59The accidental ingestion of 3-NP in humans caused nausea, vomiting, encephalopathy, 
coma and, if the patient survived, chorea and dystonia in the context of basal ganglia 
degeneration (Ludolph et al. 1991).
The intrastriatal administration of 3-NP to rats caused neuronal loss in the striatum (Beal 
et al. 1993a). This neuronal loss was ameliorated by decortication of the rats and 
suggested that the glutaminergic input from the corticostriatal pathway may be required to 
cause excitotoxic damage in 3-NP-mediated cell death (Beal et al. 1993a). NMDA 
receptor antagonists, such as MK-801, also block the toxic effects of 3-NP indicating that 
mitochondrial respiratory chain dysfunction and impaired  energy metabolism may 
predispose to excitotoxic damage (Beal et al. 1993b). Malonate has also been injected 
intrastriatally into rats to produce similar but milder lesions than were seen with 3-NP. 
These lesions were also reduced by glutamate antagonists suggesting an excitotoxic 
mechanism (Greene et al. 1995). 
The chronic systemic administration of 3-NP in rats produced an animal model displaying 
lesions that closely resembled the neuropathological features of HD with selective loss of 
striatal medium spiny neurons. This suggested that the cell population that was most 
vulnerable in HD was sensitive to energy impairment (Beal et al. 1993a).
The systemic administration of 3-NP to primates caused spontaneous dystonia and 
dyskinesia   accompanied   by   lesions   in   the   caudate   and   putamen   on   MRI.   The 
histopathology was similar to HD with depletion of calbindin-positive neurons, gliosis, 
sparing of NADPH-diaphorase neurons, and growth-related proliferative changes in 
dendrites of spiny neurons (Brouillet et al. 1995).
60The addition of 3-NP to neuronal cell cultures resulted in a dose-dependent increase in 
neuronal death after 48 hours. Some neurons underwent rapid necrotic cell death while 
others exhibited a slow apoptotic cell death over 48 hours. The rapid necrosis was 
inhibited by MK-801, an allosteric inhibitor of the NMDA receptors, whereas the delayed 
mechanism was not inhibited (Pang et al. 1997) suggesting that 3-NP induced cell death 
was mediated by both excitotoxic and non-excitotoxic mechanisms.
1.10.7. Mitochondrial dysfunction and the R6/2 mouse
The R6/2 mouse exhibited progressive neurological disease from 2 months of age and 
both the light microscopic and ultrastructural pathology were very similar to those seen in 
HD brain. These neuropathological features occur approximately 4 weeks prior to a 
progressive movement disorder and muscle wasting, and 10 weeks before neuronal cell 
death in selected brain regions. This suggested that, in this model at least, neuronal 
dysfunction is responsible for the initial phenotype rather than cell death. A reduction in 
complex IV in the striatum and cerebral cortex of 12 week old R6/2 mice and a reduction 
in aconitase in the striatum have been described (Tabrizi et al. 2000). These changes were 
associated with increased immunostaining for inducible nitric oxide synthase (iNOS) and 
nitrotyrosine (a marker of increased peroxynitrate generation) in the mouse brains 
(Tabrizi et al. 2000). These results suggested that complex IV deficiency and elevated 
nitric oxide and superoxide radical generation precede neuronal death in the R6/2 mouse 
and may have contributed to subsequent neurodegeneration. An increase in the lesion size 
produced by 3-NP in the R6/2 mice and increased striatal 3,4-dihydroxybenzoic acid (a 
marker of ROS) also support a role for mitochondrial dysfunction and free radical damage 
in the R6/2 model (Bogdanov et al. 1998).
611.10.8. Mitochondrial respiratory chain dysfunction in cell models of HD
There have been four studies investigating mitochondrial respiratory chain activities in N-
terminal htt cell models (Table 1.3). The first, by Wyttenbach et al. (2001), did not find 
any reduction in respiratory chain activities in an inducible PC12 “Tet-ON” cell model 
expressing exon 1 of htt with 21 and 72 CAGs for 18 hours. The MT clones did not 
demonstrate excess cell death at this time point but were found to have inclusions in 13% 
of cells. These findings were in contrast to Solans et al (2006) who described a reduced 
complex II/III:CS ratio, but not complex IV:CS ratio, 4-6 hours following induction of 
exon 1 of htt (90aa with respect to 21 CAGs) containing 101 CAGs in yeast. Aggregates 
formed in 50% of the cells 2 hours post-induction. The mitochondrial morphology and 
distribution were altered by the aggregates. The third model by Fukui et al. (2007) was a 
mifeprostone-inducible model in human osteosarcoma 143B cells which expressed 25 or 
103Q in exon 1 of htt. MT clones demonstrated a reduced complex II/III:CS ratio and 
reduced isolated complex III:CS ratio at day 3 post-induction. An increase in complex 
IV:CS ratio was also observed and complex I activity was not measured. The authors 
subsequently established a link between MT htt aggregation, reduced complex III activity, 
increased complex IV activity and reduced chymotrypsin-like activity of the proteasome, 
independently of free radical and ATP levels. They also found that complex III inhibitors, 
antimycin A (AA) and myxothiazol, selectively promoted the accumulation of htt 
aggregates. Inhibitors of other components of the respiratory chain did not have 
significant effects on the formation of htt aggregates and therefore the process was 
independent of the reduction in ATP. The fourth model used rat primary striatal cultures 
constitutively expressing the first 171aa of htt with 19Q or 82Q from a lentiviral vector 
(Benchoua et al. 2006). The authors described a reduction in complex II specific activity 
(corrected for protein) in the MT clones associated with a reduction in complex II levels 
62on Western blots by 6 weeks post-transfection. Cell death at 8 weeks was prevented by 
overexpression of complex II in the MT clones. Other complex activities were not 
investigated. The authors also described a downregulation of subunits of complex II in 
HD post-mortem striatum.  These studies are summarised in Table 1.3. These models 
suggested that a reduction in complex II/III activity is a consistent abnormality following 
early expression of highly truncated and expanded MT htt (exon 1 with 82-103Q). The 
cell model by Wyttenbach et al. (2001) may not have demonstrated any abnormalities of 
mitochondrial function because of the relatively smaller polyQ and short induction time 
compared to the other three models (Table 1.3 and Section 6.4.3. for further discussion).
Study Cell type Induction
PolyQ
(WT/MT)
Htt Time/hrs
Complex CS ratios 
in MT clones
Wyttenbach et al. 
(2001)
PC12 Yes 23/74 Exon 1 18
No difference 
compared to WT
Solans et al 
(2006)
Yeast Yes 25/103 Exon 1 4-6
↓CxII/III
CxIV normal
Fukui et al. 
(2007)
143B Yes 25/103 Exon 1 72
↓CxII/III
↑Cx IV
Benchoua et al. 
(2006)
Primary rat 
striatal
No
(Constitutive)
19/82 171aa 1008
↓CxII (specific 
activity)
Table 1.3. Summary of HD N-terminal cell models and MRC activities
1.10.9. Htt localisation to mitochondria
The direct association of htt with mitochondria was first described by Panov et al. (2002) 
who   demonstrated   by   electron   microscopy   that   N-terminal   MT   htt   localised   to 
mitochondria in the brain of an HD transgenic FL htt mouse model. Subsequently, in SH-
SY5Y and clonal striatal cells established from HdhQ7 (WT) and HdhQ111 (MT) 
63homozygote mouse knock-in embryos, FL htt was present in the purified mitochondrial 
fraction and was associated with the outer membrane of mitochondria (Choo et al. 2004). 
Htt inclusions have been described in association with mitochondria in a rat transgenic 
model of HD (Petrasch-Parwez et al. 2007).  The direct association of MT htt with 
mitochondria may have inhibited complex II/III activities in an N-terminal htt yeast cell 
model of HD (Solans et al. 2006). A further study suggested that MT htt disrupted the 
normal intracellular trafficking and distribution of mitochondria in primary cortical 
neurons (Chang et al. 2005). In the skeletal muscle of desmin-null mice, failure of 
locating mitochondria to the correct position within the cell impaired mitochondrial 
function (Milner et al. 2000). Solans et al. (2006) have proposed that misfolded or 
aggregated htt can disturb the network of actin cytoskeleton, which in turn leads to the 
alteration of mitochondrial distribution and an early reduction in complex II/III function. 
The role of the co-activator PGC-1α in the pathogenesis of HD has provided an exciting 
link   between   abnormalities   in   mitochondrial   biogenesis   and   respiration,   with 
abnormalities in several transcription factors (McGill et al 2006 for review and Section 
1.8.6).
1.10.10. The pathogenic role of free radicals in HD
Mitochondria form the majority of intracellular reactive oxygen species (ROS) which are 
constantly being produced as a byproduct of aerobic metabolism. Complex III and, to a 
lesser extent complex I, are major sites of generation of ROS (Beal et al. 1997). 
Mitochondrial production of free radicals increases when the electron transport chain is 
64inhibited or acquires mutations in mitochondrial DNA (Dykens et al. 1994, Dugan et al. 
1995).  An  adaptive cellular  response to increased  free  radicals   is  to  up-regulate 
components of the anti-oxidant system such as superoxide dismutase (SOD) (Warner et 
al. 2004), catalase and reduced glutathione (GSH) (Bains et al. 1997). When these 
systems become overwhelmed and fail to control macromolecular oxidation, the system 
undergoes oxidative damage. Mitochondrial DNA (mtDNA) is especially susceptible to 
oxidative damage due to its location in the mitochondrial matrix next to the respiratory 
chain and its lack of histones (Browne et al. 1999). The paucity of mtDNA repair 
mechanisms was also suggested to predispose mtDNA to oxidative damage, although 
recent studies have suggested that mtDNA repair mechanisms are present (Larsen et al. 
2005). 
Several mechanisms by which oxidative stress may be produced in HD have been 
proposed.   These  include  cellular   energetic   defects  (section   1.10.4-8),   nitric   oxide 
dysregulation   (section   1.10.11),   excitotoxicity   (section   1.10.11),   an   uncontrolled 
inflammatory response (Simmons et al. 2007), dopamine (Hattori et al. 1998, McLaughlin 
et al. 1998, Petersen et al. (2001) and heavy metal accumulation (Barzokis et al. 1999, 
Hilditch-Maguire et al 2000).
There is evidence in vivo and in vitro in HD of free radical damage to DNA (Butterworth 
et al. 1998, Ferrante et al. 1996, Browne et al. 1997, Alam et al. 2000), lipids (Tellez-
Nagel et al. 1974, Ferrante et al. 1996, Greco et al. 2000, Ferrante et al. 1996, Perez-
Severiano et al. 2000). and proteins (Ferrante et al. 1996, Browne et al. 1997, La Fontaine 
et al. 2000).
65Aconitase is an iron-sulphur (FeS) containing enzyme that is involved in the Kreb’s cycle 
and iron homeostasis. Aconitase activity is especially susceptible to inhibition by O2
×- and 
by the reaction product of O2
×-  with NO
×, peroxynitrate (ONOO
-) (Hausladen, 1994, 
Gardner 1994, Patel 1996). Complexes II and III are also FeS–containing compounds and 
they are also susceptible to inhibition by free radicals. Aconitase deficiency has been 
found in HD caudate (92%), putamen (73%) and cortex (48%) but not cerebellum and this 
deficiency closely followed the pathology in HD (Tabrizi et al. 1999). The pattern of 
aconitase deficiency in HD is therefore consistent with ROS having a role in the 
pathogenesis of the disease.
1.10.11. Excitotoxicity and nitric oxide
Na
+/K
+ATPase and Ca
2+ATPase are very active in neurons and are required to maintain 
the correct ionic gradients and membrane potential. Both of these ionic pumps utilise high 
levels of ATP. Mitochondrial oxidative phosphorylation produces most of the ATP in 
neurons. Impairment of respiratory chain function can cause a failure of maintenance of 
ionic gradients and partial depolarisation of the neuronal membrane. This has been shown 
to lead to a loss of the Mg
2+-dependent block of the NMDA Ca
2+ channel and enable 
ambient levels of glutamate to activate the receptor (Beal 1992, Raymond 2003). This 
leads to elevated intracellular calcium and causes calcium entry into mitochondria which 
is linked with opening of the mitochondrial permeability transition pore and cell death 
(Rizzuto et al. 2001, Petersen et al. 1999). This unifying cellular mechanism, leading to 
apoptosis, has been called the “slow excitotoxic theory” (Albin and Greenamyre 1992, 
Beal 1992). 
66In support of an excitotoxic mechanism in HD, Seong et al (2005) have reported a 
relationship between the number of CAG repeats and mitochondrial ATP production. In 
striatal cells expressing htt, ATP production decreased as CAG repeats increased 
independently of whether the repeat number was in the WT or MT range. The decreased 
ATP/ADP ratio was linked to enhanced calcium influx through NMDA receptors. 
Impaired energy metabolism has been demonstrated to cause reduced ATP production, 
with a concomitant reduced mitochondrial membrane potential and a higher vulnerability 
to NMDA-mediated calcium influx and excitotoxicity (Novelli et al 1998, Fagni et al 
1994). A potentiating effect of MT htt on NMDA receptor activity has been described as 
NMDA-evoked currents and NMDA-mediated calcium transients were significantly 
increased in striatal neurons from YAC72 transgenic mice compared with WT controls 
leading to increased excitotoxicity (Zeron et al 2002 and 2004). Further support for the 
excitotoxic hypothesis comes from evidence that the striatal injection of NMDA agonists, 
such as quinolinic acid, into rats and primates produced lesions that closely followed the 
neurochemical, neuropathological and behavioural changes seen in HD (Hantraye et al. 
1990, Cull-Candy et al. 2001). Levine et al. (1999) have demonstrated increased 
sensitivity to NMDA receptor activation in HD mouse models. Zeron et al. (2001) 
demonstrated increased apoptosis in cell culture systems co-expressing glutamate receptor 
NR1A/NR2B with MT htt. Several components in the intracellular signaling pathways 
involved in excitotoxicity in HD have been found to be modulated by htt (Liu et al. 2000, 
Sun et al. 2001). MT htt may therefore directly increase the sensitivity of NMDA 
receptors   to   background   levels   of   glutamate,   causing   greater   calcium   influx   and 
excitotoxicity. Isolated mitochondria from HD mice demonstrated decreased membrane 
potential, depolarized at lower calcium loads compared with controls (Panov et al 2002) 
and were more sensitive to calcium-induced cytochrome c release (Choo et al 2004). 
These effects could be reproduced by incubating normal mitochondria with MT htt in 
67vitro and further support a role for MT htt inducing cell death by a possible excitotoxic 
mechanism. In spite of the evidence discussed above, there is limited data directly 
demonstrating excitotoxicity in HD apart from a study on HD post-mortem brain which 
showed that striatal neurons with high levels of NMDA receptor expression had increased 
degeneration (Albin et al. 1990).
Elevated intracellular calcium levels also cause an increase in activation of nitric oxide 
synthase and generation of nitric oxide (NO) and peroxynitrite. Tabrizi et al. (2000) 
demonstrated increased levels of inducible NOS immunostaining in 12 week old R6/2 
mice (Section 1.10.7). The experimental data (Deckel 2001 for review) in HD patients 
and HD mice suggest that there is an overall reduction, and not an increase, in NOS 
activity and NO production in HD. Increased NOS activity in localised regions could still 
be occurring in the HD brain with a subsequent reduction following the death of neurons. 
Shin et al (2005) have further suggested a role for the impairment of glial uptake of 
glutamate in causing excitotoxicity in HD.
In summary, the slow progressive nature of HD could be explained by an excitotoxic 
mechanism involving a cycle of energy impairment and oxidative damage initiated by 
MT htt. The evidence for an excitotoxic mechanism in HD is mostly indirect and a 
definitve study demonstrating the proposed sequence of excitotoxic events has not been 
demonstrated.
1.10.12. Weight loss and HD
It is has been a clinically observed but unexplained observation that HD patients suffer 
extreme weight loss in spite of an adequate calorific intake. Further studies have found 
that a higher BMI at presentation is associated with slower disease progression (Myers et 
68al. 1991). Weight loss was initially felt to be related to the severity of chorea but a 
subsequent study did not find a relationship between the severity of chorea and energy 
expenditure   (Pratley   et   al.   2000).   Patient’s   sedentary   energy   expenditure   was 
proportionately related to the severity of the movement disorder, but total energy 
expenditure was the same as controls because HD patients tended not to take part in as 
much voluntary physical activity. It therefore remains uncertain whether the weight loss 
observed in HD is due to a generalised metabolic defect or other causes as yet to be 
elucidated.
1.10.13. Treatment of mitochondrial dysfunction in HD
Increasing brain levels of ubiquinone (co-enzyme Q10) may ameliorate some of the 
energetic defects that have been demonstrated and theoretically delay neurodegeneration 
in HD. Ubiquinone has been demonstrated to protect cultured neurons against glutamate 
toxicity (Favit et al. 1992). Ubiquinone has anti-oxidant properties (Favit et al. 1992) and 
protects against malonate and 3-NP-induced striatal lesions in rats (Beal et al. 1994). The 
oral administration of 600mg/day of ubiquinone for 30 months significantly reduced 
occipital cortex lactate levels as measured by 
1H MRS in 18 symptomatic HD patients. 
The levels of lactate returned to pre-treatment values when ubiquinone was stopped and 
therefore this supported a treatment-related effect (Koroshetz et al. 1997). A randomised 
placebo-controlled trial of 300mg twice daily of ubiquinone and 200mg three times daily 
of remacemide (a noncompetitive N-Methyl-D-Aspartate (NMDA) receptor antagonist) 
has been performed (Huntington’s Disease Study Group 2001). The primary measure of 
efficacy was the change in total functional capacity (TFC) of the UHDRS between 
baseline and following 30 months of treatment or placebo. Neither drug significantly 
altered the decline in TFC. There was a trend towards slower disease progression (13% 
69decline in TFC) with ubiquinone but remacemide had no clinical benefit. Unfortunately, 
the trial was designed to identify an approximate 35-40% slowing in functional decline 
and so smaller benefits would have been missed (Huntington’s Disease Study Group 
2001). A transgenic mouse model study with the R6/2 and N171-82Q mice, has 
demonstrated a significant benefit from remacemide and ubiquinone on the phenotype 
and pathology of the mice when treatment was commenced on day 21 following birth 
(Ferrante et al. 2002). There was an approximately 32 and 17% increase in survival in the 
R6/2 and N171-82Q mice respectively. Treatment of HD patients may therefore need to 
occur sooner and for longer before a clinical effect can be observed. 
Creatine has been found to have a protective effect in the R6/2 mouse. Dietary creatine 
improved survival, slowed the development of brain atrophy and delayed degeneration of 
striatal neurons and the formation of intranuclear inclusions. The onset of diabetes was 
also delayed. NMR in these mice demonstrated delayed decreases in NAA and elevated 
brain creatine concentrations (Matthews et al. 1998, Ferrante et al. 2000). The mechanism 
causing improvement may involve increasing intracellular energy reserves in order to 
clear misfolded and/or aggregated MT htt. Subsequently, Tabrizi et al (2005) have 
described clinical benefit to some HD patients taking 10g creatine per day. The results of 
the CREST-HD trial (a large placebo-controlled double-blind study of 8g/day creatine in 
HD) is awaited.
In summary, there is substantial evidence from imaging, post-mortem, animal and in vitro 
studies of a metabolic defect in association with MT htt expression and a reduction in 
mitochondrial respiratory chain activity. The mechanism by which this occurs may 
involve direct inhibition of the mitochondria by MT htt or by an indirect effect from other 
pathological  processes  such   as alter   mitochondrial  biogenesis,   excess  free  radical 
production and excitotoxicity. The precise molecular mechanisms involved in causing the 
70metabolic disturbance in HD and the timing of this disturbance in relationship to cell 
dysfunction and death remain undetermined.
1.11. The molecular pathogenesis of HD: The polyglutamine diseases
The polyglutamine diseases include HD, spinal bulbar muscular atrophy (SBMA) 
(Lieberman and Fischbeck 2000, La Spada et al 1991), dentatorubralpallidoluysian 
atrophy (DRPLA) (Tsuji 2000) and seven of the spinocerebellar ataxias (SCAs). They are 
characterised by CAG triplet repeat expansions and typically cause a progressive 
neurological phenotype with onset in middle age (Table 1.4). All the polyglutamine 
diseases are autosomal dominant except for SBMA which is X-linked, and they all 
demonstrate anticipation. There is heterogeneity in the clinical phenotype and the 
molecular pathogenesis of these diseases but there are also many similar features which 
have given insights into unifying pathogenic mechanisms in the polyglutamine diseases.
All polyglutamine diseases demonstrate an inverse relationship between age of clinical 
onset and the CAG repeat length (Gusella and MacDonald 2000). The correlation is not 
absolute, and for any repeat length there is a wide variation in the age of onset suggesting 
other epigenetic and environmental factors are involved (MacDonald et al. 1999, 
Georgiou et al. 1999).
71Table 1.4. The Polyglutamine diseases. N=nuclear, C=cytoplasmic. CS Corpus Striatum. 
SN Substantia Nigra. STN Subthalamic Nucleus. AHC Anterior Horn Cell. BSMN 
brainstem motor nuclei. DRG Dorsal Root Ganglia. GP Globus Pallidus. CTX Cerebral 
Cortex. CBL cerebellum THL thalamus.
Three of the ten polyglutamine diseases have protein products of known function. The 
androgen receptor in SBMA, the α1A voltage-dependent calcium channel (CACNA1A) in 
Disease Protein Normal 
Repeats
Mutant 
Repeats
Clinical Features  Neuropathology  Inclusions
HD Huntingtin 6-39 36->200 Chorea, dementia CS, CTX N/C
SCA1 Ataxin 1 6-44 39-83 Ataxia, 
ophthalmoplegia, 
pyramidal signs
CBL, BSMN N
SCA2 Ataxin 2 13-33 32->200 Ataxia, 
ophthalmoplegia, 
neuropathy
CBL, BSMN N/C
SCA3 Ataxin 3 3-40 54-89 Ataxia, extra-
pyramidal, 
amyotrophy
CBL, AHC, SN, 
STN, GP, BSMN
N
SCA6 CACNA1A 4-19 20-33 Ataxia CBL N/C
SCA7 Ataxin 7 4-35 37-306 Ataxia and 
macular 
dystrophy
CBL, retina N
SCA12 PPP2R2B <29 66-78 Tremor with 
ataxia
Unknown Unknown
SCA17 TBP 25-44 43-63 Ataxia, 
psychiatric, extra-
pyramidal
CS, CTX, THL 
and CBL
N
SBMA Androgen 
Receptor
9-33 38-65 Amyotrophy, 
hypogonadism
AHC, BSMN, 
DRG
N
DRPLA Atrophin 1 3-35 49-88 Ataxia, chorea, 
epilepsy, 
dementia
CS, CBL, CTX, 
STN, SN,
N
72SCA6 and TATA-binding protein (TBP) in SCA 17. The protein products of the other 
polyglutamine diseases have unknown function and apart from the CAG repeat sequence 
have unrelated sequences.
The polyglutamine proteins are expressed in a wide variety of neuronal and peripheral 
tissues eventhough the pathology is often largely confined to the CNS. The protein 
products localise to the nucleus and cytoplasm, although TBP is found exclusively in the 
nucleus and CACNA1A and ataxin 2 are mainly found in the cytoplasm. The major sites 
of neuronal loss are summarised in Table 1.4. In common with HD, larger repeat numbers 
are associated with more widespread and overlapping neurodegeneration which suggests 
common pathogenic mechanisms. Ubiquitinated nuclear polyglutamine aggregates have 
been described in all polyglutamine diseases. The aggregates in HD, DRPLA, SBMA, 
SCA 2 and SCA 7 are associated with possible cleavage products but not in SCA 1 and 3 
(Servadio et al. 1995 and Perez et al. 1999). SCA 17 can be phenotypically similar to HD 
with patients developing dementia, and involuntary movements, including chorea and 
dystonia  (Wild   et   al.   2007   for   review   of   HD  phenocopies).   The  association   of 
transcriptional changes related to TATA-binding protein (TBP) in HD and the CAG 
expansion   within   TBP   in   SCA   17   has   suggested   a   possible   molecular   link   to 
transcriptional dysregulation in neurodegeneration, as well as the clinical link with chorea 
and dementia. (Schaffer et al. 2004, for a review of polyglutamine diseases, see Chapter 
14 in “Huntington’s Disease” eds. Bates, Harper, Jones 3
rd Ed).
1.12. The molecular pathogenesis of HD: “loss” or “gain” of htt function
73HD is a dominantly inherited disease and haploinsufficiency or a “dominant negative” 
effect would result in a loss of function in WT htt (reviewed by Cattaneo et al. 2001). A 
more probable third mechanism suggests that a toxic gain of function of MT htt causes 
the majority or neuronal dysfunction and death in HD.
Haploinsufficiency occurs when a single copy of a gene produces insufficient protein to 
enable cellular function or survival. This appears unlikely in HD, as there are reports of 
loss of the relevant part of chromosome 4p without the development of HD (Ambrose et 
al. 1994). Nullizygous WT HD mice are embryonic lethal but heterozygous WT HD mice 
do not show any signs of HD which suggests that haploinsufficiency does not a 
significant contribution on neurodegeneration in HD.
A “dominant negative” effect occurs when a MT protein affects the normal function of 
the WT protein in a deleterious manner for the cell. The sequestration of WT htt into 
aggregates resulting in a reduction in WT htt and its physiological effects may occur 
although there is little experimental evidence for this happening  in vitro  or  in vivo 
(Section 1.7.5). BDNF is an important neuronal survival factor generated in the cortical 
neurons and released into the striatum (Canals et al. 2001). Zuccato et al. (2001) 
demonstrated up-regulation of brain-derived neurotrophic factor (BDNF) in cortical 
neurons mediated by WT htt. When FL MT htt was expressed in  conditionally 
immortalized CNS cell lines, there was reduced BDNF expression. A mouse model 
carrying a transgene of FL MT htt (72CAGs) also demonstrated a 50% reduction in 
cortical BDNF and similar results were observed in HD post-mortem brain (Zuccato et al. 
2001 and Section 1.8.5.). The expression of MT htt therefore appears to inhibit the pro-
survival effects of WT htt on BDNF expression.
74Most current evidence suggests a toxic gain of function for MT htt based on evidence in 
transgenic mice and cellular models that polyglutamine stretches alone (Ikeda et al. 
1996), with N-terminal MT htt (Mangiarini et al. 1996) or in an unrelated protein 
(Ordway et al. 1997) cause neurodegeneration. This suggests that the protein context of 
MT polyQ may alter the specific sites and rate of neurodegeneration but loss of function 
of   the  protein   context  of   MT  polyQ  is   not  the  main   determinant   of   triggering 
neurodegeneration.
The possibility remains that a combination of haploinsufficiency, a dominant negative 
effect and a toxic gain of function of htt, may contribute to neuronal cell loss in HD.
1.13. Cellular models of Huntington’s Disease
There have been two main types of cellular models of Huntington’s disease. The first, and 
more commonly used, are transiently transfected cell lines. The advantages of these 
models are that the cells have not been exposed to previous ectopic protein and the 
process of cloning a stably transfected cell line can be avoided. Transient transfections 
also enable the use of primary cultures and enable high levels of protein expression to be 
achieved. There is often a lack of consistency in the proportion of the cells transfected 
and variable levels of expression. This makes controlling for expression difficult when 
whole populations of cells are investigated.
The second type of model involves the stable transfection of htt constructs. This has the 
advantage that prolonged exposure of htt can be investigated and repeated transfections 
are not needed. There is also greater predictability of construct expression levels. 
Inducible stable transfections add another level of control of expression but require an 
75inducing agent which can often be toxic. Constitutive stable transfections do not require 
an inducing agent but cells are continually exposed to construct expression throughout 
cloning and passage which may select against those cells most vulnerable to the construct. 
Therefore there is no ideal cell model and the type of model chosen depends on the issue 
being investigated.
1.13.1. Stably transfected cell models
Table 1.5 A and B. summarises the known stably-transfected (A) inducible and (B) 
constitutively expressing htt cell models.
Inducible HD cell models
The first stably transfected cell model of HD was published by Lunkes and Mandel 
(1998) using a mouse/rat neuroblastoma/glioma hybrid cell line (NG108-15). It was an 
inducible cell model expressing 15, 73 and 116 CAG repeats in FL, N-terminal 502 aa 
and 80 aa. human htt (size of htt excluding CAG repeats). The model used a tetracycline-
inducible promoter but the authors did not comment on whether they saw background 
breakthrough expression prior to induction. The authors demonstrated the formation of 
nuclear and cytoplasmic inclusions which formed faster with greater truncation of htt and 
increased CAG repeat length. They also demonstrated a positive correlation between 
apoptosis and inclusion load and cell death by day 6 post-induction with 80aa, day 12 
with 502 aa. and day 16 with FL htt. The formation of an approximately 98kDa fragment 
by day 10 following induction was consistent with 
Table 1.5A
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77cleavage at the proposed caspase 3 site. This study confirmed that truncated htt and longer 
polyQ form inclusions more rapidly and that the appearance of inclusions coincided with 
78cell death but did not prove that the inclusions were the cause of cell death.
The second stably transfected model used an inducible Ecdysone/pIND system in a 
mouse N2a cell line with exon 1 of human htt containing 16, 60 or 150 CAG repeats 
(Wang et al 1999, Jana et al. 2001). Following two days induction with ponasterone A 
(1µM) and simultaneous differentiation with dbcAMP, approximately 7% of 60Q cells 
and 85% of 150Q cells demonstrated cytoplasmic aggregates. The rate of aggregate 
formation and cell death was proportional to the length of the CAG repeat. The 
proteasomal 20S core catalytic component was redistributed to polyglutamine-containing 
aggregates in 65% of 150 CAG cells. The proteasomal inhibitor, lactacystin, dramatically 
increased the rate of aggregate formation with 60 glutamine repeats, but had very little 
influence on aggregate formation with 150 glutamine repeats. WT and MT htt were 
degraded by the proteasome, but the rate of degradation was inversely proportional to the 
CAG repeat length. The shift of the proteasomal components to the aggregates, as well as 
the comparatively slower degradation of htt with longer polyglutamines, decreased the 
availability of the proteasome for degrading other key target proteins, such as p53. This 
altered proteasomal function was associated with disrupted mitochondrial membrane 
potential, released cytochrome c from mitochondria into the cytosol and activated 
caspase-9- and caspase-3-like proteases. These results suggested that the impaired 
proteasomal function was an important step in the pathogenesis of HD. Wang et al. 
(1999) used the same model as Jana et al (2001) and found increased cell death in 60 and 
150Q cells after 4 days induction with evidence of apoptosis and caspase activation 
suggesting that apoptosis may occur in HD.
The third stably transfected inducible cell model was in HEK 293 cells using the 
Tet-“off” system and CMV promotor (Waelter et al. 2001a). The authors’ constructs 
contained human htt exon 1 with 20, 51 or 83Q. The 51Q and 83Q clones formed 
79aggresome-like perinuclear inclusions following withdrawal of doxycycline for 3 days. 
These structures contained aggregated, ubiquitinated htt exon 1 protein. Inclusion bodies 
with truncated htt protein were detected by anti-HD1 antibody (raised to the first 222 aa. 
of htt) and formed at centrosomes. The inhibition of proteasome activity by lactacystin 
resulted in a two-fold increase in the amount of ubiquitinated, SDS-resistant aggregates, 
indicating that inclusion bodies accumulated when the capacity of the ubiquitin–
proteasome system to degrade aggregation-prone htt protein was exhausted or inhibited. 
Immunofluorescence and electron microscopy with immunogold labeling revealed that 
the 20S, 19S, and 11S subunits of the 26S proteasome, the molecular chaperones 
BiP/GRP78, Hsp70, and Hsp40, as well as the RNA-binding protein TIA-1, the potential 
chaperone 14–3-3, and α-synuclein colocalised with the perinuclear inclusions (Waelter et 
al. 2001a). Inclusion body formation was associated with cell toxicity and dramatic 
ultrastructural changes such as indentations and disruption of the nuclear envelope. 
Concentrations of mitochondria around the inclusions and cytoplasmic vacuolation were 
also observed.
These findings supported the hypothesis that the ATP-dependent ubiquitin–proteasome 
system is involved in the accumulation of htt inclusions and other proteins and that the 
accumulations form in a perinuclear localisation similar to collections of mutant cystic 
fibrosis transmembrane conductance regulator (CFTR) protein observed in cystic fibrosis. 
Wigley et al. (1999) have demonstrated that the centrosome, or a closely associated 
structure, may play a functional role in the degradation of misfolded proteins in 
mammalian cells. Using immunofluorescence microscopy, they identified a specific 
structure in the centrosomal region in which components of the 26S proteasome, as well 
as ubiquitin and heat shock proteins, were concentrated under basal conditions. These 
perinuclear collections have been named “aggresomes” (Johnston et al.1998) and may be 
80part of a generalised response of the cell following failure of misfolded/damaged proteins.
Wyttenbach et al (2001) published the fourth inducible htt cell model using differentiated 
and mitotic PC12 cells with Tet-“On” system expressing exon 1 of human htt containing 
23,43, 53 and 74Q. Components of the UPS and HSP40/70 were described in association 
with htt inclusions which formed in the nucleus in differentiated cells. Using the TUNEL 
method to assess apoptosis, they found 7% cell death in the 53Q and 15-20% cell death in 
74Q after 6 days post-induction. Cell death was reduced with the broad caspase inhibitor 
zVAD-fmk in mitotic cells in spite of similar levels of inclusions. The 53 and 74Q clones 
demonstrated greater cell loss at day 6 post-differentiation than in mitotic cells. There was 
also loss of neurite outgrowth in 74Q cells post-differentiation. There was no effect of 
MT htt on mitochondrial respiratory chain activities, but there was impaired CRE 
mediated transcription after 18 hours of induction.  
Sipione et al. (2002) and Seo et al. (2007) used a primary rat striatal Tet”On” cell model 
expressing 548aa of htt with 26,67, 105 and 118Q. Sipione et al. (2002) found no htt 
aggregates   or   cell   death   by   36   hours   post-induction.   Gene   expression   profiles 
demonstrated changes in cell signalling, transcription, lipid metabolism and vesicle 
trafficking genes within 12 hours of MT htt induction. The findings of Seo et al. (2007) 
using the same model are described in Section 1.6.3. 
Sugars et al. (2004) developed a PC12 Tet”On” cell model expressing exon 1 or FL htt 
with 17/136Q which developed nuclear and cytoplasmic htt inclusions. The main findings 
were of a down regulation of CRE and RARE (retinoic acid responsive element)-
regulated genes and up regulation of NF-ĸB pathways in the MT exon 1 htt model and a 
down-regulation of the CRE pathway in the FL model. There was also a reduction in htt 
81inclusions and cell death with co-expression of CREB in the models. This study 
confirmed the role of transcriptional dysregulation in HD and suggested that reversal of 
the transcriptional abnormalities is a potential therapeutic strategy. 
The models developed by Benchoua et al. (2006), Solans et al (2006), and Fukui et al. 
(2007) investigated the role of mitochondrial dysfunction in HD cell models and are 
discussed in detail in Section 1.10.8.
Constitutive HD cell models
The first published stably transfected constitutive HD cell model used the rat PC12 cell 
line with a CMV promoter, producing constitutive expression of human htt exon 1, and 
either 20 or 150 CAGs (Li, S.H. et al. 1999). One of the main findings was that the 20Q 
cells expressed htt diffusely in the cytoplasm in contrast to the 150Q cells which 
demonstrated   diffuse   staining   in   the   nucleus.   Less   than   3%   of   the   150Q   cells 
demonstrated nuclear aggregates and the authors suggested this may have been due to cell 
division preventing aggregate formation. The 150Q model also demonstrated poor neurite 
development in response differentiation with nerve growth factor (NGF) and was more 
susceptible to staurosporine-induced apoptosis than the 20Q model. Differential display 
PCR and expression studies showed that cells expressing 150Q had altered expression of 
multiple genes including a reduction in TrkA/NGF and p75NTR (subunits of the NGF 
receptor) and Hap-1. This suggested that the lack of response to NGF may have been due 
to reduced NGF receptor expression and impaired intra-neuronal transport which has been 
linked with Hap-1 (Section 1.9.). Their conclusion was that nuclear MT htt induced 
multiple cellular defects by interfering with gene expression even in the absence of 
aggregation (Li, S-H. et al 1999).
82Chun et al (2001 and 2002) characterised a constitutively expressing 63aa htt model with 
18/82Q in SH-SY5Y cells. The authors described that tissue transglutaminase was not 
involved in htt aggregate formation and that caspase 3 activity was increased but not 
associated with htt aggregates.
Benchoua et al. (2006) described a constitutive cell model which investigated the role of 
mitochondrial function in HD and is described in more detail in Section 1.10.8.
Ye et al. (2008) characterised a differentiated N2a cell model constitutively expressing 
exon 1 htt with 20/150Q. 150Q cells had decreased viability and were more susceptible to 
apoptotic stimulation in the absence of inclusion formation. The 150Q cells also had poor 
neuritic out growth following differentiation. 
1.13.2. Transiently transfected cell models
Several transiently-transfected models have demonstrated time and CAG repeat length-
dependent formation of htt inclusions (Cooper et al. 1998, Saudou et al. 1998, Kim et al. 
1999). They have also demonstrated that nuclear localisation of MT htt caused an 
increase in cell toxicity (Saudou et al. 1998 Cooper et al. 1998), increased susceptibility 
to apoptosis (Cooper et al. 1998, Kim et al. 1999) and activation of caspase 8 (Sanchez et 
al. 1999). The protective effect of WT htt (Ho et al 2001) and caspase inhibitors (Kim et 
al 1999, Wellington et al. 2000) on cell death has also been described. The co-expression 
of the NMDA glutamate receptor subtype NR2B with N-terminal MT htt (138Q in exon 
1) in HEK 293 cells produced greater cell death in response to NMDA (Zeron et al. 2001) 
suggesting a possible excitotoxic mechanism for cell death in HD.
831.14. The investigation of the molecular pathogenesis of HD
There are several important issues in the molecular pathogenesis of HD that remain 
poorly understood. Some of these issues, and the questions that still surround them, will 
be summarised as they formed the main areas of investigation in the current thesis.
1.14.1. CAG repeat size
The size of the CAG repeat in HD is associated with an earlier onset of disease, more 
severe   neuropathological   findings,   imaging   abnormalities   and   clinical   phenotype 
(Brinkman et al 1997, Penney et al. 1997, Jenkins et al. 1998). The CAG repeat length 
accounts for between 47-73% of the variance in the age of onset of symptoms (Brinkman 
et al 1997, Squitieri et al. 2000). There is less evidence for a relationship between the rate 
of progression of disease and psychiatric features, although psychiatric features correlate 
within each affected family (Brandt et al. 1996, Weigell-Weber et al. 1996, Tsuang, D. et 
al. 1998). Foroud et al. (1995), Siemers et al (1996) and Jason et al (1997) have found a 
correlation between CAG repeat length with subtle cognitive and motor dysfunction in 
presymptomatic HD patients suggesting that CAG repeat length may determine early 
clinical features before gross motor symptoms develop. It is well established that the 
greater the number of CAG repeats, the more likely MT htt is to aggregate in non-cell and 
cell-based in vitro models and in transgenic mouse models (Section 1.7). The molecular 
basis for the pathogenic threshold of CAG repeat number and the molecular effects of a 
pathological number of CAG repeats on the processing and function of MT htt remain are 
less well understood.
841.14.2. Full length versus N-terminal htt: processing of htt
One of the most important aspects of the molecular pathogenesis of HD is the potential 
role of processing of FL-htt to a toxic N-terminal fragment (Section 1.6). Htt inclusions 
have only been found to contain N-terminal htt epitopes in mouse models, including the 
R6/2 mouse (Mangiarini et al. 1996), and in HD post-mortem brain (DiFiglia et al. 1997). 
There is some evidence that the UPS, caspases/calpains as well as other proteases are 
involved in processing htt to an N-terminal fragment (Section 1.6.). The exact size of the 
toxic N-terminal fragment in HD remains uncertain. WT htt may also undergo N-terminal 
truncation which raises the questions as to how the effects of N terminal WT and MT htt 
differ, are the N-terminal fragments identical in length except for the CAG repeats and is 
the N-terminal MT fragment the toxic molecule in HD?
1.14.3. Sub-cellular localisation of htt and htt aggregates
The sub-cellular localisation of WT and MT htt has been described predominantly in the 
cytoplasm but also in the nucleus and in a perinuclear distribution (Section 1.5.3.). MT htt 
N-terminal aggregates form mostly in the neuropil and cytoplasm, and less often in the 
nucleus in HD brain (Section 1.7.1), in comparison to HD mice, such as the R6/2, and 
inducible cell models of HD (Table 1.5), in which nuclear aggregates are common 
(Section 1.7.3). The transfer of N-terminal or FL-MT htt into the nucleus may represent 
an important step in the development of MT htt toxicity. The relative contribution of 
nuclear and cytoplasmic htt aggregates to the pathogenesis of HD is unknown (Martindale 
et al 1998, Hackam et al. 1999). In cell culture models, nuclear
 localization of htt is 
associated with greater toxicity (Peters et al. 1999, Saudou et al. 1998). MT htt localised 
to the nucleus may disrupt the function and/or transport of transcription factors
 (Nucifora 
85et al. 2001) and alter the normal transcriptional profile of neurons (Luthi-Carter et al. 
2000, and 2002). In addition, in most other polyglutamine diseases, the predominant 
pathological finding is of MT protein and inclusions only in the nucleus, suggesting that 
nuclear localisation may be important in the pathogenesis of triplet repeat disorders 
(Section 1.11 and Gusella et al. 2000). Schilling et al. (2004) described a transgenic 
mouse model with the first 171 aa. of htt containing 82 CAG repeats with a nuclear 
localising signal (NLS). MT htt was only detected in the nucleus and the neurological 
phenotype of the mouse was similar to a mouse model without the NLS. This suggested 
that cytoplasmic MT htt was not necessary for toxicity. Several in vitro cell models of HD 
have demonstrated that by blocking the nuclear accumulation of MT htt by fusing it with 
a nuclear
  export signal (NES), neurotoxicity is significantly reduced which further 
supports the importance of subcellular location of MT htt for toxicity (Saudou et al. 1998, 
Peters et al. 1999, Benn et al. 2005). Subsequently, Steffan et al. (2004) and Rockabrand 
et al. (2007) demonstrated that the first 17aa of htt act as a strong cytoplasmic retention 
signal, controlled the mitochondrial localisation of htt and promoted the association of htt 
with the endoplasmic reticulum (ER) and Golgi. It is postulated that loss of the nuclear 
export signal (NES) function of the first 17aa. by an expanded polyglutamine tract may 
cause accumulation of nuclear htt and toxicity.
In contrast, nuclear localisation of MT htt may be an epiphenomena of expanded CAG 
repeats and not necessarily the main toxic event in HD. Cytoplasmic aggregates are 
described in other polyglutamines disease such as micro-aggregates in SCA2 (Huynh et 
al. 2002) and equal numbers of nuclear and cytoplasmic aggregates in SCA6 (Ishikawa et 
al 2001). Several studies have demonstrated that
 cytoplasmic MT htt can inhibit synaptic 
function and glutamate
 release, disrupt the axonal transport of protein and vesicles, and 
impair mitochondrial and proteasome function (Li, J.Y. et al 2003, Li, H et al 2003, 
86Bence et al. 2001, and Petrasch-Parwez et al. 2007). The relative roles of cytoplasmic 
compared to nuclear toxicity of MT htt therefore remains to be fully investigated.
1.14.4. Energetic defects in HD
Energetic defects have been described in HD, before the gene was cloned, using 
18F-
deoxyglucose PET (Section 1.10.4). Subsequently, defects in mitochondrial respiratory 
chain function have been described in HD post-mortem brain, as well as in animal and 
cell models of HD (Section 1.10.5-7). The association of htt with mitochondria has 
recently been described. A direct role for MT htt in causing mitochondrial dysfunction 
through direct inhibition of the MRC, loss of calcium homeostasis, free radical generation 
and impaired mitochondrial biogenesis and trafficking have been postulated but the 
precise mechanism by which MT htt causes mitochondrial impairment remains elusive 
(Section 6.9.2 and 1.10.8-12). The timing of mitochondrial dysfunction in the cascade of 
events leading to neurodegeneration is also poorly understood. The impairment of 
mitochondrial function during neurodegeneration is probably inevitable at some point in 
cell degeneration, but whether it is a primary initiating event or a secondary, albeit 
possibly still important, downstream secondary mechanism rquires investigation.
1.14.5. Proteasome dysfunction and chaperones
The proteasome and molecular chaperone systems in cells are integral to the metabolism 
of folded and misfolded proteins. An imbalance in this system can lead  to the 
accumulation of potentially toxic proteins (Section 1.6.3-4). There is some evidence that 
MT htt may directly impair proteasome function, or sequester components of the 
proteasome system within htt aggregates causing impairment of proteasome function. An 
87alternative hypothesis states that MT htt undergoes proteasomal degradation leading to 
the production of toxic N-terminal htt fragments (Section 1.6.3-4), although there is little 
evidence for this mechanism.
1.14.6. Aims of investigation
This thesis aims to examine the molecular mechanisms involved in the pathogenesis of 
HD using two distinct in vitro cell models and HD muscle tissue. The cell models enabled 
the investigation of the processing of WT and MT htt in non-neuronal mitotic and 
neuronal mitotic and post-mitotic cells. Subsequently, the cell models enabled the 
investigation of the relationship of CAG repeat length, size of htt, cell background and 
length of expression of MT htt, to mitochondrial function, proteasomal function, inclusion 
formation, htt localisation, free radical production and sensitivity to mitochondrial, free 
radical and proteasomal toxins. As a parallel study, mitochondrial function in HD muscle 
biopsies was assessed and related to clinical parameters including the Unified Huntington 
Disease Rating Scale (UHDRS) and CAG repeat length.
88CHAPTER 2
Materials and methods
892.1. Materials
2.1.1. Tissue culture and human tissue handling equipment
ICN-Flow Automatic CO2 Incubator model 320 (ICN-Flow, Ltd, High Wycombe, Bucks, 
UK); Gelair (ICN Flow) for tissue culture; Class I ICN Flow Hood.
2.1.2. Centrifuges
All centrifugation steps used; Beckman GPR bench-top centrifuge with GH-3.7 swing-out 
rotor (Beckman Ltd., High Wycombe, Bucks, UK), Kontron T-124 high speed centrifuge 
with 8.24 (8x50 ml) fixed angle rotor (Kontron Instruments, Watford, Herts, UK), 
Biofuge 13 with 18x1.5ml fixed angle rotor (Heraeus, Germany), Fresco Microcentrifuge 
(Heraeus).
2.1.3. Molecular biology apparatus
Hybaid mini hybridization oven (Hybaid Ltd., Middlesex, UK), Perkin-Elmer 2400 
thermal cycler (Perkin-Elmer, Warrington, Cheshire, UK), Infors-HT orbital shaker 
(Infors Ltd., Crewe, UK), G25 Incubator-shaker (New Brunswick Scientific Co. Inc. 
Edison, NJ, USA).
2.1.4. Electrophoresis apparatus
BioRad 200/2.0 constant voltage power packs (BioRad Lab. Ltd., Hemel Hempstead, 
Herts, UK), BRL horizontal system for agarose gel electrophoresis (Bethesda Research 
90Lab., Life Tech Inc. Gaithsburg, MD, USA), the NuPAGE electrophoresis systems using 
the pre-cast 4-12% acrylamide Bis–Tris and 3-8% acrylamide Tris-acetate Novex gels 
were used for polyacrylamide gel electrophoresis (Invitrogen Ltd., Paisley, UK), UV 
transilluminator (GRI Ltd., Dunmow, Essex, UK) and Polaroid camera.
2.1.5. Cell and tissue homogenisers
Uni-form 5ml and 10ml glass/Teflon homogenizer (Jencons Ltd., Leighton Buzzard, 
Bedfordshire,   UK),   5ml  glass   homogenizer   and  Glass-Col   stirrer   (CamLam   Ltd., 
Cambridge, UK)
2.1.6. Spectrophotometers
Hitachi U-3210 (Hitachi Scientific Instruments, Wokingham, Berks, UK) and Kontron 
Uvikon 940 (Kontron Instruments, Watford, Herts, UK) split beam spectrophotometers.
2.1.7. Microscopy and photography 
All   microscopy   for   immunohistochemistry,   immunocytochemistry   and 
immunofluorescence was performed using the Zeiss axiophot microscope (Carl Zeiss 
Microscope Division, Oberkochen, Germany) with Kodak T64 film for light microscopy 
and Kodak Ektachrome 400 for fluorescence microscopy. All confocal microscopy was 
performed using the MRC 600 microscope (BioRad Microscience division, Herts, UK).
2.1.8. Chemicals
91Unless otherwise stated all chemicals were purchased from Sigma, Poole, Dorset, UK or 
Merck Ltd. Dagenham, Essex, UK.
2.2. Cell culture
2.2.1. Cell culture materials
All chemicals and plates were from Life Technologies (Paisley, UK) except DMSO and 
pyruvate which were from Sigma Chemical Co. (Poole, UK) and 100mm plates which 
were from NUNC (Roskilde, Denmark).. 
2.2.2. Cells and growth conditions
2.2.2.1. EcR HEK 293 cell line (Invitrogen, UK)
The EcR HEK 293 cell line are transformed human kidney epithelial cells which have 
been stably transfected with the pVgRxR plasmid (Invitrogen, UK) which renders them 
zeocin-resistant at a zeocin concentration of 400µg/ml. HEK 293 cells were grown in 
standard  growth   medium  which  consisted  of  Dulbeco’s  modified   Eagles   medium 
(DMEM)   containing   high   (4.5g/litre)   or   low   concentrations   of   glucose   (1g/litre). 
Glutamine (5mM), penicillin 50units/ml, streptomycin 50mg/l, 10% v/v fetal calf serum, 
0.2mM uridine, and 1mM sodium pyruvate were added.
2.2.2.2. SH-SY5Y cells
92These were obtained from the European Collection of Cell Cultures (ECACC) ECACC 
No. 94030304. The cells were originally made from a sub-clone of a human bone marrow 
biopsy-derived line SK-N-SH (ECACC No. 86012802).  The SH-SY5Y cells have a 
neuroblastoma   morphology   and   can   convert   glutamate   to   GABA   (glutamic   acid 
decarboxylase),   tyrosine   to   dopamine   (tyrosine   hydroxylase)   and   dopamine   to 
noradrenaline (dopamine-β-hydroxylase) (Biedler et al. 1978). SH-SY5Y cells were 
grown in DMEM/F12 50/50 mix containing glutamine (5mM), penicillin 50units/ml, 
streptomycin 50mg/l, 10% v/v fetal calf serum, 0.2mM uridine, and 1mM sodium 
pyruvate.
2.2.3. Cell culture maintenance and harvesting 
Cells were grown on 100mm cell culture dishes (NUNC, Denmark). Standard growth 
medium was changed every 48-72 hours. Cells were harvested, when approximately 80% 
confluent, by first washing in phosphate buffered saline (PBS, Sigma UK, consisting of 
137mM NaCl, 2.7mM KCl, 10mM Na2HPO4 and 1.8mM KH2PO4 pH 7.4) before 1ml of 
trypsin (4% v/v in Versene) was added for 2 minutes (SH-SY5Y) or 30-60 seconds 
(HEK293) at 37
0C until the cells were easily dislodged by gentle tapping of the plate. The 
trypsin was inactivated by the addition of 9mls of fresh growth medium. The cells were 
split 1:2-1:8 onto fresh plates.
2.2.4. Cell freezing and defrosting
93A 90% confluent plate of cells was harvested and centrifuged at 350g for 10mins at room 
temperature. The pellet was resuspended in sterile freezing medium. For all cell lines 
freezing medium consisted of 90% growth medium and 10% DMSO filter sterilized. All 
cells were frozen in 1.5ml cryotubes and put in sealed polystyrene boxes at -80
0C 
overnight, before transfer to liquid nitrogen for long term storage.
Frozen cells were defrosted by rapidly thawing the vial at 37
0C. The vial contents were 
transferred to 20mls of pre-warmed growth medium in a 100mm plastic culture dish and 
incubated overnight at 37
0C. The plate was gently washed with 10 mls of PBS and 
replaced with 8 mls of standard growth medium the following day.
2.2.5. Immunofluorescence staining
Cells were harvested and grown on 22mm sterile glass coverslips in a well from a 6-well 
plate and allowed to adhere to the coverslips overnight. The cells were washed three times 
in PBS, fixed in 4% paraformaldehyde and permeabilised in methanol at -20
0C for 15 
minutes. The coverslips were washed three times in PBS and then incubated in 10% goat 
serum in PBS at 37
0C in a humidified chamber for 1 hour. They were drained and then 
incubated with 100µl of PBS-diluted primary antibody overnight at 4
0C. This was 
followed by three washes in PBS before being incubated for 1 hour at 37
0C in 1 in 1000 
in PBS goat anti-mouse IgG Alexa 488 (FITC linked) for mouse monoclonal primary 
antibodies or goat anti-rabbit IgG Alexa 568 (rhodamine linked), for rabbit polyclonal 
primary antibodies. The coverslips were washed three times in PBS and mounted on glass 
slides in Citifluor/PBS/glycerol (Agar. Stansted, UK) with 1µg/ml of DAPI (Sigma) to 
counterstain the nuclei. A control was set up during each experiment which was 
processed identically except the cells were incubated in PBS only and not primary 
94antibody. Double immunofluorescence was performed on the HEK 293 cells using the 
protocol for single IF except two primary antibodies from different species were used. A 
rabbit polyclonal antibody to huntingtin, “675”, and a mouse monoclonal antibody, to 
various subcellular compartments, were combined. The secondary antibodies were also a 
combination of goat anti-rabbit IgG Alexa 488 (FITC linked) and goat anti-mouse IgG 
Alexa 568 (rhodamine linked) at a dilution of 1 in 1000. 
2.2.6. Primary antibodies.
2.2.6.1. Huntingtin antibodies
There are many antibodies to various portions of the huntingtin protein (Wilkinson et al 
1999). Fig. 2.1 illustrates the antibodies, and their epitopes, that were used during the 
study. Table 2.1 shows the dilutions the antibodies were used in IF and Western blotting. 
The primary antibody, “675” used was a kind donation by Dr Lesley Jones, University of 
Cardiff, Wales. It is a polyclonal primary antibody and was raised to the first 9 amino 
acids of huntingtin.
Table 2.1.
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EM 48
1-256aa
EYFP (239aa.)
Ab7667
1844-2131aa
Ab7666
2703-2911aa
Anti-EYFP Ab2168
2146-2541aa
Ab2166
181-810aa
Huntingtin protein (3144aa.) 
N-terminal C-terminal
Ab7668
997-1276aa
Fig. 2.1. Schematic representation of epitopes of anti-huntingtin antibodies
Ab675
1-9aa2.2.6.2. Other primary antibodies
96Primary antibodies used in co-localisation studies in the HEK 293 model are listed in 
Table 2.2a. and those used in co-localisation studies in the SH-SY5Y model are listed in 
Table 2.2b. All antibodies were used overnight at 4
0C at the dilutions shown and 
developed with the Alexa 568 (red) linked secondary antibody.
2.2.7. Differentiation of SH-SY5Y cells
Cells were plated out at 1x10
5/well in a 6-well plate containing a sterile glass coverslip for 
immunofluorescence or 6.5x10
5/10cm plate for Western blots. The surface area of a 10cm 
plate was calculated as 6.5 times greater than a 6-well plate. The cells were left to adhere 
overnight and the following morning, the medium was replaced and all trans-retinoic acid 
(Sigma) was added to a final concentration of 30µM. The medium and retinoic acid were 
replaced every 48 hours for prolonged experiments.
2.3. Plasmid transfections
All transfections were performed with Escort transfection reagent (Sigma). Cells were 
plated out at 50% confluence on 6-well plates. The DNA transfection mixture was 
prepared with 230µl of unsupplemented DMEM, 5µg plasmid DNA and 15µl Escort 
reagent and mixed by gentle tapping of the vial. This was then incubated for 15 minutes at 
room temperature and then added to 2mls of pre-warmed standard growth medium. 
0.7mls of the Escort/DNA mixture was then added to the each well and incubated at 37
0C 
for 6 hours. Following this the Escort/DNA mixture was aspirated and replaced with 
growth medium.
Table 2.2.
972.3.1. EYFP-C1 plasmid 
98The pEYFP-C1 (Clontech, San Jose, CA, USA) encodes an enhanced yellow-green 
variant of the Aequorea victoria green fluorescent protein (GFP). It is maximally excited 
at 513nm and the emission spectrum has a peak at 527nm, to give a green-yellow 
fluorescence. The EYFP sequence lies at the 5’ end of a multiple cloning site (MCS) and 
therefore expressed proteins will have an N-terminal EYFP tag. The EYFP sequence is 
preceded by a CMVIE (“immediate early”) promoter and the plasmid contains a neomycin 
resistance gene for selection purposes. The EYFP-C1 plasmid was a very generous 
donation by Dr. Lesley Jones, University of Cardiff, Wales. The full-length htt cDNA 
with a 23 and a 88 CAG repeat was first cloned into pRc/CMV by Dr Jones and then into 
EYFP-C1 within the MCS at the EcoR I and Sma I sites (Fig. 2.2.).
2.3.2. pIND plasmid and the Ecdysone-Inducible Expression Kit
The plasmid, pIND, was used as a part of the Ecdysone-Inducible Expression Kit 
(Invitrogen, San Diego, CA, USA). This is designed for mammalian gene transcription 
based on the ability of the insect hormone 20-OH Ecdysone to activate gene expression 
via the Ecdysone receptor. The system uses a heterodimer of the Ecdysone receptor 
(VgEcR) and the retinoid X receptor (RXR) that binds a modified ecdysone response 
element (EcRE) in the presence of ecdysone or a synthetic analogue such as ponasterone 
A (pon A) (Fig. 2.3.). Binding of the heterodimer to the EcRE activates transcription. 
Mammalian cells are not responsive to ecdysone and do not contain the ecdysone receptor 
leading to very low or absent basal levels of expression (No et al. 1996). HEK 293 EcR 
cells, which already has the pVgRXR plasmid stably integrated, was purchased from 
Invitrogen (San Diego, USA). This plasmid contains the zeocin 
Fig. 2.2.
99Fig.2.3.
100resistance gene for selection purposes. The pIND plasmids were a generous donation 
from Dr Lesley Jones (University of Cardiff, UK). These plasmids contain the EcRE, a 
101multiple cloning site and the neomycin resistance gene for selection with antibiotic G418. 
An N-terminal huntingtin construct, containing 21 or 57 CAG repeats, was cloned into the 
multiple cloning site of pIND by Dr Jones. Construct expression was induced by the 
addition of pon A to the growth medium. Pon A was bought as aliquots of 250µg 
lyophilized powder (Invitrogen) and stored at -20
0C. Prior to use, the lyophilizate was 
solubilised in 500µl of DMSO and excess was stored at 4
0C to prevent freeze/thaw cycles.
2.3.3. Isolation of stably transfected clones
Titration experiments demonstrated HEK293 cells died within 1 week when treated with 
400µg/ml of Zeocin. In similar titration experiments EcR HEK293 cells (containing the 
Zeocin resistance gene) and SH-SY5Y cells died within one week at 250µg/ml for G418. 
For isolation of stably transfected clones, the cells were harvested from the 6 well plates 
24 hours post-transfection and split 1:4 into 100mm plates. Cell with stable vector 
expression were selected with 8 mls of standard growth medium containing 400µg/ml of 
Zeocin and 250µg/ml of G418 for the HEK 293 cells or 250µg/ml of G418 only for the 
SH-SY5Y cells. The development of individual clones was monitored using phase-
contrast microscopy and circles were drawn below the clones on the under surface of the 
plate. When clones had formed at between 4 and 6 weeks, they were harvested by 
aspirating off the medium from a plate, washing and aspirating the plate in PBS and then 
gently scraping a clone, using a yellow (200µl.) pipette tip, until the cells were loosened 
from the plate. The loosened cells were gently aspirated into the pipette tip using a 200µl 
pipette and transferred directly into fresh medium. This was repeated for between 4 and 
10 clones per plate and each clone was then labeled and grown up separately. Cells from 
harvested clones were grown up in 100mm plates and then processed for freezing 
(Section 2.2.4.) and immunofluorescence (Section 2.2.5.).
1022.4. DNA methods
2.4.1. DNA extraction 
DNA was extracted from one cell pellet from a 80% confluent 100mm plate using the 
Nucleon DNA extraction kit (Scotlab, UK) according to the manufacturers’ instructions. 
The extracted DNA was dissolved and stored in TE (Appendix 1.4)
2.4.2. Estimation of DNA purity and concentration
5µl of DNA solution was added to 995µl of 100% ethanol in a 1ml silica cuvette and 
mixed by inverting with parafilm. The solution was scanned by measuring the absorbance 
pattern between 310nm and 210nm. The DNA concentration (µg/µl) was calculated 
assuming a 1mg/ml DNA solution had an absorbance of 20 at 260nm. The purity was 
accepted when the A260/A280 ration was greater than 1.7.
2.4.3. Polymerase chain reaction (PCR)
DNA primers were obtained from MWG-Biotech (Milton Keynes, UK) (Section 2.4.7 for 
primers). ReddyMix PCR Master Mix (x2) was obtained from ABgene (Epsom, UK). 
This contained 1.25 units Taq DNA polymerase, 75mM Tris-HCl (pH8.8 at 25
0C), 20mM 
(NH4)2SO4, 1.5mM MgCl2, 0.01% (v/v) Tween 20, 0.2mM each of dATP, dCTP, dGTP, 
and dTTP and precipitant and red dye for electrophoresis. The standard reaction mixture 
(25µl) contained 12.5µl of PCR Master Mix, forward and reverse primers (25 picomoles 
of each), DNA (50ng to 5µg) and made up to 25µl with autoclaved double-distilled water. 
103The reaction was performed in a 0.3ml thin-walled PCR tube in a Perkin-Elmer 24000 
thermal cycler. All PCR reactions performed with CAG repeats included 10% DMSO 
(Sigma).
The standard reaction conditions for HEK 293 cells using G49 and G50 primers can be 
found in Appendix 1.1. The standard conditions for sequencing the 5’ junction between 
EYFP sequence and the 5’ end of full-length huntingtin sequence in SHSY5Y cells, using 
the EYFPfor and RS2 can be found in Appendix 1.2. The standard conditions for 
sequencing the 3’ junction between EYFP-C1 plasmid and the 3’ end of full-length 
huntingtin sequence in SHSY5Y cells, using the R2 and F3 can be found in Appendix 1.3.
These conditions were adjusted according to the nature of the template and the primers 
and specific details can be found in the relevant chapters.
2.4.4. Clean-up of PCR products
PCR products were purified using the Qiaquick PCR clean-up kit (Qiagen, West Sussex, 
UK) according to manufacture’s instructions. The cleaned-up DNA products were stored 
in Tris-EDTA (pH8.0) at -20
0C (see Appendix).
2.4.5. Detection of DNA products
All PCR reaction products were separated on agarose gels using the BRL horizontal 
system for agarose gel electrophoresis (Bethesda Res. Lab, Life Technologies Inc) 1.5% 
(w/v) agarose gels (Sigma) were prepared in 1xTAE Buffer (Appendix 1.4.) containing 
1041µg/ml ethidium bromide. 5µl of PCR product was loaded carefully into each lane and 
lµg of 2-log ladder (New England Biolabs, Beverly, MA) or Benchtop 1kb DNA ladder 
(Promega, Southampton, UK) were used as markers. Electrophoresis was performed in 
1X TAE buffer at 100V for 1-3 hours. The sample was visualized using a UV 
transilluminator and photographed with a black and white Polaroid film.
2.4.6. Sequencing of PCR products
DNA sequencing was outsourced to MWG Biotech (Milton Keynes, UK).
2.4.7. Primers used in sequencing and PCR reactions
Primers used with EYFP-C1 plasmids
5’ 3’ Primer binding site
5’ EYFP 
EYFP-F CATGGTCCTGCTGGAGTTCGTG EYFP 1266-1287
RS1-F ATGGCGACCCTGGAAAAGCTGATGAA
GGCCTTCGAGTCCCTCAAGTCCTTC Htt 316-366
RS2-R GGTCGGTGCAGCGGCTCCTCAG (exonic)
/GTGAGTTT(intronic) Htt 563-574(exonic)
105EL2-R ATGCCCAGAAGTTTCTGAAA Htt 682-701
3’EYFP
F1  TTCTGTCCAACCAGCAGCCAT Htt 9323-9343
F2 TGAACATTCACAGCCAGCAGC Htt 8783-8803
F3 AGGTGGACGTGAACCTTTTCT Htt 9575-9595
R1 CCTCTACAAATGTGGTATGGCTG  EYFP MCS
R2 GATCAGTTATCTAGATCCGGTGG EYFP MCS
R3 CACAAGGGCACAGACTTCCAA 3’ UTR of htt
Primers used with pIND plasmids
G49 (Ecdysone Forward priming site) 5’-CTCTGAATACTTTCAACAAGTTAC-3’
G50 (BGH Reverse priming site) 5’-TAGAAGGCACAGTCGAGG-3’
2.4.8. Analysis of sequences
“Edit Seq” and “Seqman 2” software packages by DNASTAR, Inc. (Madison, USA) were 
used to analyse the DNA sequences.
1062.5. Enzyme Analyses
All assays were performed at 30
0C in a final volume of 1ml. Each enzyme was assayed in 
triplicate and values accepted if they were within 15% of each other.
2.5.1. Citrate Synthase (CS)
Respiratory chain activities were expressed as CS (a mitochondrial matrix protein) ratios 
to correct for variations in the purity of mitochondrial preparations or to correct for the 
mitochondrial mass in tissue homogenates. The assay is based on the method of Coore et 
al. (1971). The enzyme catalyses the condensation of acetyl-CoA and oxaloacetate to 
form   citrate,   producing   CoA   whose   free   thiol   group   combines   with   5-5’-
dithiobisnitrobenzoic acid (DTNB), resulting in an increase in absorbance at 412nm. 
Two cuvettes were set up containing: final concentrations of 100mM of Tris-HCl buffer 
pH8.0, 200µM Acetyl-CoA, 200µM DTNB, 0.1% (v/v) Triton-X-100 and sample, and the 
reaction was initiated by adding 10µl of 10mM oxaloacetate to the test cuvette only to 
make a final volume of 1ml in both cuvettes. The increase in absorbance at 412nm was 
measured during the reaction. Citrate synthase activity was calculated using the molar 
extinction coefficient of 13.6x10
3 for the DTNB-CoA-SH complex and activity expressed 
as nmol/min/mg protein.
2.5.1.1 Preparation of Acetyl CoA
Acetyl CoA was prepared by the method of Ochoa (1955) from free Coenzyme A and 
acetic anhydride. Briefly, 1ml of dd H2O was added to 10mg of enzyme CoA and 100µl 
of 1M potassium hydrogen carbonate. The eppendorf was vortexed briefly, put on ice to 
107cool down to approximately 0
oC for 5 mins and 1µl of acetic anhydride was added to the 
first eppendorf. The contents were vortexed immediately and the eppendorf put back on 
ice to cool down for 3 minutes as the reaction is exothermic. The cycle of adding 1µl of 
acetic anhydride/eppendorf, vortexing and cooling was repeated a further 3 times until a 
total volume of 4µl of acetic anhydride had been added per eppendorf. The tube was left 
on ice for a further 15 mins to enable the reaction to attain completion. The pH was 
checked using pH strips to ensure that the reaction was complete, as indicated by a pH 
value within the range of 6.3 to 6.5. The acetyl CoA was used within a few months and 
was stored at -20
oC.
2.5.2. NADH-CoQ1 oxidoreductase (complex I activity)
The assay is based on the method of Ragan et al. (1987) and measures the rotenone 
sensitive CoQ1 dependent oxidation of NADH at 340nm. The CoQ1 was a generous gift 
from the Eisai Chemical Co., Japan. A dilution of the stock CoQ1 was made in ethanol 
and the absorbance of the CoQ1 at 275nm noted. An excess of sodium borohydride was 
added to the reference cuvette to completely reduce the quinone to quinol and the 
absorbance change was used to calculate the CoQ1  concentration using the molar 
extinction coefficient of 2.25x10
3 (Redfearn et al. 1967). Two identical cuvettes were set 
up containing (final concentrations) 20mM potassium phosphate buffer pH 7.2 with 
8.2mM MgCl2, 150µM NADH, 1mM KCN, 2.5mg/ml BSA and 50µM CoQ1. 10µl of 
ethanol was added to the reference cuvette and 10µl of rotenone, to a final concentration 
of 10µM of rotenone, was added to the sample cuvette and double-distilled water was 
added to make the volume up to 1ml minus the sample volume. The cuvettes were mixed 
by three inversions using parafilm and zeroed in the spectrophotometer. The reaction was 
initiated by adding the sample to both cuvettes followed by further mixing with parafilm. 
108The rate of NADH oxidation was monitored by the change in the absorbance at 340nm. 
The linear rate for the first 2-3 minutes was taken as the rotenone sensitive component of 
the reaction. The molar extinction co-efficient of NADH is 6.22x10
3, but the oxidation of 
the quinine to a quinol causes an increase in absorbance at 340nm and therefore the 
corrected value of 6.81x10
3 was used for the calculation of complex I activity. Enzyme 
activity was expressed as nmol/min/mg of protein and also as a ratio with citrate synthase 
(CS).
2.5.3. Succinate cytochrome c oxidoreductase (complex II/III)
This assay determines the activity of both complex II and III and is based on the method 
of King (1967). It detects the antimycin A sensitive, succinate dependent reduction of 
cytochrome   c   at   550nm.   Two   identical   cuvettes   were   set   up   containing   (final 
concentrations) 0.1M potassium phosphate buffer pH 7.4, 0.3mM potassium EDTA (K2-
EDTA), 0.1mM cytochrome c. Two separate eppendorfs were set up containing 1mM 
KCN, 20mM succinate and sample, and these were incubated at 30
0C for two minutes to 
fully activate the enzyme. This was then added to the cuvettes to initiate the reaction. The 
change in absorbance was measured at 550nm. After 10 minutes 20µM antimycin A was 
added. The antimycin A-sensitive complex II/III activity was calculated using the molar 
extinction coefficient of cytochrome c of 19.2x10
3. Activity was expressed as nmol/min/
mg and as a CS ratio.
2.5.4. Cytochrome c oxidase (complex IV)
This assay is based on the method of Wharton and colleagues (Wharton et al 1967) which 
monitors the oxidation of the reduced cytochrome c at 550nm. 
2.5.4.1 Preparation of reduced cytochrome c
109In brief, 100 ml of 1% solution of cytochrome c (horse heart) was made up in 10mM 
potassium phosphate buffer. This was reduced by adding an excess of ascorbate (13mg), 
gently mixed and checked that it was fully reduced at 550nm. This was performed by 
adding 50µl of the cytochrome c solution to each of the two cuvettes containing 950µl of 
10mM potassium phosphate buffer. To the sample cuvette 10µl of freshly made ascorbate 
solution and the change in absorbance was noted. If the change was positive, i.e. the 
cytochrome c could be further reduced by the addition of ascorbate, then the cytochrome 
c solution was reduced further. If the cytochrome c was fully reduced, then the sample 
was   dialysed   to   remove  excess  ascorbate  using  size   1   dialysis   tubing  (Medicell 
International Ltd., London) and dialysing against 5L of 10mM potassium phosphate 
buffer pH 7.0 at 4
0C overnight. To check that excess ascorbate did not remain, oxidised 
cytochrome c was added to the dialysed reduced sample and if no change in the 
absorbance occurred, then the ascorbate was removed.
2.5.4.2 Calculation of the concentration of reduced cytochrome c
Two identical cuvettes were made up with 100µl of 100mM potassium phosphate buffer 
pH7.0, 850µl of ddH20 and 50µlof reduced cytochrome c. To the reference cuvette was 
added 10µl of 0.1M potassium ferric cyanide to oxidize the reduced cytochrome c. The 
change in absorbance was noted and the concentration calculated by the following 
equation with 50µM of cytochrome c producing an absorbance of 0.96, (0.96/absorbance) 
x 50 =volume of stock reduced cytochrome c required for a 50µM solution in final 1ml 
reaction.
2.5.4.3 Assay
110Two identical cuvettes were set up containing 10mM potassium phosphate buffer pH7.0 
and 50µM reduced cytochrome c. 10µl of 100mM potassium ferric cyanide was added to 
the reference cuvette to oxidise the cytochrome c. The reaction was commenced by the 
addition of sample to the test cuvette and monitored at 550nm. 
2.5.4.4 Calculation of the pseudo first-order rate constant (k) 
This was performed by the extrapolation of the absorbance back to time=0 secs. and the 
calculation of the change in absorbance at time points 1,2 and 3 minutes. The non-enzyme 
rate of absorbance was calculated and subtracted from the sample absorbance values. 
K/min/ml was therefore calculated by: ln0.96-ln(0.96-change in absorbance at time t) x 
1000/sample volume(µl) x dilution factor, where 0.96 represents the absorbance of 
cytochrome c when fully reduced. The k/ml values for four time points (0,1,2,3 mins) 
were plotted against time and the gradient of the line calculated using linear regression 
analysis to obtain complex IV activity (k/min/ml). The final results were expressed as 
k/min/mg protein and as a CS ratio.
2.5.5. Aconitase 
This assay measures the activity of aconitase which catalyses the isomerisation of citrate 
to isocitrate which in turn forms α-ketoglutarate with the reduction of NADP to NADPH. 
The rate of formation of NADPH can be measured at 340nm. Two identical cuvettes were 
111set up containing: 50mM Tris-HCl pH7.4, 0.4mM NADP, 5mM sodium citrate, 0.6mM 
MgCl2, 1% (v/v) Triton X-100 and 2 units of isocitrate dehydrogenase. The sample was 
added to the test cuvette only. Both cuvettes were incubated at 30
0C for 30 minutes pre-
incubation and the absorbance change at 340nm was measured for 15 minutes and 
aconitase activity was calculated using the molar extinction coefficient for NADP 
(ε=6.22x10
3).
2.6. Preparation of mitochondrial-enriched fractions (MEFs)
MEFs were prepared from 20 confluent 10cm plates of cells based on the method by 
Ragan et al (1987). Harvested cells were washed three times in PBS and the resultant 
pellets frozen overnight at -70
0C. The pellets were thawed and resuspended in 2 ml of ice-
cold homogenisation buffer (Appendix 1.4). Each sample was homogenized on ice using 
a Potter homogenizer for 20 strokes at 1000rpm, and then spun at 1500g for 10 minutes 
4
0C. The resultant post-nuclear supernatant (PNS) was collected in a fresh tube on ice. 
Homogenisation of the residual pellet and centrifugation was repeated a further 2 times. 
The combined PNS was further centrifuged for 10minutes and any residual pellet 
discarded. The final PNS was further centrifuged at 10,000g for 12 minutes at 4
0C on a 
Kontron Centrikon T-124 centrifuge which resulted in a brownish pellet (MEF). This 
pellet was resuspended in 200-800µl of ice-cold homogenisation buffer, snap frozen in 
liquid nitrogen and stored at -70
0C for up to 6 days before assaying. To assay complexes 
I, II/III and IV samples were freeze-thawed in liquid nitrogen three times before assaying 
to maximize the mitochondrial enzyme activities.
2.7. Preparation of muscle homogenates
112Samples were stored at -70
0C and immediately homogenized in ice-cold homogenization 
buffer using a glass/glass homogenizer. The samples were freeze-thawed in liquid 
nitrogen as described above and assayed within one hour.
2.8. Protein Assays 
All protein assays were performed using the Pierce BCA Protein Assay Reagent Kit 
(Rockford, IL). This system uses the reaction of protein with Cu
2+ which is then detected 
by the reagent bicinchoninic acid (BCA). The purple reaction product of BCA and Cu
2+ is 
water soluble and exhibits a strong absorbance at 562nm. For each assay a set of protein 
standards was made using dilutions of bovine serum albumin (BSA) in the sample diluent 
and these were used to create a standard curve. The “enhanced protocol” was used which 
required incubation at 60
0C for 30 minutes and subsequent immediate cooling of the 
samples on ice to stop the reaction before measuring the absorbance of the samples at 
562nm. Each assay was performed in triplicate and calibrated relative to a control assay 
of diluent and reaction mixture only.
2.9. Protein extraction from cells and preparation for electrophoresis
2.9.1. Preparation of cell pellet
113One confluent plate of cells was washed in PBS and the cells were harvested using a cell 
scraper. The pellet was washed twice in PBS and resuspended in 0.4-0.8ml of dissociation 
buffer and protease inhibitors (Appendix 1.4). The sample was needle-sheared using a 
19G needle and 1ml syringe to break up the genomic DNA and reduce its viscosity. The 
sample was stored at -70
0C until needed. A protein assay, using the BCA protocol as 
described above, was performed on all samples to adjust for protein loading during 
electrophoresis. 
2.9.2. Cell pellet solubilisation
The NuPAGE Bis-Tris and Tris-acetate systems (Invitrogen, Life Technologies) were 
used to solubilise the samples. In summary, 30µl of each sample was made up from:
1) 7.5µl of NuPAGE LDS Sample Buffer (x4)
2) 3µl of NuPAGE Reducing Agent (x10)
3) Sample (between 5 and 50µg of protein per lane)
4) Made up to 30µl with ddH2O 
The samples were vortexed briefly to enable mixing, heated at 70
0C for 10 minutes and 
then centrifuged for 10 secs at 6000g to concentrate any insoluble material at the bottom 
of the eppendorf, before the supernatant was loaded.
2.9.3. Concentration of protein extracts
The long-term differentiation of some SH-SY5Y samples made it impractical to harvest 
the small residual number of cells on many plates into concentrated extracts. The 
114centricon YM-3 centrifugal filter devices (Millipore, Bedford, MA, USA) were used to 
concentrate samples with the loss of proteins below 25kDa.
2.10. SDS-PAGE of protein extracts
The NuPAGE Bis-Tris and Tris-acetate systems (Invitrogen, Life Technologies) were 
used to separate proteins. For large proteins (>100kDa) the Tris-acetate system was used 
with a 3-8% pre-cast polyacrylamide gel and the Bis-Tris system was used for smaller 
proteins (<100kDa) with a 4-12% pre-cast polyacrylamide gel. These gels did not contain 
SDS   but   were   used   for   denaturing   gel   electrophoresis   in   conjunction   with   the 
recommended denaturing SDS running and sample buffers. For constituents of individual 
buffers see (Appendix 1.4). Between 5 and 50µg of protein was loaded per well as well as 
a pre-stained molecular weight marker, MultiMark Multi-Colored Standard, which covers 
between myosin (approximately 189kDa) and insulin (approximately 3kDa). The gel was 
run at 150V for between 2 and 3 hours for the Tris-acetate gels and at 200V for 35 
minutes (MES buffer) or 50 minutes (MOPS buffer) for Tris-Bis gels.
2.11. Western Blotting
A polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA) was 
briefly (approximately 30 seconds) wetted in methanol. NuPAGE transfer buffer was 
made up fresh and 1 ml of NuPAGE antioxidant was added. The blot pads, filter paper 
and the PVDF membrane were soaked for 5 minutes in the transfer buffer, making sure 
not to allow the membrane to dry. The pre-cast gel was carefully separated. The gel was 
transferred onto a transfer buffer-soaked piece of blotting paper and then placed face-up 
onto two soaked blot pads. The PVDF was carefully placed onto the gel and covered with 
115a further layer of soaked filter paper and two more layers of blot pads. The PVDF was 
upper most towards the anode. The whole blot module was slid into the lower buffer 
chamber of the blot tank and topped up with transfer buffer to just cover the pads, filter 
paper, membrane and gel. The outer chamber was filled with ddH2O. The transfer was 
performed using 30V constant supply for 1 hour. 
2.12. Staining of PVDF membrane for protein extracts
Adequate loading and separation of protein was confirmed by immersing the membrane 
for  1 minute in Ponceau S solution (Sigma), which contains 0.1% Ponceau S (w/v) and 
5% acetic acid (w/v). Ponceau S binds to positively charged amino groups and also non-
covalently to non-polar regions of the protein. To remove the Ponceau S, the membrane 
was gently washed with PBS until all the stain was removed and prior to blocking in 10% 
low fat milk (Marvel
TM) in PBS for 2 hours at room temperature. After two 10 minute 
washes in PBS at room temperature, the membrane was incubated for 2 hours at room 
temperature in primary antibody made up in 0.3% Tween/PBS (v/v) (PBS-T), and left on 
a shaker. After 3 further washes for 10 minutes in PBS-T, the membrane was incubated in 
the appropriate secondary antibody (HRP conjugated) diluted in PBS-T for 1 hour at 
room temperature. The membrane was then washed 3 times in PBS-T for 10 minutes per 
wash followed by two 10 minute washes in PBS alone. The membrane was the developed 
for 1 minute in 1:1 volumes of chemiluminescence oxidizing reagent and enhanced 
luminal reagent (Renaissance kit, Dupont NEN, Boston, MA, USA). The membrane was 
exposed to ECL film (Amersham) for times varying from 10 seconds to 6 minutes, 
depending on the strength of the signal.
2.13. Assessment of cell proliferation 
116The Cell titer 96 Aqueous Non-Radioactive One Solution Cell Proliferation assay 
(Promega) was used to assess the cell growth in the HEK 293 cell model. The Cell Titer 
96 assay is a colorimetric method for determining the number of viable cells in 
proliferation assays. The assay uses a Cell titer 96 Aqueous One Solution Reagent which 
contains   a   novel   tetrazolium   compound   3-(4,5-dimethylthiayol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium   (MTS)   and   an   electron 
coupling reagent, phenazine ethosulfate (PES). MTS is reduced, probably due to the 
production of NADH/NADPH by metabolically active cells, into a formazan product that 
is soluble in tissue culture medium. The absorbance of the formazan product at 490nm 
was measured directly from 96 well plates without additional processing. The quantity of 
formazan product, as measured by the amount of 490nm absorbance, is directly 
proportional to the number of living cells in culture. Cells were harvested and plated out 
in triplicate into 96 well plates, at a density that had been optimized during pilot 
experiments, and allowed to adhere for three hours in an incubator. The medium was then 
aspirated and replaced with 50µl of the appropriate growth medium. To standardize for 
background reactivity, blank wells in triplicate were set up on every plate which 
contained only standard growth medium and no cells. The samples were incubated for 
0,1,2,3,4 and 5 days and the medium was carefully changed after every 48 hours because 
of a drop in pon A activity to 30% by 72 hours as stated by the manufacturers guidelines 
(Invitrogen). At each time-point, 10µl of MPS compound was added to each well using a 
multi-channel pipette and incubated at 37
0C for 2 hours. The samples were immediately 
measured using a BioRad plate reader with a 500nm filter.
2.14. LDH cytotoxicity detection assay
1172.14.1. Background
The CytoTox 96 Non-Radioactive Cytotoxicity Assay was used to assess cell death in the 
HEK 293 model. The assay quantitatively measures lactate dehydrogenase (LDH). 
Plasma membrane damage and cell death is associated with the release of LDH into the 
culture supernatant and LDH activity is measured with a 30 minute coupled colourimetric 
enzymatic assay which results in the conversion of a tetrazolium salt (INT) into a red 
formazan product. The chemical reaction on which this assay is based is divided into two 
steps. In the first step, NAD
+ is reduced to NADH/H
+ by the LDH catalysed conversion of 
lactate to pyruvate. In the second step, the catalyst (diaphorase) uses NADH to reduce the 
tetrazolium salt, INT, to form formazan (red) which shows maximum absorption at 
492nm. The amount of colour formed is proportional to the number of cells with 
disrupted or damaged cell membranes and was measured using the BioRad 96-well plate 
reader with a 500nm filter.
2.14.2. Plating of cells 
Cells were plated out at 2x10
5/well into 12-well plates at approximately 1700 hours. They 
were then left to settle and adhere to the plate overnight. At 0900 hours the next morning, 
the medium was carefully aspirated and replaced with 1ml. of growth medium containing 
low glucose (1g/L.) with either 5µl of DMSO or 5µl of 1mM pon A (final concentration 
of 5µM). After 48 hours incubation, the medium was carefully aspirated and replaced 
with medium containing pon A or DMSO together with the appropriate toxin. A well with 
low glucose medium and DMSO was also incubated at this stage to be used as a 
“medium” control.
1182.14.3. The LDH assay 
Cell death was expressed as the percentage of LDH activity in the medium versus the 
total LDH activity in an equivalent well treated with 100µl of 10% Triton-X100 (final 
concentration 1%). The cultures were examined visually and the approximate percentage 
of cell death was assessed so that an appropriate dilution could be made to ensure that the 
LDH content of any sample was within a linear activity range at the end-point of the 
reaction. Medium was carefully removed with a 1 ml pipette and placed into a 1.6ml 
microcentrifuge tube. The sample was centrifuged at 6000rpm for 5 minutes to pellet out 
any residual cell remnants that may have been aspirated into the pipette which could 
interfere with the assay. The supernatant was diluted depending of the level of cell death 
assessed prior to harvesting. To ensure the LDH activity was linear, each sample was 
assessed four times with 4 different volumes and the samples were made up to a total of 
50µl with double-distilled water. Typically, the medium controls were used neat with 20, 
30, 40 and 50µl of sample, and the toxin-treated medium samples were also used neat 
with 15, 20, 25 and 30µl of sample. In general, the triton X100-treated cells required 
greater dilution and were diluted 1 in 4 with double-distilled water and 15, 20, 25 and 
30µl. Three water blank controls were also plated out. Once the plate had been completed, 
a multi-channel pipette was used to add 50µl of the reaction mixture to each well over 
approximately 20 seconds. The 96-well reaction plate was then incubated for 30mins at 
R/T in the dark and the absorbance was measured immediately.
2.15. HD muscle analysis
2.15.1. Histochemical methods 
2.15.1.1. COX Staining 
119HD muscle sections were incubated for 1 hour at 37
0C in COX activity dye solution 
prepared as follows: 1ml of 0.5 M sodium phosphate buffer made up to  pH 7.4, 5mg of 
DAB, 10mg horse heart oxidized cytochrome c, 10µl of PBS/catalase (2mg/ml) and 9ml 
ddH2O. Sections were then washed in PBS and the nuclei were counterstained with 
Mayer’s haematoxylin, washed for 10 minutes in water and then gradually dehydrated in 
70%, 95% and 100% alcohol. The sections were cleared in xylene and mounted in DPX 
(Agar Scientific Ltd. Cambridge, UK) which is a colourless synthetic resin mounting 
medium.
2.15.1.2. Succinate dehydrogenase (SDH) staining 
Muscle sections were washed in PBS and then incubated for 1 hour at 37
0C in SDH dye 
solution prepared as follows: 5ml 0.2M sodium succinate, 5ml 0.2M potassium phosphate 
buffer, 10mg nitroblue tetrazolium. Sections were then washed in PBS and counterstained 
with haematoxylin before dehydrating, clearing and mounting in DPX as described above.
2.15.2. Immunocytochemistry
Immunocytochemistry on muscle was kindly performed by Jane Workman (Royal Free 
Hospital, London, UK) using standard protocols. The avidin-biotin-complex (ABC) 
method with horseradish peroxidase (HRP) was used. Peroxidase was demonstrated using 
3’diaminobenzidine (DAB, Sigma) chromagen. Frozen sections were cut at 7µm on a 
120CM1900 Leica cryostat and mounted on poly-L-lysine-coated slides. The sections were 
air-dried for 30 minutes at room temperature , fixed in acetone for 10 minutes and then 
air-dried for another 30 minutes. The sections were stored at -20
0C. To stain the sections, 
they were blocked by incubation with 10% v/v normal goat serum (DAKO)/ PBS for 60 
minutes at room temperature in a humidified chamber. Sections were drained and the 
primary antibody was applied and incubated further in a humidified chamber at 4
0C 
overnight. The following antibodies were used; a polyclonal antibody to the first 9 amino 
acids of huntingtin, 675, (kind gift from Dr L Jones, Cardiff), diluted 1 in 1000, 
incubated) and a monoclonal antibody to ubiquitin (Chemicon, 1 in 300). The sections 
were washed in PBS and incubated with biotinylated secondary antibody for 60mins at 
room temperature. The sections were then washed three times and the ABC (DAKO) 
added to the sections for 60 minutes at room temperature. The DAB substrate (Sigma) 
was prepared by dissolving 2.5mg of DAB in 5ml PBS and 50µl of 0.3% H2O2 was 
added. Sections were then drained and washed and the DAB substrate added. The sections 
were developed until a brown chromagen had formed and washed in running H2O. 
Sections were dehydrated, cleared and mounted in DPX as described above.
2.15.3. Electron microscopy
Electron microscopy  was kindly performed by Dr. David Landon at the Institute of 
Neurology, London.
2.16. Proteasome function
121The four clones from WT, MT and pc DNA 3.1 were grown, harvested and washed twice 
in PBS before freezing down at -80
0C.  The assay: cells were re-suspended in ‘assay 
buffer’ (50mM Tris-Cl pH: 7.4) and freeze-thawed three times. Aliquots of the cell 
suspension were put into wells of a 96-well plate and doubling dilutions made (1:1, 1:2, 
1:4 and 1:8) so each sample had 4 points for each proteasomal activity. Data was only 
taken for those points whose activity appeared to decrease in proportion to the dilution of 
the sample. Proteasomal function in whole cell suspensions was assessed by measuring 
the   rate   of   proteolysis   of   proteasomal   fluorogenic   substrates.   The   substrates   are 
polypeptides   coupled   to   the   fluorophore   7-amino-4-methylcoumarin   (AMC)   and 
proteolytic cleavage results in the release of AMC with an increase in fluorescence over 
time which was measured on a Synergy plate reader (Ex: 380nm, Em: 460nm).  The 
substrates used are described in Table 2.3. The substrates were reconstituted in DMSO 
and stored in the dark at -20
oC following reconstitution. Protein was estimated by BCA 
method and activities expressed as nmols/min/mg after relating the fluorescence to a 
standard curve of free 7-amino, 4-methyl coumarin. The proteasome assays were kindly 
performed by Dr Mike Cleeter, UCL. 
Substrate Supplier Proteolytic
target
Sequence Excitation Emission
II Calbiochem
539141
Trypsin-like Z-Leu-Leu-Glu-AMC 380nm 460nm
III Calbiochem
539142
Chymotrypsin-
like
Suc-Leu-Leu-Val-Tyr-
AMC
380nm 460nm
VI Calbiochem
539149
Post acidic Z-Ala-Arg-Arg-AMC 
. HCl 360-380nm 430-460nm
122Table 2.3. Reagents used in proteasome function analysis. 
2.17. Statistical methods
Statistical analysis in the HEK 293 and SH-SY5Y cell models was performed using the 
Student's t test. Statistical analyses were performed using the unpaired two-tailed Mann-
Whitney U test and the Spearman correlation test for the analysis and correlation of 
mitochondrial enzyme activities and clinical parameters in HD muscle where a normal 
distribution could not be assumed.
123CHAPTER 3
Results
An inducible N-terminal htt 
HEK 293 cell model
1243.1. Plasmid sequencing
The plasmids LJ21CAG and LJ57CAG were a kind gift from Dr Lesley Jones, University 
of Cardiff and were plasmids pIND (Invitrogen) containing an N-terminal fragment of 
huntingtin with either 21 or 57 CAG repeats. Prior to transfection, PCR amplification 
with the G49/G50 primers was performed and the PCR products sequenced commercially 
by MWG Biotech (Milton Keynes, UK) (Section 2.4.3. for PCR method, 2.4.6 and 2.4.7. 
for sequencing of plasmids and the Figs.3.1. A and B for sequence chromatograms of 
plasmids). The constructs were correctly inserted into the Nhe-1 (5’end of construct) and 
Xba-1 (3’end of construct) multiple cloning sites (MCS) of pIND. There were two ATG 
start codons (out of frame with one another) within close proximity at the start of the htt 
sequence although the first ATG was immediately followed by a TAG stop codon and 
would therefore not transcribe and the second ATG was correctly followed by the htt 
sequence. The second ATG also had a strong Kozac consensus sequence with an A at 
position -3 and a G at position +4. There were 57 CAGs in the mutant (MT) sequence and 
21 CAGs in the wild-type (WT) htt sequence. A base change (T to a C) in the 3’end of 
both constructs was identified, converting a leucine to a proline at amino acid 165 of the 
htt sequence. The stop codon was 6 codons 3’ to the end of the htt sequence and included 
5 additional codons of the pIND 0 sequence at the Xba-1 restriction site. The analysis of 
the sequences suggested that the WT construct would produce a protein of 176aa 
including the first 171aa of htt with 23 polyglutamines, and an additional 5aa (serine, 
arginine, glycine, proline and valine) from the pIND sequence. Similarly, the MT 
construct would produce the same protein except with 59 polyglutamines.
Fig. 3.1 A
125Fig. 3.1 B
1263.2. Plasmid transfections and cloning
127EcR293 cells were transfected with 5µg of both the MT (LJ57CAG) and WT (LJ21CAG) 
htt constructs in pIND using the Escort (Sigma) lipofection method in 6-well plates 
(Section 2.3.2.). Twenty-four hours post-transfection, stable clones were selected by 
adding Zeocin (400µg/ml medium) and G418 (250µg/ml medium) to the medium and the 
cells were transferred to 10 cm plates. Three weeks after transfection 13 WT and 15 MT 
clones were cloned and transferred to a 10cm plate and allowed to divide. EcR293 cells 
were also transfected with an “empty” pIND plasmid without any construct and called 
“pIND 0”. These were cloned by the same method as cells containing a construct.
3.3. Construct expression 
3.3.1. Immunofluorescence (IF) of clones using the “675” anti-N-terminal htt antibody
Once the clones had divided sufficiently to split the plates (approximately 10 days), cells 
were plated on coverslips, allowed to adhere overnight and pre-treated for 48 hours with 
5µM ponasterone A (pon A) to induce construct expression. Immunofluorescence (IF) 
was performed on the 13 WT and 15 MT harvested clones as described in Section 2.2.5 
using the 675 primary antibody to N-terminal huntingtin. Fig. 3.2. shows 2 representative 
WT clones, 21 2 c and 2d, and 2 representative mutant clones, 57 1g and 2e, with and 
without 5µM pon A treatment for 48 hours. All clones demonstrated punctate cytoplasmic 
staining with and without pon A induction (dotted arrow in Fig. 3.2). This represented 
endogenous htt or non-specific staining. Induction with pon A produced a greater degree 
of cytoplasmic staining as well as dense nuclear staining in 
Fig. 3.2.
128between 30-70% of cells in both WT and MT clones (solid arrow Fig. 3.2). There were no 
discernable differences in the pattern of staining between WT and MT clones and there 
129were no obvious inclusions. In general, all cells, with and without pon A, tended to clump 
together and there were few individual cells in spite of being plated out as single cells. 
Clumping of cells is a natural characteristic of HEK293 cells and due to the effects of 
DMSO.
Positive clones to be taken forward to the next level of selection were defined by those 
which demonstrated greater than 50% of the cells with strong Ab675 cross-reactivity 
following pon A induction and where there was a distinct difference in the intensity and 
pattern of staining between induced and non-induced clones. Seven WT and five MT 
clones (Table 3.1) were found to follow these criteria and each clone was expanded and 
frozen down for storage as described in Section 2.2.4. The clones were named after the 
number of CAG repeats (21 or 57), the plate from which they were cloned (1, 2 or 2a) and 
the number of the clone taken from the plate (a to j).
Wild-type Mutant
21 1 d 57 1 f
21 1 h 57 1 g
21 1 j 57 2 e
21 2 a 57 2a d
21 2 b 57 2a e
21 2 c
21 2 d
Table 3.1. HEK 293 clones with positive immunostaining confirmed with 675.
3.3.2. Western Blots of HEK 293 transfected cells
To confirm the expression of the construct and to assess the size of the protein product, 7 
WT and 5 MT clones were processed for Western Blot analysis as described in Section 
2.9-11. Fig. 3.3. A-D demonstrates the Western blots of all clones following induction 
with 5µM pon A (“pon +”) or only the DMSO vector (“pon –“) for 48 hours. In the 
130absence of pon A, there were a number of minor bands. Exposure to pon A generated a 
protein product that cross-reacted with the Ab675 at approximate molecular weights of 
29.5 kDa (WT) and 36kDa (MT) in all the clones treated (Fig. 3.3 A-D). The predicted 
sizes of the constructs, based on sequencing, were 19.5 kDa (WT) and 23.5 kDa (MT). 
There was no evidence of smaller cleaved products post-induction with pon A and non-
specific bands were equal in induced and non-induced clones. Two representative pIND 0 
clones (1 and 2) showed non-specific bands (Fig. 3.3D). One of these bands ran at a 
similar level to the MT N-terminal htt (arrow) but was equal in ponA treated and 
untreated clones. Fig. 3.4. demonstrates Western blots of clones 21 2 c and d (A) as well 
as 57 2a d and e (B) developed with Ab675. All clones produced a strong band at a size 
greater than 188kDa which suggested it was endogenous htt. Fig. 3.4 also demonstrates 
that for protein loading of 3, 10 and 30µg, there was a proportionate increase in band 
intensity. Fig. 3.5 demonstrates that there was no evidence of breakthrough expression 
within the clones that were not treated with pon A, even with high levels of protein 
loading (120µg) and when the ECL film was heavily exposed. Construct expression was 
clearly seen with pon A exposure (arrows). Fig. 3.6 demonstrates all 7 WT and 5 MT 
clones on Western blots developed with Ab675 and shows the relation of construct htt to 
endogenous htt. There was no evidence of aggregate formation such as larger bands or 
product staining within the wells. The relative intensities of the bands of construct N-
terminal htt were similar although there 
Fig 3.3.
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134was a difference of approximately one to three-fold in expression levels between the WT 
clones e.g. 21 2c versus 21 1 j, and the expression of 57 2ad was slightly less than the 
other MT clones (Figs. 3.3 and 3.6). There also tended to be similar band strength with 
construct versus endogenous htt expression with a trend to greater expression levels of the 
construct (Figs. 3.6).
1353.4. Subcloning of WT and MT clones
The immunofluorescence of the cloned cells suggested that there was a wide variation of 
staining within the cells of each clone. Most clones had some cells which were stained 
very strongly positive and others which were similar to untransfected cells with punctate 
cytoplasmic staining only. This could have been due to a mixed population of cells being 
cloned or due to differences within transfected cells, for instance, at various stages in the 
cell cycle. To elucidate this further, subcloning of all 7 WT and 5 MT clones was 
undertaken   which   involved   plating   out   a   low   concentration   (approximately 
1x10
4cells/10cm plate) of well-triturated cells from each clone. These were grown to form 
subclones. After approximately 2 weeks, between 3 and 6 subclones were harvested from 
each plate, induced with 5µM pon A for 48 hours and immunofluorescence with antibody 
675 was performed. Fig. 3.7. demonstrates the immunofluorescence of a representative 
parent clone (21 1 h) with its subclones 1-3. It was found that there was no difference in 
the subcloned cells from the parent clones suggesting that the variable expression levels 
within each clone was a property of the cells, possibly due to variable induction, and not 
due to the clones containing cells with and without transfected construct.
Fig. 3.7
1363.5. Sequencing of clones
To establish the sequence of the stably integrated cDNA constructs, DNA was extracted 
from the seven WT and five MT clones and PCR amplification was performed using G49 
and G50 primers (Section 2.4.7 for details of primers). Fig. 3.8 demonstrates the PCR 
products, run on a 2% agarose gel, from two representative clones, 21 2 d (WT), 57 2a e 
(MT), and pIND 0. The predicted band size was calculated to be 626bp (21 2 d), 734bp 
137(57 2a e) and 192bp (pIND0) using the G49/50 primers, which approximately matched 
the band lengths of the PCR products observed in Fig. 3.8. In order to clarify the size of 
the PCR products, the distance from the well to each band in the DNA ladder was 
measured and plotted against the natural log of the known band length in the markers 
(Appendix 1.5.) to produce a standard curve. The distance from the loading wells to the 
PCR product bands was also measured and the base-pair length of the products was 
extrapolated from the standard curve in Appendix 1.5. Table 3.2. below shows the 
extrapolated base pair lengths which were 209bp (pIND0), 618bp (21 2 d) and 726 (58 2a 
e). The PCR products were commercially sequenced by MWG Biotech. (Milton Keynes, 
UK). The correct integration of the construct was confirmed in all clones (data not shown) 
and the sequence was identical to the chromatograms for the LJ21CAG and LJ57CAG 
transfecting plasmids (Figs. 3.1 A and B).
PCR product
Distance from 
well (mm) ln base pair
Extrapolated 
base pairs
Predicted base 
pairs
pIND0 108 5.34 209 192
21 CAG 80 6.42 618 626
57 CAG 76 6.58 726 734
Table 3.2. Predicted base pair length of PCR products
Fig 3.8
1383.6. Influence of pon A concentration and time on expression
The response of the clones to varying doses and times of exposure to pon A was studied 
in 2 representative WT (21 1 h and 2 c) and 2 MT (57 2a d and 2 e) clones. The clones 
were plated out on glass coverslips for immunofluorescence and a 10cm plate for Western 
analysis as described previously, and developed using the primary anti-huntingtin 
antibody, 675. The cells were induced with doses of pon A at 0, 1, 2, 5, 10, 20µM for 48 
hours. The immunofluorescence of MT clone 57 2ad and WT clone 21 1 h, showed 
increasing intensity of fluorescence staining with increasing doses of pon A up to 20µM 
139(Figs. 3.9a and 3.10a). The Western blots of 58 2a d and 21 1 h also demonstrated an 
increasing intensity of the predicted 36kDa (MT) and 29.5kDa (WT) bands up to 20µM 
(Figs. 3.9b and 3.10b). A similar pattern of positive immunofluorescence occured with all 
doses of pon A between 1 and 20µM with clones 21 2 c and 57 2 e (Figs. 3.11a and 
3.12a). The Western blot also demonstrated a predicted band at 29.5kDa (21 2 c) and 36 
kDa (57 2 e), that was equal in intensity at all concentrations of pon A (Figs. 3.11b and 
3.12b). The optimum expression, i.e. the maximum induction with the smallest dose of 
pon A and solvent, DMSO, for the clones was 5µM for 48 hours. 
In order to determine the effects of the length of exposure to pon A on expression, the 2 
WT and 2 MT clones (21 1 h and 2 c, 57 2a d and 2 e) used in the dose-dependence 
studies described above, were cultured for immunofluorescence and Western analysis for 
2 weeks. The medium was replaced (with and without 5µM pon A) every 48 hours. Data 
from Invitrogen (Paisley, UK) indicates that pon A retains 70% activity at 48 hours and 
this   decreases   to   30%   at   72   hours.   Figs.   3.13   and   3.14   demonstrate   the 
immunofluorescence and Western blots developed with Ab675 of representative WT 
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145(21 2 c) and MT (58 2 e) clones. The immunofluorescence showed that by day 12 the 
intensity and number of positive cells was reducing in all clones and that by day 18 there 
was less than approximately 10% intensely positive staining cells. This was mirrored in 
the Western blots where there was a more obvious earlier reduction in intensity of the 
predicted bands by day 4 and by day 18 the Western blot was similar to untreated cells i.e. 
DMSO only.
3.7. Time-dependent expression of alpha-synuclein
146A similar Ecdysone-based model using EcR HEK 293 cells transfected with pIND 
containing alpha-synuclein with the A53T point mutation has been described (Tabrizi et 
al 2000). To investigate whether the time-dependent effects of pon A were similar in this 
model, and therefore due to the model system rather than an effect of the construct, a 
time-dependent experiment was performed similar to the one described above using the 
A53T alpha-synuclein HEK 293 model. Fig. 3.15. demonstrates the Western blots which 
were developed with an anti-haemagluttinin (HA) antibody to a tag at the C-terminus of 
the construct. It shows that expression of the predicted construct was stable up to 12 days 
of pon A induction and that there was a slight reduction in the intensity of the band with 
time of the wild-type alpha-synuclein versus the mutant which appeared to continue to 
express similar levels up to day 12.
3.8. Subcellular localisation studies
A panel of primary antibodies to components of subcellular organelles (Table. 2.2 A) and 
the   anti-N-terminal   huntingtin   antibody,   Ab675,   were   used   to   perform   double 
immunofluorescence on one WT (21 2 c) and one MT (57 2 e) clone, in order to localise 
Fig. 3.15.
147subcellular expression of the construct (Section 2.2.5. for method). These clones were 
treated   with   and   without   5µM   pon   A   for   48   hours   prior   to   processing   for 
immunofluorescence. Fluorescence was detected using a confocal microscope and Figs. 
3.16-3.18 demonstrate the pattern of staining observed in the WT clone (21 2 c) and Figs. 
3.19-3.21 in the representative MT clone (57 2 e). Confocal microscopy confirmed that 
the central staining with Ab675 in the pon A-treated cells was nuclear and not dense 
cytoplasmic staining as viewed from conventional immunofluorescence (Solid arrows in 
Figs. 3.16-3.21). The COX 1 staining was cytoplasmic and punctate and accumulated in 
the indentation formed by the typical kidney-shaped nucleus of HEK 293 cells (Dotted 
148arrow in Figs. 3.16a and 3.19a). There was no difference in distribution or intensity of the 
COX 1 staining in the pon A-treated and untreated cells. The yellow arrows in Figs. 3.16a 
and 3.19a demonstrate that there was partial co-localisation between COX 1 and Ab675 
staining in MT and WT clones especially in a perinuclear distribution. The Golgi staining 
also tended to accumulate in the nuclear indentation of the cells in the cytoplasm but there 
were no clear differences between the MT and WT treated and untreated cells and no 
evidence of co-localisation (Figs. 3.16b and 3.19b).
Anti-LAMP antibody labels lysosomes and produced a fine granular cytoplasmic stain 
that was similar to the 675 stain but there was no evidence of co-localisation in treated or 
untreated cells (Figs. 3.17a and 3.20a). Figs. 3.17b and 3.20b demonstrate that vesicle-
associated membrane protein (VAMP) staining was punctate and cytoplasmic and 
colocalised with 675. Fig. 3.18a demonstrates that synaptophysin had a weak cytoplasmic 
punctate staining with and without pon A in the WT clone but had intense staining in 
some cells in pon A treated MT clones (Fig. 3.21a). In some pon A treated cells, there 
was punctate staining with synaptophysin which weakly colocalised with 
Fig 3.16. 
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154punctate 675 staining (Dotted arrows in Figs. 3.18a and 3.21a). There was very weak 
cytoplasmic synaptophysin staining of untreated cells. The association of WT and MT htt 
with VAMP and synaptophysin was unlikely to be non-specific as demonstrated in Figs. 
3.16 a and b and Fig. 3.17 a as well as Figs. 3.19a and b and Fig. 3.20a, where there was 
no co-localisation with LAMP or Golgi network antibodies. Figs. 3.18b and 3.21b 
demonstrate that ubiquitin staining was very weak in both pon A treated and untreated 
cells and there was no evidence of ubiquitin positive inclusion formation.
3.9. Cell Proliferation
155Cell proliferation was studied using the Aqueous One Cyt96 Cell Proliferation Assay 
(Promega) as described in Section 2.13. A pilot experiment was performed to determine 
the length of incubation in the MTS solution before the absorbance was measured and the 
optimum number of cells to plate at the start of the experiment so that there was an 
exponential increase in cell number that was within the limits of detection at both 
extremes of the plate reader. The data from these pilot studies is not shown but suggested 
that the plates were optimally read two hours after incubation with MTS. The optimum 
concentration of cells was 500/well. Subsequently, five WT (21 1 h, 2a 2b, 2c, and 2 d), 
five MT (57 1f, 1g, 2ad, 2ae, and 2e) and 5 pIND 0 (1-5) clones were analysed and the 
mean absorbance of the WT, MT and pIND 0 clones was plotted against time. Fig. 3.22. 
demonstrates that DMSO alone did not inhibit cell growth but pon A inhibited cell growth 
in all clones equally as can be seen in Fig. 3.22 C compared with 3.22 A and B, and also 
in 3.22 D, E, and F comparing the diamond points (pon A) versus the DMSO (square) and 
cells only (triangle). There was also an apparent reduction in cell growth with the MT 
versus WT and WT versus pIND 0 clones as can be seen in Figs. 3.22 A-C. When the 
graphs were adjusted for starting cell numbers and the rate of cell 
Fig 3.22.
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157growth expressed as a percentage of the initial cell count versus time (Fig. 3.23.) there 
was no gross difference in the rate of growth between pIND 0, WT and MT clones (Fig. 
3.23 A, B and C). It was confirmed that there was a reduction in cell growth caused by 
5µM pon A (Fig. 3.23 D, E and F) which was similar in pIND0, 21 CAG and 57 CAG 
clones and therefore independent of N-terminal htt expression and CAG repeats.
3.10. Mitochondrial function 
Mitochondrial function was measured in five WT (21 1 h, 2 a 2 b, 2 c,and 2 d), five MT 
(57 1f, 1g, 2a d, 2a e, and 2 e) and five pIND 0 (1-5) clones with and without 5µM pon A 
158induction for 48 hours as described in Section 2.5. All assays were performed blinded. 
Table 3.3. and Figs. 3.24. and 3.25. show the enzyme specific activities and the ratio of 
these activities to citrate synthase (CS) enzyme specific activity or “CS ratio” with and 
without pon A induction. There was a significant reduction of 9% in complex II/III CS 
ratios in the untreated versus treated MT clones (p=0.05) (Fig. 3.25). There were no other 
significant differences between the treated and untreated clones in all cell types. For each 
of the 5 pIND 0, WT and MT clones, the pon A treated activities and ratios were 
subtracted from the untreated values to obtain the difference in activity related to pon A 
(Figs 3.26a and b and Table 3.4). There was no significant difference in either the CS 
ratios or the specific activities between WT, MT and pIND0 clones (Fig. 3.26c). There 
was a trend for lower specific activities in WT and MT clones for complexes II/III and IV 
versus pIND 0 (Fig. 3.26a) but this did not reach statistical significance and was not 
present when CS-corrected for total mitochondrial numbers (Fig. 3.26b).
Enzyme/Clone pIND 0 pIND 0 WT WT MT MT
Pon A + - + - + -
I
(nmols/mg/min)
80.0
±11.3
70.3
±8.2
104.0
±19.0
90.5
±19.0
73.4
±10.0
70.6
±9.2
II/III (nmols/mg/min) 260
±34
259
±29
271
±26
301
±53
223
±17
256
±26
IV (nmols/mg/min) 7.90
±0.58
7.71
±0.47
8.86
±1.06
9.19
±1.33
7.62
±0.91
8.68
±0.83
CS x 10 
(nmols/mg/min)
814
±46
898
±88
919
±89
992
±110
779
±58
984
±80
I (CS ratio) 0.101
±0.018
0.082
±0.014
0.120
±0.026
0.092
±0.016
0.119
±0.057
0.091
±0.046
II/III (CS ratio) 0.317
±0.029
0.288
±0.014
0.297
±0.018
0.299
±0.028
0.286
±0.010
0.260
±0.006
IVx10
-2 (CS ratio) 0.972
±0.047
0.877
±0.062
0.978
±0.115
0.923
±0.010
0.966
±0.088
0.885
±0.046
159Table 3.3 Specific enzyme activities and CS ratios for WT, MT and pIND 0 clones ±SEM 
(Figs. 3.24 and 3.25.).
Enzyme pIND 0 Wild-type Mutant
I (nmols/mg/min) 9.67±6.36 14.0±15.3 2.77±4.69
II/III (nmols/mg/min) 1.55±23.6 -30.2±36.4 -30.7±14.3
IV (nmols/mg/min) 1.84±7.83 -3.36±10.5 -10.06±6.25
CS x 10 (nmols/mg/min) -8.45±8.21 -7.31±9.65 -20.5±8.42
I (CS ratio) 0.019±0.007 0.027±0.012 0.028±0.01
II/III (CS ratio) 0.028±0.023 -0.002±0.020 0.026±0.011
IV x 10
-2 (CS ratio) 0.085±0.036 0.055±0.042 0.081±0.048
Table 3.4. Mean pon A-induced differences in specific enzyme activities and CS ratios 
(pon A+ minus pon A-) for WT, MT and pIND 0 clones ±SEM (Fig. 3.26.).
Fig. 3.24.
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1623.11. Aconitase function 
Aconitase can be used as an indirect measure of free radical damage especially by 
peroxynitrite. Aconitase activity was measured in five WT (21 1 h, 2a 2b, 2c, and 2 d), 
five MT (57 1f, 1g, 2ad, 2ae, and 2e) and 5 pIND 0 (1-5) clones using the technique 
described in Section 2.5.5. following induction with and without 5µM pon A for 48 hours. 
Fig. 3.27a. and Table 3.5. demonstrate the mean specific aconitase activities in pon A 
treated and untreated clones. There was no significant difference between the activities in 
treated and untreated MT, WT or pIND 0 clones (Fig. 3.27a).
Cell Type
Mean specific aconitase activity (nmols/mg/
min) ±SEM
Mean specific aconitase activity (nmols/mg/
min) ±SEM
Pon A + -
pIND 0 9.30±1.16 7.49±0.68
WT 10.1±1.3 8.43±0.30
MT 7.81±0.81 6.38±0.76
Table 3.5. Mean specific aconitase activities for 5 WT, 5 MT and 5 pIND 0 clones ± SEM 
(Fig. 3.27a).
Fig. 3.27b and Table 3.6. demonstrate the mean pon A-induced difference in specific 
aconitase activities between treated and untreated clones i.e. pon A–DMSO treated 
163clones. Table 3.6. demonstrates that there was a trend for lower activities in the WT than 
pIND 0 and in the MT versus WT but there was no significant differences (Fig. 3.27b). 
There was also an increase in aconitase activity in pIND 0, WT and MT clones treated 
with pon A. This may have been caused by an induction of aconitase activity by pon A.
Fig 3.27.
164Cell Type Mean ponA-induced difference in specific activity (nmols/mg/min)
pIND 0 1.82±1.34
21 CAG 1.67±1.40
58 CAG 1.43±0.460
Table 3.6. Mean pon A-induced difference in specific aconitase activities for 5 WT, 5 MT 
and 5 pIND 0 clones ± SEM (Fig. 3.27b).
3.12. Toxicity of construct expression and in response to cellular toxins
Cell death was analysed using the lactate dehydrogenase (LDH) release assay to express 
the released LDH activity as a percentage of the total LDH activity within cells grown 
under identical conditions as described previously in Section 2.14.3. The five WT (21 1 h, 
2a 2b, 2c, and 2 d), five MT (57 1f, 1g, 2ad, 2ae, and 2e) and 5 pIND 0 (1-5) clones were 
used for these experiments and were grown in low glucose (1g/L) growth medium in 
order to metabolically stress the cells  and maximize the impact of any mitochondrial 
dysfunction.   Initial   pilot   experiments   were   performed   to   determine   the   optimum 
concentration of cells to add to the 12-well plates. Cells from three representative clones 
(pIND 0 1, 21 2 c and 57 2 e) were plated at 1x10
4, 5x10
4, 1x10
5, 2x10
5 and 5x10
5 per 
well at approximately 5pm and allowed to settle overnight. The next morning, the cells 
were treated with and without 5µM pon A. After 48 hours the medium was aspirated and 
replaced with the fresh medium with and without 5µM pon A. The cells were observed by 
phase-contrast microscopy every day and an estimation was made of the density of cells. 
165It was found that after 48 hours, a concentration of cells at 2x10
5/well produced 
approximately 30-50% confluency with pon A and 40-70% without pon A in pIND 0 WT 
and MT clones.
3.12.1. Background cell death 
Prior to adding toxins to the clones, the background cell death was assessed. The five MT, 
five WT and pIND 1-4 clones were plated into 12-well plates at 2x10
5/well left overnight, 
and 1 ml. of fresh medium with and without 5µM pon A was added the following 
morning. The medium was carefully aspirated after 48 hours and replaced with 1ml of 
fresh medium with and without 5µM pon A. A separate well with medium only and no 
cells was also incubated for the next 48 hours to use as control medium. After 96 hours 
following induction, an LDH assay was performed as described in Section 2.14.3. Fig. 
3.28 A and Table 3.7. demonstrate that there was a mean pon A-associated cell death of 
-1.63%± 0.406 (p=0.0024) in the pIND 0 clones, 2.85%± 0.711 (p=0.058) in the WT 
clones and -0.0491%± 0.364 (p=0.95) in the MT clones. The negative percentages means 
that there was an excess cell death in the DMSO-treated clones versus the ponA-treated 
clones. Fig. 3.28 B and Table 3.7. demonstrate the mean percentage pon A-induced cell 
death for pIND 0, WT and MT clones. There was a significant reduction in pon A-
induced cell death in pIND 0 versus WT clones (p=0.0014) and versus MT clones 
(p=0.023) (Fig. 3.28 B). There was also a significant reduction in cell death in MT versus 
WT clones (p=0.0067) (Fig. 3.28 B). Table 3.7. also demonstrates that the percentage cell 
death associated with or without pon A treatment was greater in the WT (1.59-9.58%) and 
MT (2.97-5.84%) than the pIND 0 clones (0.39-2.9%).
166Fig. 3.28.
167% Cell Death 
Pon A +
% Cell Death 
Pon A -
Pon A-induced cell death (pon A 
+ minus pon A -)
Mean % cell 
death±SEM
pIND 0 1 1.08 1.57 -0.49
pIND 0 2 0.67 2.90 -2.22 -1.63± 0.41
pIND 0 3 0.53 2.15 -1.62
pIND 0 4 0.39 2.59 -2.20
Mean 0.67 2.30 -1.63
21 1 h 2.59 1.59 1.00
21 2 a 4.81 1.77 3.03
21 2 b 9.58 4.29 5.29 2.85± 0.71
21 2 c 4.51 2.52 2.00
21 2 d 6.59 3.68 2.90
Mean 5.62 2.77 2.85
57 1 f 5.35 4.34 1.01
57 1 g 2.97 3.15 -0.18
57 2a d 3.37 3.51 -0.14 -0.05± 0.36
57 2a e 4.62 5.84 -1.22
57 2 e 5.36 5.07 0.29
Mean 4.33 4.38 -0.05
Table 3.7. Background % cell death in 4 pIND 0, 5 WT and 5 MT clones with and 
without 5µM pon A for 96 hours.
3.12.2. Toxin-induced cell death
The relative toxicity of four toxins (malonate, cyanide, paraquat and lactacystin) to the 
five WT (21 1 h, 2a 2b, 2c, and 2 d), five MT (57 1f, 1g, 2ad, 2ae, and 2e) and 5 pIND 0 
(1-5) clones following 48 hours induction with and without 5µM pon A was investigated. 
The concentration of toxin to use in subsequent experiments was determined by plating 
pIND 0 1 clone at 2x10
5  per well in 12-well plates and, allowing the cells to settle 
overnight. The cells were then treated for two days with growth medium and DMSO 
(5µL/ml of medium) and the medium was carefully aspirated and replaced with fresh 
medium containing a broad range of toxin doses (see below for details on individual 
168toxins). Cell death was visually assessed using phase-contrast microscopy after 48 hour 
toxin exposure and the concentration which produced approximately 30-50% cell death 
was taken as a dose around which to base a subsequent toxicity curve. This range was 
taken, because of concerns that the combination of pon A and a toxic would produce 
rapid and early cell death. For each toxin a similar experiment was then repeated, except 
with clones pIND 0 1, 21 2 c and 57 2 e, and rather than visually assessing the degree of 
toxicity after 48 hours the samples were processed for the LDH assay.
3.12.3. Toxicity experiments
3.12.3.1. Malonate
Malonate is a reversible inhibitor of complex II of the mitochondrial respiratory chain. A 
toxicity curve (data not shown) using malonate at doses between 0 and 200mM suggested 
that 150mM of malonate produced between 20-40% cell death at 48 hours in the three 
clones. Five WT (21 1 h, 2a 2b, 2c, and 2 d), five MT (57 1f, 1g, 2ad, 2ae, and 2e) and 5 
pIND 0 (1-5) clones were induced with and without 5µM pon A for 48 hours and 
subsequently a further 48 hours with 150mM malonate. An LDH assay was performed on 
all clones as described in Section 2.14.3. and performed a total of four times. Table 3.8. 
demonstrates the combined results from these 4 experiments. The mean % cell death for 
each clone with (column 2 Table 3.8.) and without ponA (column 3 Table 3.8.) induction 
and the mean % pon A-induced cell death (pon A –DMSO) for each clone (columns 4 
Table 3.8.) were calculated. Fig. 3.29 A demonstrates that there was a significant increase 
in the cell death between treated and untreated pIND 0, WT and MT clones (pIND 0 
p=0.0007, WT p=0.0337, MT p=0.0018). Fig. 3.29 B demonstrates that there was a trend 
169for greater toxicity in MT versus WT versus pIND 0 clones but that this was not 
significant.
Clone
Mean % Cell 
death pon A
Mean % Cell 
death DMSO
Pon A-induced % 
cell death (pon A –
DMSO)
Mean pon A-induced 
% cell death±SEM
pIND 0 1 31.8 15.9 15.9
pIND 0 2 31.3 11.8 19.5
pIND 0 3 25.7 16.9 8.78 12.3±2.84
pIND 0 4 32.3 18.1 14.1
pIND 0 5 26.5 23.2 3.37
21 1 h 55.1 32.2 23.0
21 2 a 25.3 14.4 10.9
21 2 b 33.1 24.3 8.74 15.5±2.95
21 2 c 35.1 13.0 22.1
21 2 d 34.4 21.6 12.8
58 1 f 40.9 22.5 18.5
58 1 g 32.0 15.1 16.9
58 2a d 35.0 17.2 17.8 17.5±3.08
58 2a e 49.8 23.0 26.8
58 2 e 33.8 26.3 7.46
Table 3.8. Malonate-induced % cell death in 5 pIND 0, 5 WT and 5 MT clones with and 
without 5µM pon A for 96 hours and malonate (150mM) for 48 hours.
Fig. 3.29.
1703.12.3.2. Cyanide
Cyanide is an irreversible inhibitor of complex IV of the mitochondrial respiratory chain. 
A toxicity curve using cyanide at doses between 0 and 50mM suggested that 20mM 
cyanide produced approximately 40-80% cell death. Five WT (21 1 h, 2a 2b, 2c, and 2 d), 
five MT (57 1f, 1g, 2ad, 2ae, and 2e) and 5 pIND 0 (1-5) clones were induced with and 
without 5µM pon A for 48 hours and subsequently a further 48 hours with 20mM 
cyanide. An LDH assay was performed on all clones as described in Section 2.14.3. and 
performed a total of four times. Table 3.9. demonstrates the combined results from these 4 
experiments. The mean % cell death for each clone with (column 2 Table 3.9.) and 
171without ponA (column 3 Table 3.9.) induction and the mean % pon A-induced cell death 
(pon A –DMSO) for each clone (column 4 Table 3.9.) were calculated. Fig. 3.30 A 
demonstrates that there was a significant reduction in cell death with cyanide in all pon A 
treated   clones   (pIND   0   p=0.0001,   WT   p=0.0019,   MT   p=0.0012).  Fig.   3.30   B 
demonstrates that there was a significant (p=0.0406) reduction in cell death in MT cells 
versus pIND 0 clones.
 
Table 3.9. Cyanide-induced % cell death in 5 pIND 0, 5 WT and 5 MT clones with and 
without 5µM pon A for 96 hours and cyanide (20mM) for 48 hours.
Clone
Mean % Cell 
death pon A
Mean % Cell 
death DMSO
Pon A-induced % 
cell death (pon A –
DMSO)
Mean pon A-induced 
% cell death±SEM
pIND 0 1 43.5 60.9 -17.3
pIND 0 2 46.8 60.1 -13.4
pIND 0 3 42.7 59.3 -16.6 -16.2±1.41
pIND 0 4 34.3 54.9 -20.6
pIND 0 5 43.0 55.9 -12.9
21 1 h 43.8 59.1 -15.3
21 2 a 34.6 66.7 -32.2
21 2 b 43.9 69.7 -25.8 -21.0±3.42
21 2 c 32.2 48.5 -16.4
21 2 d 38.2 53.4 -15.3
57 1 f 48.1 78.3 -30.1
57 1 g 47.9 79.6 -31.8
57 2a d 46.1 65.5 -19.4 -27.9±4.59
57 2a e 24.8 66.6 -41.8
57 2 e 46.35 62.6 7.46
172Fig. 3.30.
1733.12.3.3. Paraquat
Paraquat is an intracellular generator of the free radical, superoxide. A toxicity curve 
using paraquat at doses between 0 and 5 mM suggested that 5mM of paraquat produced 
approximately 20-50% cell death. Five WT (21 1 h, 2a 2b, 2c, and 2 d), five MT (57 1f, 
1g, 2ad, 2ae, and 2e) and 5 pIND 0 (1-5) clones were induced with and without 5µM pon 
A for 48 hours and subsequently for a further 48 hours with 5 mM paraquat. An LDH 
assay was performed on all clones as described in Section 2.14.3. and performed a total of 
seven times. Table 3.10. demonstrates the combined results from these 7 experiments. 
The mean % cell death for each clone with (column 2 Table 3.10.) and without ponA 
(column 3 Table 3.10.) induction and the mean % pon A-induced cell death (pon A –
DMSO) for each clone (columns 4 Table 3.10.) were calculated. Fig. 3.31 A demonstrates 
that there was a significant increase in cell death with paraquat in pIND 0 and MT pon A 
treated clones (pIND 0 p=0.0015 and MT p=0.0375) but not in WT clones (p=0.2486). 
Fig. 3.31 B demonstrates that paraquat produced a significant increase in cell death in MT 
(23.5%±3.68) versus pIND 0 (11.7%±1.83) clones (p=0.0350). There was also a trend for 
WT (16.0%±4.65) clones to also demonstrate increased cell death but this was not 
significant (p=0.429).
174Clone
Mean % Cell 
death pon A
Mean % Cell 
death DMSO
Pon A-induced % 
cell death (pon A –
DMSO)
Mean pon A-induced 
% cell death±SEM
pIND 0 1 37.9 22.6 15.3
pIND 0 2 30.4 22.7 7.75
pIND 0 3 30.4 21.4 8.98 11.7±1.83
pIND 0 4 42.7 25.8 16.9
pIND 0 5 33.2 23.6 9.68
21 1 h 80.2 80.9 -0.670
21 2 a 60.68 33.2 27.3
21 2 b 60.5 41.1 19.43 16.0±4.65
21 2 c 37.7 18.3 19.4
21 2 d 71.6 57.1 14.5
57 1 f 75.6 48.8 26.8
57 1 g 69.8 36.4 33.4
57 2a d 68.5 43.3 25.2 23.5±3.68
57 2a e 55.2 34.2 21.0
57 2 e 30.7 19.5 11.1
Table 3.10. Paraquat-induced % cell death in 5 pIND 0, 5 WT and 5 MT clones with and 
without 5µM pon A for 96 hours and paraquat (5mM) for 48 hours.
175Fig 3.31
1763.12.3.4. Lactacystin
Lactacystin is a proteosomal inhibitor. A toxicity curve using lactacystin at doses between 
0 and 10µM suggested that with 7.5µM of lactacystin produced approximately 20-50% 
cell death. Five WT (21 1 h, 2a 2b, 2c, and 2 d), five MT (57 1 f, 1 g, 2a d, 2a e, and 2 e) 
and 5 pIND 0 (1-5) clones were induced with and without 5µM pon A for 48 hours and 
subsequently for a further 48 hours with 7.5µM paraquat. An LDH assay was performed 
on all clones as described in Section 2.14.3. and performed a total of seven times. Table 
3.11. demonstrates the combined results from these 7 experiments. The mean % cell death 
for each clone with (column 2 Table 3.11.) and without ponA (column 3 Table 3.11.) 
induction and the mean % pon A-induced cell death (pon A –DMSO) for each clone 
(columns 4 Table 3.11.) were calculated. Fig. 3.32 A demonstrates that there was no 
significant change in cell death with lactacystin in all pon A treated versus untreated 
clones (pIND 0 p=0.894, WT p=0.0544 and MT p=0.747). Fig. 3.32 B demonstrates that 
lactacystin treatment showed a significant increase in cell death in MT (1.57±1.22%) 
clones versus WT (-5.62%±1.63) (p=0.0097) and a significant decrease between in cell 
death in WT (-5.62%±1.63) versus pIND 0 (-0.138%±0.352) (p=0.030). There was trend 
for slightly greater cell death in MT versus pIND 0 but this was not significant (p=0.252). 
177Clone
Mean % Cell 
death pon A
Mean % Cell 
death DMSO
Pon A-induced % 
cell death (pon A –
DMSO)
Mean pon A-induced 
% cell death±SEM
pIND 0 1 20.7 21.4 -0.715
pIND 0 2 18.9 18.7 0.196
pIND 0 3 19.8 19.0 0.793 -0.138±0.352
pIND 0 4 20.2 20.0 0.201
pIND 0 5 17.0 18.1 -1.16
21 1 h 22.6 33.8 -11.2
21 2 a 18.7 20.2 -1.50
21 2 b 21.5 25.2 -3.65 -5.62±1.63
21 2 c 18.9 23.9 -5.00
21 2 d 22.7 29.6 -6.82
57 1 f 33.1 28.9 4.28
57 1 g 29.3 25.0 4.25
57 2a d 27.24 27.6 -0.37 1.57±1.22
57 2a e 20.9 19.4 1.52
57 2 e 11.8 13.6 -1.85
Table 3.11. Lactacystin-induced % cell death in 5 pIND 0, 5 WT and 5 MT clones with 
and without 5µM pon A for 96 hours and lactacystin (7.5µM) for 48 hours.
Fig. 3.32
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Results
A constitutive EYFP-tagged 
full-length htt 
SH-SY5Y cell model
1804.1. Plasmids
The pEYFP-C1 (Clontech, San Jose, CA, USA) encodes an enhanced yellow fluorescent 
protein (EYFP) 5’ to the multiple cloning site. The EYFP-C1 plasmids were a kind 
donation by Dr. Lesley Jones, University of Cardiff, UK. Details of the donated plasmids 
are in Section 2.3.1. and Fig. 2.2. PcDNA 3.1 (Invitrogen, UK) is a 5.4kb vector derived 
from pcDNA3 and is designed for high-level transient or stable expression in mammalian 
hosts. It also contains a multiple cloning site and a neomycin resistance gene.
4.2. Transfections
SH-SY5Y cells were transfected with the EYFP-C1 containing 88 CAGs in FL htt (MT), 
23 CAGs in FL htt (WT), and EYFP-C1 without any insert (EYFPcon). Clones were 
grown and harvested as described in section 2.3.3. using G418 at 250µg/ml of medium 
for selection (Clontech). Thirty WT clones and thirty MT clones were taken forward for 
further analysis. Four EYFP-C1 clones with no construct were also investigated and were 
labeled “EYFPcon”. SH-SY5Y cells transfected with the pcDNA 3.1 plasmid and 
contained no construct were used as a cloned control cell line with G418 selection.
4.3. Expression of constructs on fluorescence microscopy
Cells from each cell line were processed for fluorescence microscopy as described in 
section 2.2.5. The clones were named such that they were either “23” or “88” representing 
the WT and MT number of CAG repeats, the next number represented the plate that the 
clone was taken from and the final number was the number of the clone from the plate. 
Figs. 4.1A and B demonstrate clones 23 1 1, 23 3 3, 23 6 7 and 23 7 2 and 88 1 3, 88 2 8, 
18188 2 9, and 88 2 11 on fluorescence microscopy using the FITC filter, which gave a bright 
green homogenous cytoplasmic fluorescence from all the WT and MT cells. Cells without 
fluorescence were rare in the clones that were selected. Fig. 4.1. C demonstrates a 
representative positive EYFP control clone, EYFPcon 2 2, without any construct, which 
displayed   intense  homogeneous   nuclear   (Arrows   in   fig.   4.1.   C)   and   cytoplasmic 
fluorescence, and a typical pcDNA3.1 control clone (pcDNA3.1 1) which demonstrated 
background fluorescence only. The nuclear translocation of the EYFP tag in EYFPcon 
clones, which was absent in the WT and MT EYFP clones, was considered to render the 
EYFPcon clones inappropriate as controls. PcDNA3.1 clones were therefore used as 
control cells. Table 4.1. lists the clones isolated based on positive fluorescence. The 
clones 23 1 1, 23 3 3, 23 6 7, 23 7 2, 23 7 7, 23 7 8 and 23 7 10 and 88 1 3, 88 2 8, 88 2 9, 
88 2 11, 88 3 1, 88 3 3, 88 3 10 and 88 3 11 demonstrated greater than 99% of cells with 
EYFP fluorescence and were taken forward to Western blot analysis. There was no 
evidence of inclusion formation on fluorescence microscopy of the EYFP tag in any of 
the WT or MT clones. The MT clones took longer to reach confluence suggesting they 
grew slightly slower than the WT although this was not quantified experimentally. There 
were otherwise no clear differences between the WT and MT clones on fluorescence 
microscopy and no difference in the cellular morphology between the WT, MT, EYFPcon 
or pcDNA 3.1 clones. The MT and WT clones expressed similar intensities of EYFP 
fluorescence as assessed qualitatively on fluorescence microscopy.
Fig. 4.1.
182Wild-type clones Mutant clones pcDNA 3.1 EYFPcon
23 1 1 88 1 3 pc DNA 3.1 1 EYFPcon 1 2
23 3 3 88 2 8 pc DNA 3.1 2 EYFPcon 2 2
23 6 7 88 2 9 pc DNA 3.1 3 EYFPcon 3 1
23 7 2 88 2 11 pc DNA 3 .1 4 EYFPcon 3 2
23 7 7 88 3 1
23 7 8 88 3 3
18323 7 10 88 3 10
88 3 11
Table 4.1. WT, MT, pcDNA 3.1 and EYFPcon clones.
4.4. Western blots of EYFP clones
The 7 WT and 8 MT clones were prepared for Western Blot analysis as described in 
Section 2.9. The tris-acetate pre-cast gels (Invitrogen) were used because of the large size 
of the htt product (370kDa for WT htt EYFP and 377 kDa for MT EYFP) and the gels 
were run for three hours. The blots were probed with anti-EYFP antibody (1 in 1000) 
(Clontech). All WT and MT clones expressed cross-reactive bands to anti-EYFP (Fig. 
4.2A and B). A single band at approximately 370kDa was apparent in the WT clones and 
there was no evidence of additional bands or material in the wells. The strongest 
expressing clones were 23 1 1, 6 7, 7 7 and 7 10. Clone 7 8 had the lowest levels of 
expression on Western blot. Of the 8 MT clones, four (88 1 3, 2 8, 2 9 and 2 11) 
expressed a single band at the predicted size of 377kDa (solid arrow in Fig. 4.2B), two 
(88 3 3 and 3 10) expressed an intense band at 335kDa. (dashed arrow in Fig. 4.2B) and a 
faint band at 377kDa.(not seen in Fig. 4.2B)and two (88 3 1 and 3 11) expressed bands at 
377kDa and 335 kDa. The anti-EYFP antibody did not detect any construct expression 
from clone pcDNA 3.1 1. All MT clones demonstrated similar levels of construct 
expression although clone 88 1 3 was consistently stronger. 
Fig. 4.2.
184To compare the relative mobility of the WT and MT EYFP expressed proteins with 
endogenous htt, 3 clones were separated in two groups on the same gel, and one half was 
probed with anti-EYFP and the other half with Ab675 (Fig. 4.2C). The WT htt EYFP 
band (red arrow in Fig. 4.2C) migrated slightly further than the MT htt EYFP band (black 
arrow in Fig. 4.2C) and both migrated slightly less than the Ab675 cross-reactive bands of 
endogenous htt (dotted arrow in Fig. 4.2C). The additional EYFP band identified in some 
of the MT clones, migrated the fastest (dashed arrow in Fig. 4.2C). Neither WT nor MT 
185EYFP htt were recognised by Ab675 (dotted arrow in Fig. 4.2C). Ab675 recognises the 
first 9 amino acids of htt and the anti-EYFP antibody recognized the N-terminal EYFP 
tag. The absence of cross-reactivity of WT and MT htt EYFP with Ab675 could therefore 
have been caused by blocking of the binding site by the EYFP N-terminal tag. 
To clarify the relative mobilities of the htt species, four MT clones and four WT clones 
that did not express an additional band, were separated and probed with anti-EYFP and 
Ab675 simultaneously (Fig. 4.2D). The WT and MT htt EYFP clones demonstrated a 
construct htt band (red arrow for WT and black arrow for MT in Fig. 4.2D) and an 
endogenous htt band (dotted arrow in Fig. 4.2D). The representative pcDNA3.1 clone 
demonstrated only an endogenous htt band (dotted arrow in Fig. 4.2D). The difference in 
size between the WT and MT htt EYFP bands is also demonstrated and would be 
compatible with the predicted 7.1 kDa difference between WT and MT constructs.
4.5. Anti-huntingtin antibodies and immunofluorescence
The anti-huntingtin antibodies and their respective epitopes can be found in Fig. 2.1. and 
Table 2.1. In order to characterise the location of different sized fragments of htt in both 
WT and MT htt EYPC clones, mitotic cells from clones 23 1 1 and 88 1 3, as 
representative WT and MT clones, were developed with the panel of htt antibodies. The 
immunofluorescence is shown in Fig. 4.3. All htt antibodies showed diffuse cytoplasmic 
co-localisation with the EYFP fluorescent tag in WT and MT clones. Antibody 7667 
consistently demonstrated uniform punctate nuclear staining in the WT clones which was 
more prominent than in MT cells (solid arrows in Fig. 4.3). This also occurred in the other 
WT and MT clones (data not shown). There were occasional rare cytoplasmic inclusions 
186noted only in the MT cell lines, as seen with antibody 2168 in Fig. 4.3 (round stippled 
arrow).
Pc DNA 3.1 clones demonstrated cytoplasmic staining that was less intense and more 
punctate than the htt transfected clones with all antibodies. Antibodies EM48, Ab2166 
and Ab2168 stained much less intensely than Ab7668, Ab7667, and Ab7666. There was 
punctate nuclear staining with antibody Ab7667 similar, but more intense, than the EYFP 
htt-transfected cells and a less intense nuclear pattern with Ab7668 (Fig. 4.3 solid arrow). 
There was also a collection of punctate staining in a perinuclear location with Ab7667 
and Ab7668 antibodies which was more difficult to observe in EYFP htt-transfected 
clones, possibly due to strong cytoplasmic staining (Fig. 4.3 stippled square arrows). 
Ab7666 demonstrated a diffuse cytoplasmic staining in controls similar to WT and MT 
clones.
4.6. Characterisation of the anti-EYFP cross-reactive bands in MT clones
The additional bands in some MT htt EYFP clones were further characterised on Western 
blotting using anti-huntingtin antibodies to define which epitopes were cross-reactive. 
The most C-terminal anti-htt antibody, Ab7666 (2703-2911aa), did not detect 
Fig. 4.3.
187the additional lower molecular weight band in clones 88 3 1, 3 3, 3 10 and 3 11 (Fig. 4.4. 
A) but did recognize both endogenous htt (dotted arrow) and WT (red arrow) and MT 
(black arrow) htt bands. Ab2168 (2146-2541aa) and Ab7667 (1844-2131aa) detected 
endogenous htt (round stippled arrow) as well as the expected (black arrow) and 
additional (square stippled arrow) MT htt bands (Fig. 4.4. B and C). This suggests that the 
additional band had lost the most C-terminal epitope of Ab7666 (aa2703-2911) but had 
188retained the epitope recognised by Ab2168 (aa2146-2541). The additional band was 
therefore a truncated form of htt with the C-terminal between aa 2541 and 2703.
The WT htt band would be predicted to migrate at 370kDa, the MT htt band at 
approximately 377kDa and endogenous htt at 348kDa. The additional band in some of the 
MT clones would therefore be predicted to be approximately 335kDa with loss of 
approximately 320aa at the C-terminus.
Fig. 4.4.
1894.7. Sequencing of 5’ and 3’ ends of the inserted cDNA in each clone
DNA from WT htt clones 1 1, 3 3, 6 7, 7 2, 7 7, 7 8 and 7 10 and MT htt clones 1 3, 2 8, 2 
9 and 2 11 was PCR amplified using the EYFP-F (sequencing from base -111) and RS2-R 
(reverse sequencing from base+282) primers (Section 2.4.7. for sequence of primers) to 
sequence the 5’ junction between EYFP plasmid and the construct (Fig. 4.5A). The 
190products were run on an agarose gel as described in section 2.4.5. The predicted products, 
based on the correct insertion of the constructs at the restriction sites, were 393 base-pairs 
for WT clones and 588 base-pairs for MT clones. Fig. 4.6. demonstrates an approximately 
400bp product from all the WT clones and an approximately 600bp product from all the 
MT clones. The PCR products were purified with Qiagen PCR clean-up kit and 
commercially sequenced by MWG biotech (Milton Keynes, UK). The WT constructs 
were found to be correctly sequenced and in frame for all clones. The MT constructs were 
also correctly sequenced and in frame for all clones. The sequencing of the CAG repeats 
could not precisely confirm the number of repeats in the MT clones as the sequencing 
reaction terminated in both directions before sequencing the whole of the repeat region. 
The PCR product size was still compatible with 88 CAG repeats and the sequencing 
reliably demonstrated over 75 CAGs i.e. MT range, in each clone (Fig. 4.7.A and B for 
sample sequence chromatograms).
DNA from WT htt clones 23 1 1, 3 3, 6 7, 7 2, 7 7, 7 8 and 7 10 and MT htt clones 88 1 3, 
2 8, 2 9 and 2 11 were PCR amplified using the using the R2 and F3 primers to sequence 
the 5’ junction between EYFP plasmid and the construct (Fig. 4.5B). The predicted 900bp 
PCR product was observed with all WT clones (Fig. 4.8A) and six out of eight of the MT 
clones (Fig. 4.8B) as well as from the parent WT and MT EYFP-C1 plasmids (Fig. 4.8C). 
Clones 88 3 3 and 3 10 did not demonstrate a 900bp band and this
Fig. 4.5.
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196 would be consistent with the relative absence of a FL MT htt band on Western blotting 
and suggests that these clones contained 3’ truncated cDNA. The R2/F3 PCR products 
were purified with Qiagen PCR clean-up kit and commercially sequenced by MWG 
biotech (Milton Keynes, UK). The correct 3’ sequence and frame were found in all clones 
(Fig. 4.7C demonstrated sequence chromatograms for a representative WT clone, 23 3 3).
1974.8. Selection of clones
Clones 23 1 1, 3 3, 6 7 and 7 2 and 88 1 3, 2 8, 2 9, and 2 11 were chosen as 
representative  clones   for   WT  and  MT  cell   lines  to   perform  subsequent  detailed 
experiments. These clones demonstrated positive EYFP immunofluorescence, a predicted 
band on Western Blot analysis and the correct sequence at 5’ and 3’ ends of the integrated 
constructs. Clones 88 3 1, 3 3, 3 10 and 3 11 were not taken forward because of the 
uncertainty of the additional band on Western blotting which was probably due to a 3’ 
truncated species of MT htt EYFP cDNA.
4.9. Differentiation of EYFP clones 
4.9.1. Growth characteristics and IF of differentiated SH-SY5Y clones
Four MT, WT and pcDNA 3.1 clones were differentiated for 2, 7 and 14 days and 
processed for EYFP fluorescence microscopy as described in section 2.2.7. The WT 
clones demonstrated processes by day 2 and continued to develop complex networks of 
198processes by day 14 (stippled arrows in Fig. 4.9.). One WT clone (23 1 1) consistently 
demonstrated uniform nuclear fluorescence in approximately 50% of cells up to day 14 
differentiation (solid arrows Fig. 4.9.). The other WT clones, especially 23 6 7, 
demonstrated inconsistent nuclear fluorescence (solid arrows Fig. 4.9). The MT htt clones 
demonstrated formation of processes by day 7 which were still present at day 14 (solid 
arrows Fig.4.10.). The MT clones formed shorter and thicker processes (stippled arrows 
Fig. 4.10.). There was an absence of nuclear fluorescence at all stages of differentiation in 
all MT clones. There was no evidence of inclusion formation in any of the clones within 
the two week study period of differentiation. The WT clones readily differentiated by day 
2 compared to day 7 in the MT clones (Figs. 4.9 and 4.10). The WT clones (Fig. 4.11 A) 
also developed more interconnecting and complex networks of processes than the MT 
clones (Fig. 4.11B). The control clone pcDNA 3.1 1 differentiated by day 2 with complex 
networks of processes similar to WT clones (figures not shown) in the absence of 
fluorescence.
Fig 4.9.
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200Fig. 4.11. 
2014.9.2. Immunofluorescence and Western blots in differentiated clones
To investigate the effects of differentiation on processing of WT and MT EYFP htt and 
endogenous htt, the representative MT (88 1 3) and WT (23 1 1) clones and control cells 
(pcDNA3.1 1) were differentiated for two weeks with retinoic acid and then developed 
with the panel of anti-htt antibodies using the protocols previously described in sections 
2.2.5, 2.2.6.1 and 2.2.7. Figs. 4.12-14 show the patterns of staining demonstrated with 
202anti-htt antibodies. These were similar to mitotic clones except for the following 
considerations. Firstly, antibody 7666 demonstrated a granular cytoplasmic pattern of 
staining (solid arrows in Figs. 4.12-14) with evidence of perinuclear accumulation in 
pcDNA 3.1, WT and MT clones (yellow arrows in figures 4.12-14) unlike in mitotic cells 
where there was greater uniformity of cytoplasmic staining and without perinuclear 
accumulation. Secondly, there was an increase in nuclear punctate staining with Ab7667 
in differentiated versus cycling MT clones (Fig. 4.3 versus 4.13). This was also observed, 
to a lesser degree, in the WT clones (Fig. 4.3 versus 4.12).
To further investigate the effects of differentiation on processing of WT and MT EYFP 
htt and endogenous htt, the representative MT (88 1 3) and WT (23 1 1) clones and 
control cells (pcDNA3.1 1) were differentiated for three days with retinoic acid and 
processed for Western blotting and developed with anti-huntingtin antibodies. Fig. 4.15. 
A. demonstrates that following two weeks differentiation of 23 1 1 and 88 1 3 clones, 
there  was   a  marked   reduction   in   the  intensity   of   the  cross-reactivity   of   Ab675 
(endogenous htt) and anti-EYFP (EYFP htt) on Western blots compared to mitotic 88 1 3 
and pcDNA 3.1 cells with equal protein loading. Fig. 4.15. B. demonstrates the full 
Western blot of mitotic and 2 week differentiated 23 1 1, 88 1 3 and pcDNA 3.1 1 clones 
probed with Ab675 and anti-EYFP in parallel. There was no evidence of signal 
Fig. 4.12.
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206within the loading well with either Ab675 or anti EYFP in any of the clones which 
suggested that aggregates were not formed. Anti-EYFP probing demonstrated that there 
was loss of a 60 kDa band (red arrow) and a 100kDa band (round stippled arrow) in all 
the differentiated clones including pcDNA 3.1 1, suggesting that this was a non-specific 
change   in   cross-reactivity   to   anti-EYFP   following   differentiation.   In   the   three 
differentiated clones tested (23 1 1, 88 1 3 and pcDNA 3.1 1) there was a gain of a band 
at 63kDa (yellow arrow in Fig.4.15.B) which was non-specific as it was present with 
207pcDNA 3.1 1. Ab675 demonstrated a reduction in endogenous htt expression in 
differentiated 23 1 1 and 88 1 3 (square stippled arrow Fig. 4.15. B) but not in 
differentiated pcDNA 3.1 1 clones and mitotic 88 1 3 cells, suggesting a reduction in 
endogenous htt expression in MT and WT EYFP clones following differentiation. To 
investigate the effects of more prolonged differentiation on inclusion formation and htt 
processing, 23 1 1, 88 1 3 and pcDNA 3.1 1 clones were differentiated for four weeks and 
a Western blot performed and probed with EM48, which preferentially recognises 
expanded polyglutamine tracts, and anti-EYFP in parallel on the same blot (Fig. 4.16). By 
4 weeks differentiation, there was still ongoing WT and MT EYFP htt expression as 
recognised by anti-EYFP cross-reactivity (Fig. 4.16. red arrow). The intensity of the 
cross-reactivity to anti-EYFP, was less in the differentiated clones versus the mitotic 88 1 
3 clone which was similar to that seen at 2 weeks differentiation. An additional band of 
approximately 90kDa was observed in the four week differentiated 23 1 1 clone with anti-
EYFP (Fig. 4.16 yellow arrow) that was not observed at two weeks differentiation. This 
may have represented an N-terminal truncated species of WT EYFP htt that formed 
during differentiation. The EM48 antibody poorly recognised WT and MT EYFP htt 
expression (Fig. 4.16. dotted arrow on left of figure). Cross-reactivity to EM 48 at a 
position consistent with endogenous huntingtin was observed in all the differentiated 
clones greater than in the mitotic 88 1 3 clone (Fig. 4.16. blue arrow).
Fig. 4.16.
2084.10. Treatment with lactacystin
4.10.1. Inclusion formation within mitotic WT and MT htt EYFP clones
Lactacystin causes UPS inhibition and therefore reduces the degradation of ubiquitinated 
protein. In order to investigate the effects of lactacystin on inclusion formation, WT and 
MT EYFP htt, as well as pcDNA 3.1, clones were plated out onto coverslips at 4x10
5/well 
209of a 6-well plate and left to attach overnight. The cells were treated with 5µM lactacystin 
for 24 hours, and processed for fluorescence microscopy as previously described in 
Section 2.2.5. All 4 WT and MT  htt EYFP  clones treated with 5µM lactacystin 
demonstrated brilliant green perinuclear inclusions with EYFP fluorescence (Fig. 4.17. 
white arrows) which indented the nuclear membrane. The inclusions were not present in 
pcDNA   3.1   or   untransfected   SH-SY5Y   cells   (Fig.   4.17C).   The   inclusions   were 
qualitatively more frequent in the WT clones than the MT clones and there was also 
qualitatively greater and earlier cell death in the MT clones and therefore fewer live cells 
at 24 hours. The Ab7667 antibody recognised the inclusions (Fig. 4.17. A and B yellow 
arrows) and this was confirmed by merging the two images to form yellow-green 
fluorescence (Fig. 4.17. A and B stippled arrows). 
4.10.2. Subcellular localisation of inclusions
Four WT and four MT clones were plated out at 2x10
5/well onto coverslips in a 6-well 
plate, left overnight to adhere, and treated for 24 hours with 5µM lactacystin and 
processed for immunofluorescence using the primary antibodies to localise subcellular 
compartments as shown in Table 2.2B.
Fig. 4.17.
210The perinuclear inclusions co-localised to regions of strong COX 1 fluorescence (Fig. 
4.18. A) but not to Golgi complex (Fig. 4.18. B). Subcellular compartment staining for 
pcDNA 3.1 is demonstrated in Fig. 4.19. except for ubiquitin which poorly stained. There 
was evidence of perinuclear COX 1 accumulation in the lactacystin-treated pcDNA 3.1 
cells (Fig. 4.19 arrow). The cross-reactivity to ubiquitin, VMAT-1 and 2 and LAMP 
antibodies, following lactacystin treatment, did not demonstrate any co-localisation with 
EYFP in WT or MT htt EYFP clones (data not shown). 
2114.10.3. Inclusions and anti-htt antibodies in mitotic and differentiated cells
In order to investigate whether truncated htt products were present in the lactacystin-
induced inclusions, the three representative clones (23 1 1, 88 1 3 and pcDNA 3.1 1) were 
treated with 5.0µM lactacystin for up to 24 hours and developed with EM 48, Ab2166, 
Ab7668, Ab7667, Ab2168 and Ab7666 anti-htt antibodies. If co-localisation of an anti-htt 
antibody with EYFP inclusion fluorescence was absent then this would suggest truncation 
of htt. Fig.4.20. A (23 1 1) and B (88 1 3) demonstrate that all of the anti-huntingtin 
antibodies positively stained the perinuclear inclusions in MT and WT clones following 
lactacystin treatment, except for Ab7666 which consistently poorly stained the edges of 
the inclusions (Fig.4.20.A and B arrows). This suggested that htt truncation between 
Ab2168 (aa2146-2541) and Ab7666 (aa2703-2911) may have occurred in WT and MT 
clones. The most intense staining of the inclusions occurred with antibodies EM48, 
Ab2166 and Ab2168 supplied by the same manufacturer (Fig.4.20.A and B) suggesting 
that the intensity of inclusion fluorescence was, at least in part, determined by the source 
of the anti-huntingtin antibody as the htt epitopes recognised by these antibodies were 
evenly distributed along the whole protein.
Fig. 4.18.
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214Lactacystin–treated pcDNA 3.1 clones demonstrated a pattern of staining with anti-
huntingtin antibodies that was similar to that seen in untreated pc DNA 3.1 cells (Fig. 
4.20C). The staining was absent with EM48 and relatively weak with antibodies Ab2166 
and Ab2168. The htt staining was stronger with more punctate cytoplasmic granules using 
Ab7666, Ab7667 and Ab7668. This was consistent with earlier observations that the 
EM48, Ab2166 and Ab2168 recognised ectopically expressed htt better than endogenous 
htt on immunofluorescence.
215Htt inclusions have been found to form more readily in differentiated cells in comparison 
to mitotic cells and following treatment with lactacystin. The influence of differentiation 
on inclusion formation following treatment with lactacystin, was therefore investigated. A 
representative WT (23 1 1) and MT (88 1 3) clone and control cells (pcDNA3.1 1) were 
differentiated for 48 hours with retinoic acid. Fresh medium containing retinoic acid and 
lactacystin was then added to the cells for 24 hours. The cells were developed with the 
panel of anti-htt antibodies. The staining pattern was similar to cycling cells treated with 
5µM lactacystin for 24 hours alone (Fig. 4.21A (23 1 1), 4.21B (88 1 3) and 4.21C (pc 
DNA 3.1 1).
4.10.4. Western blots of clones treated with lactacystin
To investigate the formation of htt cleavage products, the representative WT (23 1 1) and 
MT (88 1 3) clones and control cells (pcDNA3.1 1) were treated with lactacystin at 0, 1 or 
5µM for 24 hours. A Western blot was performed and developed with anti-EYFP. The 
WT clone treated with 1 and 5µM lactacystin demonstrated an additional band at 
approximately 44kDa (Fig. 4.22A and B solid arrow) and 34kDa (Fig. 4.22A and B red 
arrow). These bands may have been faintly present in untreated 23 1 1 cells 
Fig 4.21.
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217but were absent from MT and control cells. There was also a loss of a band in the 23 1 1 
clones at approximately 60kDa (Fig. 4.22 A and B stippled arrow). To investigate 
whether   these   changes   persisted   with   more   prolonged   lactacystin   treatment,   the 
representative clones were treated with 0 and 1µM lactacystin for 4 days with a change in 
the medium and fresh lactacystin added after 48 hours. There was no evidence of the 
additional 44kDa and 34kDa bands observed with only 24 hours lactacystin treatment in 
218the 23 1 1 clone (Fig. 4.22C). There was a 52kDa band ((Fig. 4.22C arrow) which was 
present in WT, MT and pc DNA 3.1 following treatment with 1µM lactacystin.
4.10.5. Western blots of lactacystin-treated clones using anti-htt antibodies
To investigate the processing of htt into smaller fragments following proteasome 
inhibition, clones 23 1 1, 88 1 3 and pcDNA 3.1 were treated with lactacystin for 24hrs at 
0, 1 and 5µM, separated and then probed with Ab675, EM 48, Ab2168 and Ab7666 (Fig. 
4.23).
In Fig. 4.23. A, antibody Ab675 demonstrated a band at greater than 209kDa consistent 
with endogenous huntingtin expression (see arrow in Fig. 4.23. A). There was a reduction 
in the intensity of the endogenous htt band in all three clones with increasing lactacystin 
concentration which was more pronounced with the 88 1 3 than 23 1 1 or pcDNA 3.1, 
eventhough other bands were of similar intensity suggesting that endogenous htt levels 
were reduced by lactacystin. There were no evidence of extra bands when 23 1 1 and 88 1 
3 were compared with pcDNA 3.1. 
In Fig. 4.23. B, EM 48 did not demonstrate any staining for endogenous htt in any of the 
clones. Clones 23 1 1 and 88 1 3 demonstrated a band at greater than 209kDa consistent 
Fig 4.23.
219with EYFP htt expression (red arrow). The intensity of this band reduced with increasing 
lactacystin concentration in the 88 1 3 clone but not the 23 1 1 clone. This suggests that 
lactacystin inhibition may have caused increased non-UPS degradation of MT htt, 
increased aggregation of MT htt or there was a reduction in cell construct expression. 
220In Figs. 4.23. C and D, antibodies Ab2168 and Ab7666 demonstrated a low intensity band 
in all three clones at greater than 185kDa (arrows) which represented endogenous htt. 
When probed with Ab2168, clones 23 1 1 and 88 1 3 both demonstrated strong bands 
(Figs. 4.23. C red arrow) of equal intensity at all lactacystin concentrations which 
migrated less than endogenous htt which represented EYFP htt expression. When probed 
with Ab7666, a band present at approximately 80kDa. (Figs. 4.23. D stippled arrow) 
demonstrated reduced intensity in all clones with increasing lactacystin concentration. 
This may have represented a UPS-cleaved htt fragment.
4.10.6. Western blots of lactacystin-treated clones developed with anti-EYFP
To investigate whether the changes on Western blotting following lactacystin treatment, 
occurred in other clones, the four MT and WT clones were treated for 24 hours with 5µM 
lactacystin, a Western blot performed and probed with anti-EYFP. The Western blot is 
shown in Fig. 4.24. and demonstrated an additional band at 44kDa in clone 23 1 1 (red 
arrow) as seen on previous Western blots (see Fig. 4.22. A). An additional band at 
111kDa was also observed in clone 23 6 7 (black arrow). There was also an extra band at 
36 kDa in 88 2 8, 88 2 9 and 88 2 11 clones (stippled arrows), which suggested 
processing of FL MT htt in 3 out of 4 clones to form an N-terminal fragment. This 
coincided with a reduction in the levels of EYFP MT htt 
Fig. 4.24.
221(Fig. 4.24. A. blue arrow). This suggested that lactacystin caused a reduced in MT EYFP 
htt expression by one of several mechanisms, including toxicity to strongly expressing 
cells leaving a population of proliferating poorly expressing cells or due to aggregate 
formation although there was no excess of stain in the well of MT versus WT clones to 
suggest aggregates (Fig. 4.24. A). A further explanation was that MT htt was processed 
222by a non-UPS system such as autophagy, which was activated by lactacystin inhibition of 
the UPS.
4.11. Mitochondrial function in mitotic clones
The mitochondrial function in four WT, four MT and four pcDNA3.1 clones was tested 
using the standard protocols as described in section 2.5. Fig. 4.25. A demonstrates that 
there was a significant (p<0.05) reduction in the CS corrected complex IV activity in the 
MT clones compared to WT and pcDNA3.1 clones. Fig. 4.25. B demonstrates that there 
were also similar changes in the protein corrected values but in addition there was a 
significant reduction in the complex IV activities in WT versus pcDNA 3.1.
4.12. Aconitase activity in mitotic clones
Aconitase function in four WT, four MT, four EYFPcon and four pcDNA3.1 clones was 
tested using the standard protocols as described in section 2.5.5. Fig. 4.25. C demonstrates 
that there was a significant reduction in aconitase activity in the MT cells compared to 
WT clones (p<0.01) and pcDNA3.1 (p<0.05).
Fig. 4.25.
2234.13. Proteasome function in mitotic clones
The activity of proteasome function was assessed as per protocol (Section 2.16) to 
investigate proteasomal dysfunction in response to WT and MT EYFP htt expression. 
Activities were not corrected for epoxymycin. Epoxymycin has been found to inhibit 
224chymotrypsin acitivity 100%, PGP-like activity to 70% and not inhibit trypsin-like 
activity in SH-SY5Y cells (personal communication Dr Mike Cleeter, Royal Free, UK). 
Fig. 4.26. compares the means of the 4 control, 4 WT and 4 MT clones for the 3 
proteasome activities. Fig. 4.26. A demonstrates that there was no significant difference 
between   the   clones   in   chymotrypsin-like   and   PGP-like   activities.   Fig.   4.26.   B 
demonstrates that the ‘trypsin-like’ activity was reduced in the MT clones compared to 
the WT (p<0.0001) and controls (p=0.0161) as well as being reduced in the controls 
versus the WT clones (p=0.0361). These results represented total activity in the cells and 
it can not be excluded that non-proteasomal activity was included in the findings. 
Fig. 4.26.
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Results
Mitochondrial function in 
HD muscle
2275.1. HD patient and control muscle selection
A database of 43 patients with HD at the Royal Free Hospital, London, UK was used to 
select potential patients with a view to undertaking a research muscle biopsy. Ethical 
approval had been obtained from the local research ethics committee and patients and 
their general practitioners were sent information sheets regarding the study after initial 
interest   had   been   expressed   following   contact   by   telephone.   There   were   no 
inclusion/exclusion criteria for the study apart from a genetically confirmed diagnosis of 
HD and an absence of other neuromuscular disorders which could affect the biopsy such 
as co-existing polymyositis or diabetes mellitus. Patients with all levels of disability were 
deemed acceptable. Twelve HD patients underwent consented open muscle biopsy of the 
left vastus lateralis. The majority of the sample was flash frozen in isopentane cooled in 
liquid nitrogen and stored at -80
0C and the rest was processed for ultrastructural studies. 
Twelve age and sex-matched controls were picked from the muscle bank at the Royal 
Free Hospital, London, UK. The ‘control’ biopsies were taken as a diagnostic procedure 
from patients with non-specific muscle symptoms, and showed no clinical evidence of a 
mitochondrial or neurodegenerative disease. The control patients consented to the use of 
their muscle for research and this was also approved by the local research ethics 
committee. Previous detailed histochemical analysis of these control samples did not 
reveal any abnormalities.
5.2. Genetic and clinical assessment of HD patients
All HD patients had been genotyped and the number of CAG repeats quantified by the 
department of Neurogenetics at the Institute of Neurology, London, UK or at the 
Kennedy-Galton Centre, Harrow, UK. The HD patients were also assessed clinically with 
228the modified Unified Huntington’s Disease Rating Scale (UHDRS) scale as well as basic 
clinical data such as the time between biopsy and subjective onset of symptoms. The 
UHDRS can be found in Appendix 1.6. (Huntington Study Group, 1996). In summary, 
the Motor subscale was scored out of 124 with increasing scores representing increasing 
disease severity. The Cognitive subscale was the total score of the combination of a 
verbal fluency test, symbol digit modality test, and Stroop interference test with higher 
scores representing better cognitive function. The Behavioural subscale was out of a total 
of 80 with increasing scores representing worse behaviour. The Functional checklist was 
scored between 25 and 50 with a score of 25 representing no effect on daily function and 
a score of 50 representing full functional dependence of the patient. The Independence 
subscale was a percentage score with 100% representing full independence and 10% 
representing total bed care and tube feeding. The Functional Capacity was scored from 0 
to 13 with higher scores representing higher functional dependence.
5.3. Clinical data of HD patients
Table. 5.1. shows the Unified Huntington’s Disease Rating Scale (UHDRS) for each of 
the 12 HD patients and other clinical parameters. The patients were taken from a wide 
spectrum of disease severities ranging from asymptomatic, with respect to the motor 
score, in two patients (patients 2 and 3), to severely affected and unable to perform the 
cognitive tests in one patient (patient 7). Figs. 5.1. A and B demonstrate that there was a 
significant positive correlation between motor scores and age (r=0.698, p=0.014) and a 
significant negative correlation between cognitive scores and age (r=-0.597, p=0.043). 
Figs. 5.1. C and D demonstrate that there was no correlation between cognitive (p=0.49) 
or motor scores (p=0.26) with CAG repeat length. To allow for the role of increased 
Table 5.1.
229Fig. 5.1.
230231disease duration upon the clinical score, the cognitive and motor subscales of the UHDRS 
were related to the product of the age of the patient and the number of CAG repeats. This 
was called the “CAG repeat years”. This produced a highly more significant positive 
correlation for the motor score (r=0.823, p=0.0016) and negative correlation for the 
cognitive score (r=-0.727, p=0.0096) than age alone as demonstrated in Figs. 5.1. E and F. 
Fig. 5.2. A shows that there was also a significant negative correlation between the motor 
and cognitive scores (r=-0.799, p=0.0029) in HD patients. The statistical results are 
summarised in Fig. 5.2. B.
5.4. Histochemistry, immunocytochemistry and electron microscopy
Muscle histology was performed on frozen sections for all 12 patients. The histochemical 
stains for SDH and COX revealed no discernable abnormalities in any controls or patients 
except patient 12, who was one of the more severely affected patients. Fig. 5.3. A 
demonstrates that there was an excess of SDH positive and COX negative fibres on 
histochemistry in the muscle biopsy of patient 12 which is suggestive of a mitochondrial 
respiratory chain defect. Immunocytochemical analysis kindly performed by Dr Jenny 
Morton (Cambridge, UK) on two of the more severely affected patients, 9 and 11, using 
an antibody to ubiquitin was suggestive of perinuclear inclusions but was not conclusive 
(images not shown). Fig. 5.3. B demonstrates that immunocytochemical studies using 
anti-ubiquitin and 675 antibodies did not suggest any inclusion formation although there 
was inconsistent nuclear staining by 675 (white arrows) which was also seen in control 
sections. The tissue preparation and antibody protocol was checked by the demonstration 
of an ubiquitin-positive inclusion in a sample of inclusion body myositis (IBM) muscle as 
a positive control using the same protocol (black arrow in Fig. 5.3. B). 
Fig. 5.2.
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233234In patient number 10, who was also severely affected, ultrastructural studies suggested 
that there were nuclear accumulations of electron dense material (Fig. 5.3. C) consistent 
with intranuclear inclusion formation.
5.5. Spectrophotometric analyses
The spectrophotometric analyses of aconitase, citrate synthase and complexes I, II/III and 
IV activities were performed on muscle homogenates in all 12 HD patients and the age-
matched controls as previously described (Sections 2.1.5, 2.5. and 2.7.). All assays were 
performed blinded and the enzyme activities were expressed as nmols/min/mg except 
complex IV which was expressed as the first order rate constant, K (/min/mg), and as a 
citrate synthase ratio. Protein was determined by the BCA protein assay using bovine 
serum albumin as the standard as already described (Section 2.8.). Statistical analyses 
were performed using the unpaired two-tailed Mann-Whitney U test and the Spearman 
correlation test.
5.5.1. Mitochondrial activities in HD muscle
The results of specific enzyme activities and CS corrected ratios for the control and HD 
patients are shown in Tables 5.2. and 5.3. When expressed as a specific activity or as a 
ratio with citrate synthase activity, complexes I, II/III and IV were not statistically 
different in the HD patients from the control group (Fig. 5.4. summarises statistical 
comparisons).
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2385.5.2. Correlations of clinical data and mitochondrial activities
The patients represented a diverse group with respect to their age, disease duration and 
clinical status at analysis (Table 5.1.). In order to assess whether mitochondrial function 
may relate to disease progression, complex I, II/III and IV citrate synthase ratios and 
specific activities were correlated with patient age, disease duration and various clinical 
scores within the UHDRS (Table 5.4.). The significant correlations related to complex 
II/III:CS ratios apart from repeat years versus complex II/III specific activity which was 
significantly negatively correlated (r=-0.587, p=0.0489). Figs. 5.5. A-D demonstrate that 
complex II/III:CS ratios correlated positively with the cognitive subscale of the UHDRS 
(r=0.676, p=0.0185), and negatively with the age of the patient (r=-0.647, p=0.0257), 
disease duration (r=-0.681, p=0.0170) and with repeat years (r=-0.631, p=0.323). Figs. 
5.5. E-F show that of the four subscales of the UHDRS that measure behavioural and 
functional change, there was a significant negative correlation between the functional 
checklist (r=-0.656, p=0.0238), and positive correlation between the independence scale 
(r=0.593, p=0.0457) with complex II/III:CS. The statistical data is summarised in Fig. 
5.5. Fig. 5.6. A shows that there was a trend for the motor subscale to be negatively 
correlated with II/III:CS ratio but it did not reach significance (r=-0.454, p=0.140). Fig. 
5.6. B demonstrates that complex II/III:CS did not decline with increasing age in the 
control patients (r=-0.0876, p=0.783).
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242Chapter 6
Discussion
2436.1. The molecular pathogenesis of HD
It was not until the linkage of the abnormal gene to chromosome 4 in 1983 and the 
subsequent cloning of the HD gene in 1993, that research into the molecular mechanisms 
of HD started to develop rapidly. Whilst this has led to a progressive understanding of 
several important issues in the pathogenesis of HD, many issues are still unresolved. It is 
clear that truncated forms of htt with more highly expanded CAG repeats cause greater 
toxicity in cellular and animal models of HD (Section 6.7) but the mechanism by which a 
toxic fragment is formed remains uncharacterised. The primary molecular pathogenic 
event(s) caused by MT htt has also still to be clarified and the role of htt aggregates, UPS 
dysfunction, mitochondrial inhibition, excess free radicals, transcriptional dysregulation 
and impairment of vesicular transport all remain possible mechanisms mediating MT htt 
toxicity. Only by further understanding the pathogenic mechanisms will effective targets 
for future treatments for HD be possible.
This thesis generated two different cell models to investigate the proposed molecular 
mechanisms in the pathogenesis of HD. Following their characterisation, these models 
were used to study the influence of the size of htt, number of CAG repeats, localisation of 
htt, the effects of differentiation, processing of htt, mitochondrial function, generation of 
excess free radicals, the role of the proteasome and htt inclusions on the pathogenesis of 
HD. These will be discussed alongside results from the analysis of mitochondrial function 
in HD muscle. 
2446.2. Characterisation of the Ecdysone HEK293 N-terminal htt cell model
The original aim was to generate cell lines with inducible N-terminal htt expression in 
SH-SY5Y cells. The Ecdysone inducible expression system has been used to a limited 
degree in the literature (No et al. 1996, Wang et al 1999, Dela Cruz et al. 2000, Jana et al. 
2001, Downey et al. 2005) but generally has been shown to express construct proteins 
without background expression and in an inducer concentration-dependent manner. The 
inducer, pon A, has not been shown to have significant toxicity. Previous work in the 
laboratory had been unsuccessful in generating SH-SY5Y cells expressing a functional 
pVgRxR and these were not available commercially or in the literature. Consequently the 
model was generated in HEK 293 cells. These are human kidney epithelial cells used 
widely for transfection studies. While they do not express the phenotype of the cells 
predominantly affected in HD, they are suitable for investigating the expression of 
specific proteins upon generic cellular functions. The construct chosen was a kind gift 
from Dr Lesley Jones (University of Cardiff) and included the first 171 aa. of htt with 21 
CAGs in the WT construct and the first 207aa. of htt with 57 CAGs in the MT construct.
6.2.1. Isolation of clonal HEK293 lines expressing N terminal htt
Following transfection, 13 WT and 15 MT htt clones were isolated and 7 WT and 5 MT 
clones were taken for further analysis. Cells within each clone demonstrated different 
levels of expression of WT and MT N-terminal htt. Some cells had cytoplasmic punctate 
Ab675   immunoreactivity   similar   to   untransfected   clones,   whereas   other   cells 
demonstrated strong uniform nuclear and cytoplasmic immunoreactivity. This intra-clonal 
variability   was   not   due   to   variable   construct   transfection   between   cells   because 
subcloning experiments had demonstrated similar intra-clonal variation of N-terminal htt 
245expression within the subclones (Fig.3.7). It was also not due to the Ecdysone system, as 
evidenced by uniform expression throughout all cells in the alpha-synuclein model (Fig.
3.15). There is consistent reporting of variability in intra-clonal htt immunoreactivity in 
stably-transfected htt expressing in vitro cell models in the literature, although it is often 
not commented on in the published text but is present in the published photos of 
expressing clones. This variability has occurred with various cell types including 
NG105-15, N2a and PC12 cell lines, with various detection systems, including antibodies 
to htt, fluorescent tags and antibodies to non-fluorescent markers, in inducible and 
constitutive expression systems, and in WT and MT N-terminal htt clones (Lunkes et al. 
1998, Li et al 1999, Wyttenbach et al. 2001, van Roon-Mom et al. 2008 and Ye et al 
2008). The size of the htt construct expressed may have had a role as the FL htt cell 
model described by Sugars et al (2004) demonstrated uniform expression in all cells. This 
suggested that the variable expression may have been due to the effects of N-terminal htt 
itself, possibly by WT and MT N-terminal htt affecting transcription within expression 
systems (see Section 1.8 for discussion of transcription in HD).
6.2.2. Sequencing of constructs
Sequencing the plasmids and DNA from the 7 WT and 5 MT htt HEK 293 clones 
revealed sequences in keeping with that predicted for htt except a 3’end base-mutation 
resulting in a leucine to proline switch at aa.165 (relative to 21 CAG). Leucine and 
proline are both neutral non-polar amino acids and therefore any molecular consequences 
would be minimised. There was an additional 5aa (serine, arginine, glycine, proline and 
valine) at the C-terminal end of the WT and MT N-terminal constructs. These additional 
sequences were small and given the C-terminal location were not considered to exert a 
significant biological effect although this could not be ruled out (Fig 3.1. A and B).
2466.2.3. Background construct expression
One advantage of the Ecdysone model was that pon A-induced expression occurred 
reliably without background expression of the construct in all the clones that were 
investigated, even at very high protein loading (120μg) on Western blot (Fig. 3.5). This is 
essential in an inducible system in order to study the early molecular effects of N-terminal 
htt expression and the lack of influence of htt expression upon the selection of clones. 
Tetracycline-based systems e.g. T-Rex (Invitrogen), have been associated with significant 
background breakthrough expression in the absence of doxycycline (Forster et al. 1999, 
Waelter et al 2001). To address these problems, the "second-generation reverse tet-off," 
or “rtTA2S-M2” (Urlinger et al. 2000), has been developed, which shows a greater trans-
activation potential and a lowered affinity for the target gene promoter in the absence of 
doxycycline. RtTA2S-M2 has been shown to be successful in transgenic animals and 
hepatoma cell lines at reducing breakthrough expression (Koponen et al. 2003, Goldring 
2006). This system potentially has the benefits of the tetracycline-inducible systems, such 
as high expression levels and a water-soluble inducer, without the disadvantage of 
breakthrough construct expression.
6.2.4. Levels of endogenous and construct htt expression
WT and MT htt clones expressed similar levels of endogenous htt on Western blots when 
corrected for protein loading and probed with Ab675 (Fig.3.6). This enabled comparison 
of relative expression levels of WT and MT htt constructs between the clones. The levels 
of construct htt expression were up to 3 times greater than endogenous htt in the WT htt 
clones and there was a wide range of expression levels amongst all the WT clones. The 
247MT htt clones expressed approximately twice as much construct htt as endogenous htt and 
levels were more consistent between clones than in the WT clones. No et al. (1996) found 
up to four times greater expression levels of reporter genes, ß-galactocidase and 
luciferase, using the Ecdysone system in mammalian cells, which was within the limits 
found in the current HEK 293 htt model. The greater expression levels of construct htt 
compared to endogenous htt may have accelerated the toxicity of MT N-terminal htt in 
comparison to physiological levels. This enabled shorter experiments to be performed to 
demonstrate toxicity although may have confounded direct comparison with in vivo 
pathogenic mechanisms.
6.2.5. Time and concentration of pon A-dependence of expression
The clones exhibited a different response to pon A. In two clones (one WT and one MT 
clone) htt expression levels related to pon A concentration while in another 2 clones (one 
WT and one MT clone) expression was unrelated to pon A concentration. The levels of 
construct htt expression could therefore not be reliably controlled by varying pon A 
concentration (Figs. 3.9-3.12). The variable effect of pon A induction between clones was 
not related to type of protein expressed and may have been explained by variations in the 
population of HEK 293 cells or due to differential effects of random construct insertion 
within the host genome. There is no other published data to support these explanations. 
These studies were performed on 2 WT and 2 MT clones and testing further WT and MT 
clones may have clarified the response to pon A. A dose-dependent effect of the inducer 
on construct expression has been described in the Ecdysone system by Wang et al (1999) 
who made a stable inducible model of HD in N2a cells expressing exon 1 of htt using 
Muristerone A (an analogue of ponasterone A) as the inducer. The authors did not 
comment on whether this was consistent in all WT and MT clones.
248There was stable expression of WT and MT N-terminal htt over 48 hours in 2 WT and 2 
MT clones. By day 4 there was a reduction in WT and MT N-terminal htt expression on 
Western blotting (Figs 3.13-3.14) which did not enable the analysis of the effects of 
construct expression over a prolonged timeframe. This was not a feature of the HEK293 
htt model itself, as a similar model expressing a mutant α-synuclein (A53T) construct, did 
not demonstrate a reduction in expression with time following 12 days of pon A induction 
(Fig. 3.15). A time and concentration-dependent expression of metabotropic glutamate 
receptors in HEK 293 cells using the Ecdysone system has also been described (Downey 
et al. 2005). These studies suggest that the reduction in construct htt expression over time 
was due to N-terminal htt expression and not the Ecdysone expression system or cellular 
background. One explanation is that WT and MT N-terminal htt may have affected 
transcription (Section 1.8), causing down regulation of one of the components within the 
Ecdysone system, although one would expect this to be self-limiting as construct 
expression would then be turned off and transcription would commence again once N-
terminal htt levels had reduced. An alternative explanation for the reduction in htt 
expression after 8 days, was that some cells in each clone did not express the construct. 
The sub-cloning studies demonstrated similar intra-clonal variation in expression of 
construct htt in parent and sub-clones, which would argue against this. 
6.2.6. Influence of pon A
There is increasing evidence of mitochondrial dysfunction in the pathogenesis of HD 
(Section 1.10.) and therefore a mammalian expression system which uses an inducing 
249agent   that   does   not   cause   mitochondrial   toxicity   was   important,   especially   if 
mitochondrial function was to be assessed. Pon A did not affect mitochondrial function as 
demonstrated by the absence of significant differences between pon A (dissolved in 
DMSO) and DMSO-treated pIND 0 clones (Figs. 3.24-3.26). This is in contrast to other 
inducible systems, such as tetracycline-based systems e.g. T-Rex (Invitrogen), which is 
associated   with   tetracycline-induced   mitochondrial   toxicity   by   inhibition   of   the 
mitochondrial 30S ribosome. This inhibits mitochondrial protein synthesis and can cause 
cell dysfunction and death (Riesbeck et al. 1990, McKee et al 2006). One of the 
disadvantages of using pon A was that it was soluble in an organic solvent. Previous 
studies in the laboratory have demonstrated that alcohol was toxic to cells and therefore 
DMSO was used. DMSO caused the HEK 293 cells to form clumps which made 
immunocytochemistry of single cells more difficult. The effects of pon A and DMSO on 
cell growth and cell death are discussed in Section 6.2.9. 
6.2.7. Length of expressed htt N-terminal fragment and CAG repeat size
N-terminal fragments of MT htt are more toxic and form aggregates more quickly than 
FL-MT htt in transgenic HD mice and in vitro cell models of HD (Mangiarini et al 1996, 
Jana et al. 2001). It was therefore felt to be appropriate to express N-terminal htt in an 
inducible system in order to investigate the early molecular changes associated with WT 
and MT N-terminal htt expression. There has been only one study which has described 
physiological WT N-terminal htt in normal post-mortem human brain (Kim et al. 2001). 
There has been no evidence from previous stably transfected cell models of N-terminal 
WT htt toxicity (Lunkes and Mandel 1998, Li, SH. et al. 1999 and Jana et al. 2001). WT 
N-terminal htt may not exist in vivo but it was still felt to be an appropriate control for 
MT N-terminal htt in the HEK293 model. The MT N-terminal fragment used in the HEK 
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CAGs or 176 aa. WT htt with 21 CAGs (Figs. 3.1 A and B). Most studies expressing N-
terminal htt in HD cell models and transgenic HD mice have used exon 1 (90aa.) of MT 
htt with at least 80 CAG repeats (Table 1.5 tabulates the details of published HD cell 
models).   Smaller   N-terminal   htt   fragments   and   larger   CAG   repeats   have   been 
demonstrated to cause the greatest toxicity and increased htt inclusions in cell models and 
transgenic HD mice (Davies et al. 1997, Lunkes et al. 1998, Section 6.8). The relatively 
large N-terminal fragment and low MT CAG repeat number used in the current study was 
felt to more accurately recapitulate the early pathological environment in HD cells similar 
to patients with severe HD who often have CAG repeats in excess of 50 (Telenius et al. 
1993). CAG repeat lengths over 80 are uncommon in HD patients and may cause 
different molecular changes compared to most patients with HD who have between 40 
and 50 CAG repeats. At the same time, potential toxicity of MT htt was accelerated by 
moderate N-terminal truncation, in order to enable molecular studies to be performed 
within a viable timeframe.
The N-terminal fragment used in the HEK 293 model contained the polyproline-rich 
region of htt, which is putatively involved in protein–protein interactions (Cubellis et al. 
2005). Neither the putative caspase/calpain cleavage sites nor the HEAT repeat sequences 
were included in the N-terminal htt fragment used in this model (Fig. 1.1 for diagram of 
htt). This potentially enabled N-terminal fragment toxicity to occur in a background of htt 
protein, but without the need for extensive processing of the FL-htt.
6.2.8. Western blots and poly Q proteins
The Western blots of WT and MT htt expression suggested a discrepancy between the 
predicted bands (19.5 kDa for WT htt and 23.5 kDa for MT htt) and the bands seen on the 
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predicted size is approximately 50% in WT and MT clones. This can be either explained 
by the expression of constructs beyond the predicted stop codon or that these proteins did 
not migrate as predicted because of their primary structure. N-terminal htt contains polyQ 
sequences which has been demonstrated to slow the movement of the protein through the 
gel (Schilling et al 2007). The N-terminal htt constructs migrated similarly in Western 
blots in all WT and MT clones. This would have been unlikely if the random plasmid 
integration site in the host cell had caused the stop codon to be disrupted leading to 
variable alterations in the size of the protein product. The similar proportional increase in 
size of both WT and MT bands would also argue against translation beyond the predicted 
stop codon which would have caused a similar increase in construct size in both WT and 
MT clones.
6.2.9. Cell proliferation and death 
Pon A is an insect steroid hormone involved in regulating metamorphosis, especially in 
molting (Nakanishi et al. 1992). It is reported that pon A is “inert to mammalian 
physiology and does not exert any pleiotropic effects” (A.G.Scientific Inc. San Diego, 
CA, USA). Within the current study, pon A caused a reduction in cell proliferation in all 
clones independent of construct expression (Figs. 3.22 and 3.23). This response to pon A 
has not been previously described. The ecdysone receptor (VgEcR) forms a heterodimeric 
complex with the retinoid X receptor (RXR) to form pVGRXR (Fig.2.3). Therefore, 
endogenous retinoic acid receptors forming a heterodimeric complex with upregulated 
levels of construct RXR, or with pVgRXR, could bind to promoter regions of endogenous 
retinoic   acid-responsive   genes.   Pon   A   may   subsequently   induce   transcription   of 
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cell growth or induction of apoptosis (Dela Cruz et al. 2000, Gianni et al. 2000).
The background levels of cell death were higher in both WT and MT htt clones than 
pIND 0, in the absence of pon A induction (Fig. 3.28. and Table 3.7.). In the absence of 
htt expression, this suggested that the chromosomal integration of WT or MT htt pIND 
constructs was more toxic to cells than if pIND contained no construct ie. pIND 0. This 
raises the possibility of toxicity of triplet repeats at a pre-transcriptional level. There is no 
published data on the role of CAG repeat toxicity at a pre-transcriptional level, but one 
could speculate that an altered repeat sequence within a chromosome may interfere with 
transcription as proposed in facioscapulohumeral dystrophy (FSHD) where contraction of 
a non-coding repeat sequence is postulated to interfere with distant transcription (Tawil et 
al. 2006).
There was a small, but significant decrease in cell death in the pIND0 clones when treated 
with pon A (Fig. 3.28. and Table 3.7.) which was not present in the WT and MT clones. 
There was no evidence of pon A-induced toxicity in MT clones which suggested that over 
96 hours, N-terminal MT htt containing 57 CAG repeats, was not toxic. 
These findings contrast with those of Wyttenbach et al (2001), who used positive TUNEL 
staining as a marker of cell death in a “Tet-ON” PC12 cell model of HD, and described in 
cells expressing exon 1 of htt, 15-20% cell death with 74Q and 8% in 53Q cells following 
6 days of induction. Wang et al (1999) published an Ecdysone differentiated N2a cell 
model   expressing   exon   1   with   16,   60   or   150Q.   By   day   3   post-induction   and 
differentiation, there was increased cell death in the 150Q cells and after 4 days in the 
60Q cells. Lunkes et al (1998) described increased cell death, using Hoechst dye analysis, 
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in FL htt with 73Q in a differentiated NG105-15 “TetON” cell model. These three studies 
suggest  that the combination   of  a  shorter  N-terminal fragment,  increased  polyQ, 
differentiation compared to mitotic cells, and longer induction times were sufficient to 
induce cell death with N-terminal htt. The critical role of a short N-terminal htt fragment 
in causing cell death was supported by a primary rat striatal “TetON” inducible model 
expressing the first 548 aa of htt and 26, 67, 105 or 118Q (Sipione et al. 2002). The 
authors found no cell death or aggregates by 36 hours post-induction suggesting that 
highly expanded polyQ is not sufficient to cause early cell death and that a longer N-
terminal fragment probably delayed MT htt toxicity and would be compatible with the 
relatively large N-terminal htt fragment in the current HEK 293 mdoel.
6.3. Characterisation of the EYFP SH-SY5Y FL htt cell model
6.3.1. SH-SY5Y cells as a background neuronal phenotype
The SH-SY5Y cells were selected as a background neuronal phenotype that could be 
differentiated into post-mitotic cells with neuronal characteristics (Biedler et al. 1978). 
Post-mitotic cells potentially had the advantage of modelling an important parameter from 
the in vivo setting, as mitotic cells in HD tend not to be affected. SH-SY5Y cells have 
adrenergic and glutaminergic systems but not GABAergic or serotonergic systems (Ross 
et al 1981). Experiments involving induction of excitotoxicity could therefore have been 
performed although this was not eventually undertaken in the current thesis.
There has been only one other published HD cell model which used SH-SY5Y cells 
(Chun et al 2002 and Table 1.5.). The authors demonstrated that a small N-terminal 63aa. 
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with a background cytoplasmic htt construct expression. The authors did not attempt to 
differentiate the SH-SY5Y cells. Further discussion on the differentiation of SH-SY5Y 
cells can be found in Section 6.10.
6.3.2. EYFP huntingtin-length of htt fragment and CAG repeat size
The main aim of the SH-SY5Y model was to recapitulate the earliest molecular effects of 
MT htt expression, in particular the processing of FL htt into potentially toxic N-terminal 
fragments. Previous constitutive htt cell models have only expressed small N-terminal 
fragments up to 171aa in length (Section 1.13.1 and Table 1.5). In order to prevent acute 
toxicity, as has been in observed in other htt cell models expressing 148 CAGs (Table 
1.5), the CAG repeat length used was 88 CAGs. The discussion of the impact of FL htt 
and 88 CAG repeats on cellular function is discussed later.
6.3.3. EYFP-C1 as a constitutive expression system
One of the main advantages of choosing the EYFP-C1 mammalian system (Clontech) was 
that induction of protein expression was not required and therefore the potentially toxic 
effects of an inducing agent could be avoided. EYFP htt could also be monitored directly 
with fluorescence microscopy and using anti-EYFP antibody on Western blots without 
cross-reactivity with endogenous htt. One of the main disadvantages of the system was 
potential toxicity of EYFP htt during cloning, which would have selected against cells 
sensitive to EYFP htt. There was no evidence for this occurring as cells were readily 
cloned, although there remained the possibility that the clones selected for subsequent 
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stronger expressing clones died at an earlier stage before cloning took place.
6.3.4. Levels of expression of EYFP htt on Western blots
All MT clones expressed similar levels of EYFP MT htt. Expression of EYFP htt in the 
WT clones were more varied, with the lowest levels in 23 7 2 and 7 8 being 
approximately three times less than 23 6 7 (Fig.4.2). For mitochondrial respiratory chain 
enzyme activities and proteasomal function assays clones 23 6 7, 7 2 and 7 8 were 
therefore not used to standardise for expression levels. The levels of expression of EYFP 
htt were approximately four times greater than endogenous htt on Western blots in both 
WT and MT EYFP clones (Fig 4.4). Increased expression levels were expected with the 
CMVIE promoter although there is little data from other constitutively expressing htt cell 
models regarding this.
6.3.5. Control cells containing EYFP-C1 plasmid
The EYFP CON clones, which contained the EYFP-C1 plasmid without a construct, were 
found   to   have   nuclear   and   cytoplasmic   fluorescence.   Nuclear   and   cytoplasmic 
fluorescence has been described with EYFP expression and with other fluorescent tags, 
such as EGFP, and it is due to passive diffusion of EYFP into the nucleus at high 
concentrations (Clontech, UK). The WT and MT FL htt blocked this passive process as 
evidenced by the purely cytoplasmic fluorescence in mitotic EYFP WT and MT htt 
clones. This has been described in other constitutive cell models of HD including Ye et al 
(2008) in an N2a model using EGFP-tagged exon 1 of htt with 20 and 120Q (Table 1.5). 
The EYFP CON clones were therefore not used as a control and SH-SY5Y cells stably 
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integration of a plasmid into the host cell genome. 
6.4. Mitochondrial dysfunction in HD
6.4.1. The spectrum of mitochondrial dysfunction in HD
Mitochondrial   respiratory   chain   dysfunction   is   a  consistent  feature  in   HD.   Most 
importantly, there is evidence of mitochondrial respiratory chain (MRC) dysfunction in 
the striatum of post-mortem HD brain and in HD skeletal muscle (Gu et al. 1996, Browne 
et al. 1997 and Arenas 1998), as well as in the striatum and cortex of the R6/2 mouse 
(Tabrizi et al. 2000). 
1H MRS has demonstrated increased lactate in symptomatic and 
some presymptomatic HD striatum and cortex (Jenkins et al 1993 and 1998, Harms et al. 
1997) suggesting an early in vivo energetic defect. 
6.4.2. Mitochondrial function in HD skeletal muscle
Htt expression in skeletal muscle
Htt expression is not restricted to the CNS and has been documented in skeletal muscle 
and myoblast cultures from the R6/2 transgenic mouse model of HD (Sathasivam et al. 
1999, Orth et al. 2003). Studies on human post-mortem normal and HD skeletal muscle 
have detected htt mRNA by in situ hybridisation studies (Li S-H et al 1993), cytoplasmic 
htt immunoreactivity (Hoogeveen et al. 1993) and htt inclusions in HD differentiated 
myotubes (Ciammola et al. 2006). The presence of htt inclusions in post-mortem HD 
skeletal muscle has not been published.
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Brain has several limitations in the study of the pathogenesis of HD. The relative paucity 
of HD post-mortem material is a problem which will hopefully be improved by the 
development of HD “brain banks”. HD brain tissue is usually taken from post-mortems 
where there has been a delay between the death of the patient and the fixation of the brain. 
This can cause degeneration of the brain and consequently impair biochemical and 
histological analyses. Most HD post-mortem brains are end-stage in the disease process 
and this makes analysis of the progression of pathological changes difficult. In contrast, 
skeletal muscle represents a tissue that can be relatively easily biopsied at various stages 
of the disease and has the potential to be used to study molecular defects, such as 
mitochondrial dysfunction. HD patients lose muscle bulk disproportionately to their level 
of activity and calorific intake which suggests that muscle may be primarily involved in 
HD (Section 1.10.12). This suggests that HD skeletal muscle is an important tissue to 
study.
MRC activities and age in HD muscle
A specific respiratory chain defect in HD muscle was not found in the 12 muscle biopsies 
from the HD patients. Further analysis suggested that there was a relation between HD 
muscle MRC activities with various clinical parameters in the HD patients. Mitochondrial 
function has been demonstrated to decrease with age in many tissues (Coggan et al 1992, 
Trifunovic et al. 2004). Skeletal muscle mitochondrial respiratory chain activity has been 
shown to decline with increasing age over a wide age range (Coggan et al 1992). The 
controls in our study did not demonstrate a reduction in mitochondrial respiratory chain 
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group (47.9 ± 11.8 years). However, over a similar age range (46.7 ± 11.1 years), there 
was a significant negative correlation between age and complex II/III:CS ratios in the HD 
group (Fig. 5.6.). The specificity of the complex II/III:CS changes observed with age in 
HD but not the control samples mitigated against a non-specific age-related effect which 
would be expected to include complexes I and IV, and suggested that MT htt either 
directly affected skeletal muscle complex II/III activity or was a secondary consequence 
of disease progression unrelated to htt expression e.g. progressive immobility. Immobility 
was not formally assessed but the most severely clinically affected patient, number 7 
(Table. 5.1.), was still ambulant with support suggesting that MT htt may have had a 
direct effect on mitochondrial function unrelated to patient inactivity.
“Repeat years”-a possible marker of disease activity
Age and CAG repeat size are the main known risk factors for the progression of HD 
(Brinkman et al 1997). The age of the patient and the size of the CAG repeat were 
therefore incorporated to reflect severity of disease by correlating the product of age and 
CAG repeats, or “repeat years”, with clinical parameters. The cognitive and motor 
subscales of the UHDRS correlated substantially more significantly with repeat years than 
age alone. CAG repeats did not correlate with these clinical scales (Figs. 5.1. and 5.2.). 
This suggested that repeat years may be a better objective predictor of disease activity 
than age although the exact mathematical relationship between age, CAG repeats and 
disease status has yet to be determined.
Clinical parameters and MRC activities
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cognitive subscale and two measures of functional status in the UHDRS, in the absence of 
age-related changes in the control samples, also suggested that decreasing complex 
II/III:CS ratios were associated with a worsening clinical phenotype and increasing CAG 
repeats (Figs. 5.8 and 5.10). Neuropsychological impairment in HD has been shown to 
occur at least two years prior to the manifestation of the motor features (Paulsen et al. 
2001). Complex II/III:CS ratio positively correlated with the cognitive subscale and 
showed a trend, albeit not significant, to negatively correlate with the motor subscale 
(Fig. 5.5. and Table 5.4.). This suggested that mitochondrial dysfunction may be a 
sensitive indicator of early HD neuropathology and possibly underlie the cause of early 
neuronal dysfunction. It also indicated that worsening cognitive function may be a 
sensitive clinical indicator of underlying mitochondrial dysfunction within HD muscle.
Mechanisms of complex II/III dysfunction in HD skeletal muscle 
If a progressive reduction in complex II/III activity occured in HD patient’s muscle, it 
could cause a sequence of biochemical events that may induce cellular damage, as is 
proposed for HD striatum (Tabrizi et al. 1999, Jackson et al. 2006). It may also explain 
the muscle wasting that occurs in HD patients independently of nutritional intake (Section 
1.10.12). An excitotoxic mechanism in HD brain has been suggested to lead to an 
increase in nitric oxide which inhibits complex IV and subsequently complex II/III via 
free radical production (Tabrizi et al. 1999). There are few studies investigating the role 
of excitotoxicity in human muscle. Peripheral NMDA receptors in muscle, possibly on 
afferent fibre nerve terminals but also on muscle fibre membrane, are increasingly 
implicated in causing muscle pain (Cairns et al. 2003 and 2008). There is no data to 
suggest that classical neuronal excitotoxicity occurs in muscle, although a slow excess of 
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reticulum, following acetylcholine stimulation of sarcolemmal nicotinic receptors, could 
possibly modulate a similar mechanism of cellular excitotoxicity within muscle fibres as 
in neurons. 
Complex   II/III   inhibition   in   HD  muscle   may   occur   by   alternate  mechanisms   to 
excitotoxicity and free radicals as has been increasingly described in HD brain. These 
mechanisms   include   MT   htt   aggregates   impairing   mitochondrial   distribution   and 
trafficking (Chang et al 2006, Solans et al. 2006, Orr et al. 2008) a direct effect of htt on 
mitochondrial function and the proteasome (Fukui et al 2007), and altered mitochondrial 
biogenesis (McGill et al 2006). These mechanisms and their role in HD are discussed in 
more detail in Sections 6.4.3 and 6.9.2.
Mitochondrial dysfunction in HD muscle
In contrast to Arenas et al. (1998), who found a complex I defect in HD muscle compared 
to age-matched controls, a specific respiratory chain defect in HD muscle was not found 
in the 12 muscle biopsies from the HD patients. This difference may partly be explained 
by the number of patients in the respective studies; Arenas et al. (1998) examined 3 
muscle biopsies compared to 12 biopsies (Section 5.5.1). There was also a broad range of 
clinical severities within the HD patients in this study (Table 5.1) which may have caused 
a greater variability in the levels of mitochondrial function. The patients in the Arenas 
study had larger CAG repeats (mean 67 compared to a mean of 44 in this study) and 
longer disease duration (mean 14 years compared to 3.7 years in this study). Arenas et al. 
(1998) comment that all their patients were ambulatory and showed no evidence of 
muscle wasting which was unusual for patients with such high CAG repeats and long 
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years) and patient 11 (44 CAG repeats and symptoms for 8 years) were ambulatory over 
short distances and were the most severely clinically affected. Therefore, the differences 
in mitochondrial complex activity between the two studies may be partially accounted for 
by increased disease duration and CAG repeat length causing more severe disease in the 
Arenas patients. Apart from one study by Parker et al. (1990), who described a complex I 
defect in HD platelet mitochondria, there have been no other reports of complex I defects 
in HD. The absence of the reproduction of a complex I defect and the small number of 
HD patient muscle biopsies analysed in the study by Arenas et al (1998) would suggest 
that a complex I defect is unlikely to have an important role in the pathogenesis of HD. 
There have been few other studies apart from Arenas et al (1998) which have investigated 
bioenergetics in HD skeletal muscle. Using imaging techniques, energetic defects have 
been found in HD muscle using 
31P and 
1H MRS (Koroshetz et al. 1997, Lodi et al. 2000). 
In contrast, respiratory chain function in R6/2 mouse muscle at 12 weeks was normal in a 
single study by Tabrizi et al. (2000) which suggested against significant mitochondrial 
dysfunction in R6/2 mice skeletal muscle even when the brain was affected. However, 
gene expression profiles in the R6/2 mouse and HD muscle have demonstrated a 
transition from fast-twitch to slow-twitch muscle fibre types which also suggested a 
disturbance in energy metabolism in HD muscle before gross pathological features or 
respiratory chain dysfunction (Strand et al. 2005). Therefore, in spite of an absence of a 
major defect of mitochondrial function, there is evidence that the bioenergetics in HD 
muscle are not normal. The widespread association of a reduction in complex II/III 
activity with several clinical parameters in this study supports the hypotheses that either 
mitochondrial dysfunction is directly associated with clinical progression caused by MT 
htt, or that it is a direct consequence of another underlying metabolic disturbance due to 
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Irrespective of whether mitochondrial dysfunction was primary or secondary to MT htt, 
improving mitochondrial function may still have a molecular, and subsequently clinical, 
benefit.
6.4.3. Mitochondrial function in N-terminal and FL htt cell models
6.4.3.1. Mitochondrial function in the HEK 293 N-terminal htt model
The main advantage of the HEK 293 model in studying MRC activities was that cells 
naïve to MT N-terminal htt could be exposed to MT htt in order to assess if there was an 
early effect on MRC function. The expression of WT or MT N terminal htt for 48 hours 
in HEK 293 cells did not decrease MRC activities (Figs. 3.24.-3.26.).  When MRC 
activities were compared between MT and WT N-terminal htt clones in four other stably 
transfected HD cell models, one found no change (Wyttenbach et al 2001), two found a 
decrease in complex II/III activity in MT clones (Solans et al 2006 and Fukui et al. 2007) 
and one found a decrease in complex II activity in MT clones (Benchoua et al. 2006). 
Fukui et al. (2007) also demonstrated an increase in the activity of complex IV in the MT 
clones. The details of these cell models can be found in Table 1.5.
The influence of size of CAG repeat/N-terminal htt
The size of the CAG repeats and the N-terminal htt fragment in MT htt have been found 
to be important determinants of MT htt toxicity in HD cell models and transgenic mice. 
The normal MRC activities in the MT htt clones of the HEK 293 model may have been 
determined by the relatively large N-terminal htt fragment (171aa) and short number of 
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activities expressed MT N-terminal htt with 82Q (Benchoua et al. 2006) and 103Q (Fukui 
et al 2007 and Solans et al 2006). This is in comparison to 74Q in Wyttenbach et al 
(2001) and 59Q in the current HEK 293 model where there was no MRC defect. This 
suggested that the MT CAG repeat size needed to be greater than 74Q to cause MRC 
dysfunction in N-terminal HD cell models. Furthermore, Solans et al (2006) and Fukui et 
al. (2007) expressed exon 1 of htt and Benchoua et al. (2006) expressed a longer 171aa N-
terminal htt fragment and found MRC defects in comparison to Wyttenbach et al (2000) 
who expressed exon 1 of htt without finding an MRC defect. This suggested that small 
differences size in the size of the N-terminal htt fragment did not grossly influence MRC 
activities, whereas the size of the CAG repeat was a more important factor in determining 
MRC dysfunction.
The influence of the level of construct expression
The influence of levels of MT htt expression on toxicity in HD cell models and transgenic 
mice   has   not   been   studied   in   depth.   However,   the   neurons   vulnerable   to 
neurodegeneration in HD post-mortem striatum have the highest levels of htt expression 
whilst the relatively-spared interneurons express low levels of htt (Ferrante et al. 1997). 
The level of MT htt expression has also been found to be important in determining the 
rate of aggregation of MT N-terminal htt in vitro. In the HEK 293 model, the level of N-
terminal htt expression was up to 3 times greater than endogenous htt in the WT clones 
and 2 times greater in the MT clones. The level of expression of construct htt was not 
discussed in Wyttenbach et al (2001), Solans et al. (2006), Fukui et al (2007) or Benchoua 
et al. (2006) and it is therefore difficult to comment on the role of htt expression levels on 
mitochondrial toxicity in cell models. Benchoua et al. (2006) used a lentiviral vector 
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high levels of constitutive construct expression. One HD cell model which found an MRC 
defect (Fukui et al 2007) and two models which did not find an MRC defect (Wyttenbach 
et al 2001 and the current HEK 293 model) used a CMV promoter and therefore similar 
levels of construct expression would have been expected. Therefore it would appear 
unlikely that differences in the levels of MT htt expression would explain the presence of 
an MRC defect.
The influence of cell background
HD has a striking predilection for affecting medium spiny neurones in the striatum more 
than any other cell type. Cell models with a neuronal background would therefore be 
expected to recapitulate the features in HD brain better than non-neuronal models. The 
four cell models described by Wyttenbach et al (2001), Solans et al. (2006), Fukui et al 
(2007) or Benchoua et al. (2006) and the HEK293 model used different cell types making 
direct comparisons related to cellular background difficult. Benchoua et al. (2006) used a 
primary striatal model which would theoretically provide a cellular background that more 
closely modelled HD striatum and potentially would produce earlier mitochondrial 
dysfunction than non-striatal cell lines.
The influence of method of analysis of MRC function
The same spectrophotometric methods were used to assess mitochondrial respiratory 
chain complex activities in the current thesis as in Wyttenbach et al. (2001), Solans et al. 
(2006) and Fukui et al.(2007). Solans et al.  (2006) and Fukui et al.(2007) did not 
comment on why complex I activities were not assessed and Fukui et al.(2007) measured 
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complex II/III assay. Benchoua et al. (2006) used whole cell homogenates and not 
mitochondrial   fractions   to   only   assess   complex   II   activity   and   used   an 
iodonitrotetrazolium (INT) based spectrophotometric assay. They also adjusted activity to 
protein which does not compensate for the total mitochondria present in the preparation in 
contrast to comparison of citrate synthase (CS) ratios. These methodological factors may 
have significantly contributed to the finding of a complex II defect in MT clones by 
Benchoua et al. (2006) and make direct comparison with the other studies more difficult. 
For the studies performed by Wyttenbach et al. (2001), Solans et al. (2006) and Fukui et 
al.(2007) direct comparisons could be made because the same spectrophotometric 
methods were used.
The influence of experimental method of assessment of MRC activities
In the studies by Wyttenbach et al. (2001), Solans et al. (2006) and Fukui et al.(2007). 
Solans et al. (2006) and Fukui et al.(2007), a change in mitochondrial enzyme activity 
was calculated by comparing induced clones i.e. MT compared to WT. However, this 
thesis went on to compare the difference between induced and the uninduced pIND0, WT 
and MT clones because this comparison would control for the effect of the inducing 
agent, pon A, on mitochondrial function. The effects of the inducing agents, mifeprostone 
(Fukui et al 2007) and galactose (Solans et al 2006) on respiratory chain activities is 
unknown, but the mitochondrial toxicity of tetracyclines (Wyttenbach et al. 2001) is well 
established (Section 6.2). The effects of the inducing agents have therefore not been 
controlled for in the cells models used by Wyttenbach et al. (2001), Solans et al. (2006) 
and Fukui et al.(2007) and this raises uncertainty about the validity of the reductions in 
complex II/III where it was described.
266The influence of duration of induction of N-terminal htt
The construct expression induction time used in the cell models may have influenced 
mitochondrial function. Mitochondrial function was assessed at 48 hours and 18 hours 
post-induction in the models with normal mitochondrial function (the HEK 293 cell 
model and Wyttenbach et al. 2001). In the models with reductions in complex II/III 
activities, there were longer induction/expression times in 2 of the 3 cell models. Fukui et 
al (2007) assessed at 72 hours, Benchoua et al. (2006) at 6 weeks post-transfection of 
primary striatal cultures and Solans et al (2006) at 10 hours. The duration of exposure to 
N-terminal htt did not appear to have a major influence on MRC function, although the 
shorter duration of MT htt expression in the current HEK 293 model and Wyttenbach et 
al. (2001) can not be excluded as a potential factor influencing MRC function.
The influence of htt inclusions
MT htt intracellular inclusions in association with an MRC defect was described in three 
out of the four N-terminal htt cell models discussed above (Solans et al. 2006, Fukui et al.
2007 and Solans et al. 2006). The presence of inclusions in the Wyttenbach model 
(Wyttenbach et al. 2001) in the absence of MRC defects suggested that inclusions alone 
may not be sufficient to cause impaired respiratory chain function. The induction of MT 
htt occurred for only 18 hours prior to assessment of MRC function in the Wyttenbach 
model and therefore an MRC defect may have occurred at a later time point. The 
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inclusions may have been, at least in part, associated with MRC dysfunction. The role of 
htt inclusions in the pathogenesis of HD is discussed further in Section 6.8.
6.4.3.2. Mitochondrial function in the SH-SY5Y EYFP FL htt model
The constitutively expressing SH-SY5Y EYFP model enabled the investigation of MRC 
function in response to FL MT htt expression on a neuronal background without the need 
for an inducing agent. The potential disadvantage was that the SH-SY5Y cells had been 
exposed to constitutively expressing FL MT htt and this could have selected against cells 
that were more severely affected by MT htt toxicity. The brains of HD patients develop 
normally, as far as we understand, and the neurons within HD brains have been exposed 
to FL MT htt for many cell cycles during development. The SH-SY5Y model therefore 
recapitulated some of the features within neurons during the maturation of the HD brain. 
Therefore, the assessment of MRC function in the SH-SY5Y cells would enable the 
investigation of potential early defects in mitochondrial function in response to MT FL 
htt.
Complex IV defects were associated with prolonged exposure to htt
The SH-SY5Y cell model expressing FL MT htt exhibited a significant reduction in the 
complex IV:CS ratio and complex IV enzyme specific activities compared to WT htt and 
pcDNA3.1 control clones (Fig. 4.25). MRC activities in constitutive FL htt models have 
not been previously assessed in the literature. Complex IV defects have been described in 
post-mortem HD striatum (Gu et al. 1996, Browne et al. 1997 and Tabrizi et al. 1999) and 
in the striatum and cortex of the R6/2 mouse (Tabrizi et al. 2000). Tabrizi et al. (2000) 
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skeletal muscle. In contrast, several inducible N-terminal htt cell models (Table 1.5), 
including Wyttenbach et al (2001), Solans et al. (2006) and the HEK 293 model from the 
current thesis, have found complex IV activities to be normal. Fukui et al. (2007) found 
increased complex IV activities in response to MT N-terminal htt expression in their cell 
model.
One explanation for the contrast in normal or increased complex IV activities in the N-
terminal htt models (Solans et al. 2006, Wyttenbach et al. 2001, Fukui et al. 2007 and the 
HEK 293 model) with the reduced complex IV activities in the EYFP model, R6/2 mouse 
and human post-mortem brain, was that MT N-terminal htt may have inhibited complex 
IV but not for sufficiently long enough to produce a measurable reduction in activity in 
the N-terminal htt cell models. The maximum length of N-terminal htt expression was for 
72 hours (Fukui et al. 2007). In contrast, prolonged expression of either N-terminal (exon 
1 in the R6/2 mouse) or FL MT htt (HD post-mortem brain and the EYFP model) was 
associated with complex IV inhibition. It therefore appeared that the duration of MT htt 
expression was related to a complex IV defect rather than the size of the htt fragment. 
This delayed effect on complex IV activity by MT htt is in agreement with the hypothesis 
that following a reduction in complex IV activity, electron transfer is decreased leading to 
reduced oxidative phosphorylation and subsequently reduced intracellular ATP levels. As 
a secondary effect of impaired oxidative phosphorylation, increased superoxide is 
generated. As ATP levels reduce, neurons become increasingly vulnerable to glutamate-
induced excitotoxicity or the “slow excitotoxicity” hypothesis (Novelli, A et al. 1998 and 
Tabrizi et al. 2000). This subsequently leads to further free radical generation, calcium 
dysregulation   and   inhibition   of   mitochondrial   respiratory   chain   enzyme   activities 
sensitive to free radicals, such as complex II/III, and aconitase. A secondary and delayed 
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astrocytoma cell line with cyanide, a complex IV inhibitor (Hargreaves et al 2007). 
Consequently, complex IV inhibition could be involved as a primary event with complex 
II/III inhibition occurring later in the pathogenesis of HD. This would be consistent with 
the findings of complex IV inhibition, and not complex II/III, in the EYFP htt model and 
the R6/2 mouse, where exposure to MT htt would occur over weeks, whereas in HD 
brain, MT htt exposure occurs over decades in most patients enabling both complex II/III 
and complex IV defects to occur.
Complex II/III defects and cytoplasmic htt inclusions 
The complex II/III defects in some of the N-terminal htt cell models (Solans et al. 1996, 
Fukui et al. 2007 and Benchoua et al. 2006) contrast with the FL htt EYFP and R6/2 
models. The smaller N-terminal htt fragments, and/or the highly expanded CAG repeats 
used in these N-terminal models, may have by-passed the proposed early mechanism of 
complex IV inhibition, excitotoxicity and free radical generation. The mechanism by 
which this would occur is speculative but one possible explanation would be the location 
of the htt inclusions within the cells. The cell model by Wyttenbach et al. (2001) formed 
mostly nuclear, and not cytoplasmic, htt inclusions by 18 hours post-induction when 
complex activities were normal. This is in comparison to the cell models by Solans et al. 
(1996), Fukui et al. (2007) and Benchoua et al. (2006) which demonstrated cytoplasmic 
and   nuclear   inclusions   at   the  time  of   assessment   of   mitochondrial   function   and 
demonstrated complex II/III defects. The presence of cytoplasmic htt inclusions may 
therefore   have   caused   complex   II/III   defects   by   a   direct   effect   on   cytoplasmic 
mitochondria. This would also explain the findings in the R6/2 mouse which forms 
extensive mostly intranuclear htt inclusions and does not demonstrate a complex II/III 
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there are neuropil/cytoplasmic and nuclear inclusions associated with complex II/III and 
IV defects. The mechanism by which cytoplasmic htt inclusion formation could cause 
complex II/III defects may include inhibition of proteasomal function (Fukui et al. 2007 
and Section 6.6), inhibition of mitochondrial trafficking (Solans et al 2006 and section 
6.9.1), or by the rapid development of cytoplasmic inclusions which directly distort and 
affect mitochondrial function (Solans et al. 2006). The direct role of htt and htt aggregates 
in the inhibition of mitochondrial function in HD is discussed further in Sections 6.8. and 
6.9.2. 
Summary: Mitochondrial dysfunction in HD
The reduction in complex II and/or III MRC activities in three HD N-terminal cell models 
(Solans et al. 2006, Fukui et al.2007 and Benchoua et al. 2006) appears to be strongly 
determined by the size of the expressed polyQ (greater than 74Q). This defect mirrors the 
findings in human HD post-mortem brain (Mann et al. 1990, Gu et al. 1996, Browne et al. 
1997, and Tabrizi et al. 1999) and in HD muscle in this study. The R6/2 mouse, the N-
terminal cell models with shorter polyQs (HEK 293 model in this thesis and the PC12 
model (Wyttenbach et al. 2001)), and the EYFP FL htt model did not demonstrate a 
complex II/III defect. This may be partly explained by predominant cytoplasmic htt 
aggregates in systems demonstrating a complex II/III defect. 
The reduction in complex IV activity in the EYFP FL MT htt model mirrored the changes 
in mitochondrial function seen in the R6/2 mouse and HD post-mortem brain and may 
reflect an early defect in mitochondrial complex activities better than the acute toxicity of 
N-terminal cell models. N-terminal htt probably still has a significant role in the 
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complex II/III function in three N-terminal htt cell models which mirrored the major 
defect in late-stage human HD brain. However, the findings in the EYFP model are likely 
to reflect the earliest molecular changes in the HD brain and model the early disease 
process better than expression of N-terminal htt which may model molecular changes at 
the later stages of the disease. It is postulated that over many years, a complex II/III 
defect   develops  in   the  HD  brain   and  muscle,   possibly   as   a  result   of   increased 
accumulation of toxic N-terminal MT htt fragments. This would be in agreement with the 
findings in HD muscle where several clinical parameters of progression of disease were 
associated with a defect in complex II/III. Therefore, the toxic effect of FL MT htt may 
cause a reduction in complex IV as an early event in a molecular pathogenic cascade 
leading to a complex II/III defect, neurodegeneration and the HD clinical phenotype. 
6.4.4. Mitochondrial toxins in htt cell models
The toxic inhibition of the MRC was a useful method to study the competence of cells 
expressing WT or MT N-terminal htt when metabolically stressed. If MT N-terminal htt 
caused a mild reduction in MRC function or affected another metabolic process that was 
dependent on ATP production, the MT cells should have been more sensitive to the 
mitochondrial toxin than WT cells.
There was a trend towards a non-significant increase in cell death in response to complex 
II inhibition by malonate in cells expressing MT N-terminal htt (Fig.3.29B). Antimycin A 
(a complex III inhibitor) has been described to cause increased aggregate formation, 
decreased proteasomal function and increased cell death in 143B (human osteosarcoma) 
cells expressing exon1-103Q htt (Fukui et al. 2007). If the major effect of N-terminal htt 
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of complex II/III would be toxic to cells by causing a further reduction in ATP 
production. 
In contrast to these findings, MT N-terminal htt expression was associated with a 
decrease in vulnerability to CN toxicity (Fig.3.30B). This suggested that the toxic effect 
of cyanide was partly ameliorated by MT N-terminal htt expression. However, one would 
expect   that   malonate,   antimycin   A  and   cyanide  would   inhibit   the  mitochondrial 
respiratory chain and cause a reduction in the phosphorylation of ADP which would cause 
cell death/dysfunction. The contrasting findings with malonate, antimycin A and cyanide 
in the HEK 293 cell model, Fukui et al (2006) and Sawa et al (1999) would suggest that 
the mechanism causing cell death is not entirely mediated by a reduction in cellular ATP 
production. One explanation for the contrast in response to mitochondrial toxins would 
relate to the duration of MT FL or N-terminal htt expression. An increase in apoptosis in 
HD lymphoblasts in response to cyanide has been described (Sawa et al. 1999). MRC 
function was not measured in the HD lymphoblasts but it was speculated that chronic 
exposure to MT FL htt in HD lymphoblasts would produce a reduction in complex IV 
activities and in turn cause a greater sensitivity to cyanide (Sawa et al 1999). However in 
cells exposed acutely to cyanide and MT N-terminal htt, where there is no evidence of a 
complex IV defect in cell models, an increase in cyanide-induced toxicity would not be 
expected. If this hypothesis were correct, one would predict that the EYFP MT FL htt 
model would demonstrate increased sensitivity to cyanide toxicity similar to HD 
lymphoblasts (Sawa et al 1999).
The protective effect of MT N-terminal htt on CN toxicity is difficult to explain. MT N-
terminal htt could inhibit a process that is essential for mediating cyanide toxicity. 
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subunit of complex IV and therefore reduce cyanide toxicity. There has been growing 
evidence of the association of N-terminal MT htt with mitochondria (Choo et al 2004 and 
Section 6.9.2.) although there is no published data to support the association of N-
terminal htt with the components of the mitochondrial respiratory chain. A further 
alternative explanation would suggest that MT N-terminal htt protects against cyanide-
mediated toxicity of iron-containing proteins outside of the mitochondrial respiratory 
chain, such as aconitase. This has not been investigated in the literature. A final 
explanation comes from the finding of increased complex IV activity associated with 
143B (human osteosarcoma) cells expressing exon 1-103Q htt (Fukui et al. 2007). This 
would suggest that MT N-terminal htt may increase complex IV activity and therefore 
cause relative protection of MT compared to WT N-terminal htt expressing cells against 
complex IV inhibition.
There was a trend for increasing toxicity with malonate and reducing toxicity with 
cyanide in MT compared to WT compared to pIND0 cells in the HEK 293 cell model. 
WT N-terminal htt therefore caused a similar, but reduced, effect as MT N-terminal htt in 
response to cyanide and malonate. This suggested that N-terminal htt may independently 
have a toxic/protective effect unrelated to the size of the CAG repeats. WT N-terminal htt 
has been described in post-mortem brain (Kim et al. 2001) although the potential toxicity 
of WT N-terminal htt has not been investigated.
In summary, the greater cell death with malonate treatment and the reduction in cell death 
with cyanide treatment in cells expressing MT N-terminal htt expression supports the 
hypothesis that MT N-terminal causes a reduction in complex II/III function and bypassed 
the postulated initial reduction in complex IV activity to cause cell death. The protective 
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an increase in complex IV activity which has been described in one N-terminal htt 
expressing cell model (Fukui et al. 2007) but not in the current HEK 293 model. The 
potential mechanisms by which MT htt may affect mitochondrial function are discussed 
further in Section 6.9.2.
6.5. Oxidative Stress in cell models of HD
Aconitase activity as a marker of excess free radicals 
Aconitase   activity   has   been   found   to   be   extremely   sensitive   to   superoxide   and 
peroxynitrate and has been used as a marker of free radical damage (Hausladen, 1994, 
Gardner 1994, Patel 1996). Aconitase activity was reduced in the SH-SY5Y cells 
expressing MT FL htt but was normal in the WT FL htt expressing clones. This implied 
that FL MT htt caused decreased antioxidant defences and/or excess free radical 
production (Fig 4.25C). The reduction in aconitase and complex IV activity in the EYFP 
MT FL htt clones mirrored the defects in aconitase and mitochondrial function seen in the 
HD post-mortem striatum and cortex (Tabrizi et al. 1999) and in the R6/2 mouse striatum 
(Tabrizi et al. 2000). The reduction in aconitase and complex IV activities in the FL htt 
EYFP model contrasted with the normal aconitase activity in the WT and MT N-terminal 
htt HEK 293 models which suggested an absence of significant oxidative stress in 
response to N-terminal MT htt expression. 
The inhibition of aconitase by FL htt but not N-terminal htt in the SH-SY5Y and HEK293 
models suggested that FL htt may cause greater free radical production than N-terminal 
htt. This is unlikely to be due to the size of the htt fragment alone as the R6/2 mouse 
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2000). The duration that MT htt was expressed in the cells may be important and reduced 
aconitase activity may be caused by a progressive accumulation of excess free radicals 
over time. This could be investigated by assessing aconitase function in the SH-SY5Y 
model at increasing passages of the cells.
It remains unclear whether an increase in free radicals in HD results from MT htt-induced 
mitochondrial inhibition or whether MT htt-associated excess free radical production 
subsequently caused mitochondrial dysfunction. This has not been addressed in other FL 
htt cell models in the literature and could be investigated by adding antioxidants to the 
MT   FL   htt   EYFP   cells   and   measuring   mitochondrial   and   aconitase   activity.   If 
mitochondrial dysfunction was an effect of MT htt expression upstream of free radical 
production, then potentially complex IV inhibition would be observed and associated with 
normal aconitase activity.
Paraquat toxicity in the HEK 293 model 
Paraquat is an intracellular generator of free radicals, especially superoxide, which can 
rapidly react with NO to form peroxynitrate. In order to determine if N-terminal htt 
expression compromised the endogenous antioxidant system in the HEK 293 model, the 
clones were treated with paraquat. An increase in cell death in response to paraquat was 
seen in the MT N-terminal HEK 293 clones (Fig.3.31B). This supported the hypothesis 
that MT N-terminal htt expression compromised the antioxidant defences of the cells 
either by increasing production of free radicals and/or decreasing antioxidant defences. It 
also suggested that increased oxidative stress occurs within 48 hours of MT N-terminal 
htt expression, and that this is not sufficient to inhibit aconitase function. One explanation 
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or SOD, may prevent aconitase dysfunction. There is support for this in the inducible N-
terminal htt model published by Wyttenbach et al (2001) in which van Roon-Mom et al. 
(2008) found an early  up-regulation of genes in the anti-oxidant Nrf2-ARE pathway. 
Further support comes from the study by Choo et al (2005), who found similar levels of 
glutathione in the striatum and cortex of R6/2 mice compared to WT littermates, but 
found increased levels of glutathione in mitochondria isolated from the cortex and 
striatum.   This   suggested   that   compensatory   mechanisms   occurred   specifically   in 
mitochondria in response to a local excess of free radical generation that may not be 
detected when looking at whole brain tissue. Paraquat, as a source of free radicals and 
oxidative stress, has not been used extensively in the study of HD. Snider at al. (2003) 
found no difference in the effect of paraquat on cultured mouse cortical neurons from WT 
(HdhQ20) compared to MT (HdhQ111) transgenic mice but only used doses up to 100µM 
for 24 hours.
Mechanisms of free radical toxicity in HD
The generation of excess free radicals and the presence of oxidised end-products in HD 
post-mortem tissue and HD animal and cell models has been well described (Section 
1.10.10). The molecular mechanisms of excess free radical production in HD and the role 
of free radicals either as a primary toxic effect of MT htt or a secondary consequence of 
MT htt-induced neuronal dysfunction, are poorly understood (Stack et al 2008). Fukui et 
al. (2007) found that complex III inhibition, by antimycin A, in their inducible N-terminal 
htt model (Table 1.5) promoted MT htt aggregation and cell death by proteasome 
inhibition independently of free radical production and ATP depletion. This suggested 
that oxidative stress or bioenergetic defects did not have a primary role in causing 
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proteasomal dysfunction without excess free radical production and/or ATP depletion is 
uncertain. Puranam et al. (2006) have described the action of purified 62Q-GST on 
isolated mitochondria. The authors failed to demonstrate a direct effect of 62Q-GST on 
respiratory chain complex activities but did find increased free radicals and impaired 
mitochondrial respiration. The authors concluded that polyQ inhibited mitochondrial 
respiration by the generation of free radicals but the authors did not comment on the 
origin of the free radicals or the mechanism of impaired mitochondrial respiration. It 
therefore appears that isolated polyQ can generate free radicals  independently of 
inhibiting the mitochondrial respiratory chain suggesting oxidative stress may be a 
primary event. In support for the primary pathogenic role of free radicals in HD, Solans et 
al.   (2006)   published   an   inducible   N-terminal  htt  yeast   model  (Table  1.5)   which 
demonstrated an increase in free radical production 5 hours post-induction of MT N-
terminal htt and a partial reversal of the observed reduction in mitochondrial complex II 
activity by resveratrol.  Resveratrol is a compound commonly found in plants and 
activates SIRT1 and PGC-1α (peroxisome proliferators–activated receptor coactivator 1α) 
which leads to improved mitochondrial biogenesis and anti-oxidant defenses (Lagouge et 
al 2006). This suggested that in the Solans et al (2006) model, complex II inhibition is 
preceded by free radical generation and that PGC-1α may be inhibited by MT htt. A 
protective effect of PGC-1α overexpression on paraquat toxicity in a neuronal cell line 
has been described (St-Pierre et al. 2006). The authors implicated the role of PGC-1α in 
inducing mitochondrial and anti-oxidant defence genes suggesting that the impairment in 
the activity of PGC-1α may be one mechanism by which MT htt mediates its pathogenic 
effect. Cui et al. (2006), in an HD striatal cell model and HD transgenic mice, have 
described MT htt-induced disruption of mitochondrial function by inhibition of the 
transcription of PGC-1α and overexpression of PGC-1α reversed the effects of MT htt. 
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dysregulation, excess free radicals and mitochondrial dysfunction in HD.
In summary, the precise role of free radicals in the pathogenesis of HD remains unclear 
although there is increasing evidence from the current and previous studies that excess 
free radical production and increased sensitivity to free radicals is an early event which 
may be linked to transcriptional dysregulation of mitochondrial and anti-oxidant proteins 
by MT htt. In spite of this uncertainty, there is growing evidence from HD cell models, 
animal models of HD and small clinical studies (Stack et al 2008) that treatment with 
antioxidants e.g. high dose vitamin E and creatine, and respiratory chain components, e.g. 
ubiquinone, may reduce some of the pathogenic effects of MT htt in vivo. Clinical trials, 
such as CREST-E and CARE, are already investigating the treatment of HD patients with 
antioxidants, including creatine, and ubiquinone (Huntington Study Group).
6.6. The Ubiquitin-Proteasomal System (UPS) in HD
The UPS has been implicated in several neurodegenerative diseases (Ardley et al. 2005). 
The UPS may contribute to the pathogenesis of neurodegeneration due to inhibition of 
proteasomal function by toxic soluble or aggregated proteins, such as MT N-terminal htt 
and MT htt aggregates (Section 1.6.3.). The UPS may degrade proteins into toxic 
fragments, such as FL htt into N-terminal fragments, although there is little direct 
evidence for this (Section 1.6.4.). The proteasome may also have a protective role in 
removing toxic MT htt N-terminal fragments. Therefore, not only would proteasome 
inhibition   theoretically   impair   general   cellular   function   but   would   also   cause  an 
accumulation of toxic N-terminal htt fragments (Section 1.6.4.).
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FL htt expression was associated with a decrease in the trypsin-like activity of the 
proteasome but trypsin-like activity was increased in the clones expressing WT FL htt 
(Fig. 4.26). This suggested that FL MT htt inhibited and FL WT htt enhanced proteasome 
function. An isolated reduction in trypsin-like activity by MT htt has not been described 
previously in HD and may represent an early event in proteasome dysfunction. The 
inhibition of the three proteasomal enzyme activities has been found in early and late-
grade post-mortem HD cerebellum, cortex, substantia nigra and caudate/putamen, HD 
skin fibroblasts and in a primary striatal cell model expressing a 548aa. N-terminal 
fragment of htt with 105Q (Seo, H. et al 2004 and 2007). The more widespread decrease 
in proteasomal activities with the Seo et al (2007) model was possibly due to the longer 
poly Q and a shorter MT N-terminal htt fragment expressed. In the HD post-mortem brain 
and fibroblast studies the longer duration of exposure of the proteasome to FL MT htt, or 
its cleavage products, over many years may have also caused a more widespread 
reduction in proteasome activity. The mechanism by which MT FL htt or its cleavage 
products causes proteasomal dysfunction is uncertain. One possible mechanism would be 
free radical inhibition of the proteasome (Goswami et al 2007). Bulteau et al. (2001) 
described oxidative modification of the 20S proteasome and a reduction in all three 
proteolytic activities of the proteasome following reperfusion of ischaemic cardiac tissue. 
This suggested that proteasome function can be directly impaired by free radical 
modification. A study on proteasome function in rat livers found that the treatment of the 
proteasome with 4-hydroxy-2-nonenal, a major lipid peroxidation product, specifically 
inactivated trypsin-like activity and this effect was prevented by the addition of HSP 90 
(Conconi et al 2004) which suggested that free radicals and/or lipid peroxidation may 
cause impaired trypsin-like activity. The reduced aconitase activity in the MT htt EYFP 
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radicals in causing the isolated reduction in trypsin-like activity in the EYFP MT FL htt 
model. The free radical modification of proteasome components has not been investigated 
in HD.
MT htt aggregates are associated with many proteins in post-mortem brains and in HD 
transgenic mice (Section 1.7.5.). The accumulation of proteasomal components in the 
aggregates   is   an   alternative   possible   mechanism   by   which   MT   htt   could   cause 
proteasomal dysfunction. The sequestration of the 20S proteasomal subunit into htt 
inclusions has been demonstrated in the R6/1 mouse model and N-terminal htt expressing 
cell culture systems (Waelter et al. 2001a, Wyttenbach et al. 2000). The EYFP model did 
not demonstrate spontaneous inclusions but did demonstrate a reduction in trypsin-like 
activity suggesting that htt aggregates were not necessary to mediate proteasomal 
dysfunction. This is in agreement with Seo et al. (2007) who found proteasomal 
dysfunction in the absence of htt inclusions at day three post-induction in their striatal cell 
model of HD. 
The direct interference of MT htt with proteasome function may represent a further 
possible mechanism by which MT htt causes proteasomal dysfunction. In two studies, 
degradation of MT htt exon 1 by the proteasome was decreased. In the first, HEK 293 
cells transiently expressed GFP-labeled exon 1 htt with 103Q (Bence et al. 2001), whilst 
in the second, N2a cells expressed exon 1 htt with 150Q in an inducible model of HD 
(Jana et al. 2001) (Table 1.5). The inhibition of proteasomal degradation of MT exon 1 htt 
occurred in a polyQ repeat length-dependent manner, with higher polyQs causing greater 
proteasomal dysfunction. These models did not investigate individual enzyme activities of 
the proteasome or whether degradation of other proteins was more broadly inhibited by 
281MT htt. The mechanism by which MT htt degradation by the proteasome is reduced 
remains uncertain, although it could have been caused by an indirect effect of MT htt on 
proteasome function, such as free radical generation, as opposed to MT htt directly 
inhibiting proteasome function.
In contrast to the EYFP model, an N-terminal inducible cell model (exon 1-Q103 htt) 
(Fukui et al. (2007) and Table 1.5) demonstrated reduced chymotrypsin-like activity of 
the proteasome following treatment with the complex III inhibitor, antimycin A, which 
was not prevented by antioxidants. The authors did not comment on proteasome function 
in their model without antimycin A. This suggested that complex III inhibition can 
synergistically cause proteasomal dysfunction with MT N-terminal htt expression and this 
process was independent of excess free radical production. The molecular mechanism 
linking the proteasome, complex III and htt is unknown and how this relates to the finding 
in the EYFP FL htt and HD post-mortem brain is uncertain but suggests that N-terminal 
MT htt can cause proteasomal dysfunction in the presence of mitochondrial inhibition. In 
vivo   mitochondrial   inhibition,   potentially   caused   by   FL  htt,   could   potentiate   the 
subsequent proteasomal inhibition by FL MT htt or its cleavage products. 
The increased trypsin-like activity in the WT EYFP clones was a novel finding. There has 
been no link to proteasomal physiological function and htt, although WT htt has been 
linked to transcriptional regulation (Li and Li for a review 2004) which may afford one 
mechanism by which WT htt increased proteasomal function.
Sensitivity to lactacystin in the HEK293 model
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by covalently binding to the 20S catalytic core (Fenteany et al 1995; Groll et al 1997). 
The treatment of the HEK 293 N-terminal htt model with a mildly toxic dose of 
lactacystin allowed the assessment of the sensitivity of cells to WT and MT N-terminal 
htt in the context of proteasomal inhibition. If N-terminal htt impaired proteasomal 
function then an increase in cell death would have been expected. HEK 293 expressing 
WT N-terminal htt exhibited less cell death, whereas MT N-terminal htt expression 
increased lactacystin-induced cell death (Fig.3.32). A reduction in cell death by FL 
endogenous WT htt following expression of N-terminal MT htt has been described in 
cellular and transgenic models (Ho et al. 2001, Leavitt et al. 2001, Van Raamsdonk et al 
2005). The HEK 293 model demonstrated an apparent protective effect of WT N-terminal 
htt in comparison to FL WT htt. In conjunction with the finding of increased trypsin-like 
activity in the EYFP WT FL htt clones, this suggested that WT htt may have a 
physiological role in controlling proteasome function. The protective effect appeared to 
be specific to proteasomal inhibition, as the toxicity of malonate and paraquat, were not 
improved with WT N-terminal htt expression. The potential mechanisms by which this 
protective effect occured included ameliorating the downstream toxic molecular effects of 
proteasome inhibition, a direct effect on lactacystin rendering it less toxic, or a direct 
effect on the proteasome by N-terminal WT htt to inhibit the binding of lactacystin. There 
is no published data to support these hypotheses.
The increase in lactacystin-induced cell death was specific for N-terminal MT htt 
expression and suggested that either MT N-terminal htt was more toxic when it was not 
degraded by the proteasome or that inhibition of the proteasome affected other cellular 
processes, which rendered N-terminal MT htt more toxic. Cells expressing N-terminal 
MT htt have previously been demonstrated to be more vulnerable to lactacystin (Jana et al 
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presence of htt aggregates in the HEK 293 model following treatment with lactacystin 
was not investigated in the current thesis and would be important question to answer in 
future work but was investigated in the FL htt EYFP model and is discussed below. 
Proteasome inhibitors have anti-tumour activity in cell culture and induce apoptosis by 
disrupting the regulated degradation of cell cycle proteins (Adams et al. 1999). Enhanced 
cell death with N-terminal MT htt expression would suggest that N-terminal MT htt may 
potentiate the lactacystin-induced apoptotic mechanism. There is limited evidence that 
apopotosis occurs in HD but there is evidence of upregulation of proapoptotic proteins 
(Hickey et al 2003). Future work would focus on assessing the frequency of apoptosis and 
htt inclusion formation following lactacystin treatment in the HEK 293 cells and the 
effects of lactacystin on apoptotic pathways in the context of WT and MT N-terminal htt 
expression.
Inclusion formation in response to lactacystin
Htt inclusions are an important feature of HD neuropathology and have variably been 
detected in HD transgenic animal and cell models (Section 1.7. and Table 1.5). Htt 
inclusions were not a feature of the cell models studied in this thesis (Section 6.8). 
However,   EYFP   fluorescent   perinuclear   inclusions   formed   in   both   mitotic   and 
differentiated WT and MT FL htt clones treated with lactacystin but not in mitotic or 
differentiated   untreated   clones   (Fig.   4.17).   Similar   inclusion   formation   following 
treatment with lactacystin has been described in an inducible Tet-“Off” HEK 293 cell 
model expressing exon 1 (51 or 83Q) (Waelter et al 2001a). The WT htt expressing cells 
(20Q) did not form inclusions following lactacystin treatment. The cells expressing 83Q 
htt formed inclusions more quickly than the 51Q htt which suggested that inclusion 
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predominantly in a perinuclear distribution and occasionally in the nucleus. Mitochondria 
accumulated around the margins of the inclusions and the inclusions deformed and 
indented the nuclear membrane. The inclusions formed in the EYFP model displayed 
many properties similar to the inclusions in the Waelter et al. (2001a) model and were 
”aggresome-like” (Johnston et al. 1998). One of the most striking differences between the 
EYFP model and the model by Waelter et al (2001a), was that Waelter et al (2001a) 
found htt inclusions in the absence of lactacystin in the 51Q and 83Q MT clones, as has 
been described in other inducible and constitutive cell models (Table 1.5). This may be 
partially explained by the shorter htt fragment expressed in other cell models, in 
comparison to FL htt expressed in the EYFP model. FL htt delays the onset of inclusion 
pathology in FL htt knock-in HD mice (Shelbourne et al. 1999), transgenic HD mice 
(Reddy et al. 1998) and human post-mortem HD brains (Vonsattel  et al 1985) in 
comparison to transgenic HD mice expressing N-terminal htt fragments (Mangiarini et al 
1996) which rapidly form inclusions. Two inducible cell models expressing FL MT htt 
have demonstrated htt aggregate formation (Lunkes et al 1998, Sugars et al. 2004, Table 
1.5). In comparison to the EYFP FL htt model described here, the models by Lunkes et al 
(1998) and Sugars et al. (2004) expressed 116Q and 136Q in comparison to the EYFP 
MT htt model which expressed MT htt with 90Q. Therefore, longer polyglutamines were 
associated with inclusion pathology without the requirement for proteasomal inhibition.
Similar inclusions were observed in lactacystin-treated WT htt as well as MT htt EYFP 
clones, in contrast to Waelter et al (2001a) and other cell models (Table 1.5). This 
suggested  that both  EYFP  WT and MT htt  were processed  by  the  trypsin   and 
chymotrypsin-like activities i.e. lactacystin sensitive, of the proteasome. It also suggested 
that inclusions may form from WT htt if the proteasome is inhibited sufficiently. Whether 
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Inclusion pathology from FL or N-terminal WT htt has not been previously described in 
other HD cell or animal models.
One explanation for the formation of inclusions in the WT htt EYFP clones was that 
rather than forming aggregates consisting of cross-linked N-terminal fragments in ß-
pleated sheets, which was proposed for MT htt in HD (Perutz et al 1994, DiFiglia et al 
1997), the aggresome-like bodies represented accumulations of unprocessed FL WT and 
MT htt in response to failure of degradation by the proteasome. Nevertheless, this 
demonstrated that degradation of FL WT or MT htt involves proteasomal processing. This 
is supported by Martin-Aparicio et al. (2001) who found that proteasomal inhibition 
prevented the removal of htt aggregates from a conditional transgenic mouse model of 
HD.
The EYFP inclusions were immunostained by all htt antibodies used in the present study 
except for the most C-terminal antibody, Ab7666, which mostly stained the periphery of 
the inclusions but not the core (Fig. 4.20). This suggested that the inclusions did not 
consist predominantly of N-terminal htt products, as has been demonstrated for inclusions 
in HD post-mortem brain, HD mice and other cell models (DiFiglia et al 1997 and Davies 
et al. 1997). It did suggest that EYFP accumulations were mostly unprocessed FL WT 
and MT htt as suggested by the recognition of epitopes along the length of htt. The 
slightly reduced Ab7666 staining suggested that the C-terminus may have been processed 
by non-proteasomal pathways or that the epitope recognised by Ab7666 was hidden 
within the inclusion. This further suggested that processing of FL htt is dependent on the 
trypsin and chymotrypsin-like activities of the proteasome. 
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in comparison to MT cells. There were also more WT than MT cells in culture following 
lactacystin treatment suggesting that MT clones died faster or that WT cells grew more 
quickly. Waelter et al (2001a) also noted increased cell death in MT clones following 
lactacystin treatment (Table 1.5). This suggested that the perinuclear inclusions or 
proteins that were not degraded by the proteasome were more toxic in the MT than the 
WT EYFP clones.
In summary, the data from the EYFP model and other cell and animal models has 
suggested that the proteasome is involved in the processing and removal of FL WT and 
MT htt. The formation of “aggresome-like” inclusions in response to lactacystin in the 
WT and  MT clones  may  represent  a  pathophysiological  response of the  cell to 
unprocessed EYFP htt. This has been described in other cell systems (Johnston et al 1998) 
although aggresome-like inclusions have not been described following WT htt expression 
and may represent a novel insight into the physiological processing of WT htt by 
lactacystin sensitive-proteasomal mechanisms.
6.7. Processing of htt
The first step in the pathogenesis of HD may involve abnormal processing of FL MT htt 
to generate toxic N-terminal MT htt fragments (Section 1.6.). The size of these fragments 
is still uncertain. The EYFP FL htt model enabled the assessment of processing of htt 
using antibodies to epitopes across FL htt and the treatment of the cells with lactacystin 
allowed the possibility of greater detection of fragments that may have been degraded by 
the proteasome.
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without lactacystin treatment. Following lactacystin treatment of the EYFP FL htt WT 
clone 23 1 1 for 24 hours, additional htt bands at 44kDa and 34kDa were detected (Fig. 
4.22 and Table 6.1). The EYFP insertion is approximately 25kDa. and therefore these N-
terminal fragments would be predicted to be 19 and 9kDa respectively (approximately 
173 and 82 amino acids). The 82aa fragment would therefore terminate just short of the 
C-terminal end of the polyglutamine stretch (exon 1 is 92 aa with 23 CAGs), and the 173 
aa fragment at the start of exon 4. 
WT/MT EYFP clones
Size (kDa) 
on blot
Estimated amino acids of N-
terminal htt fragment
Similar bands in literature
1 WT clone
(23 1 1)
44 and 34 173 and 82
Schilling et al. (2007)
Lunkes et al (2002)
1 WT clone
(23 6 7 )
111 782
3 MT clones
(88 2 8, 2 9 and 2 11)
36 100
Sieradzan et al (1999), 
Lunkes et al (2002), 
Schilling et al (2007)
Table 6.1. Summary of extra htt bands in EYFP model following lactacystin treatment for 
24 hours. Note that the size of the band on the blot included the EYFP protein (25kDa.)
Schilling et al (2007) used a panel of 4 anti-htt antibodies within the first 171aa of htt to 
estimate the size of these fragments and described two bands of 45kD and 35 kDa in the 
MT (82Q) cells with a similar 10kDa difference between the two bands as seen in their 
WT cells. The two bands observed in the current study migrated slightly less than those 
seen by Schilling et al. (2007) in their WT clones (44 and 34 kDa compared to 27 and 
17kDa). This was partly due to the EYFP tag in the EYFP clones and therefore the 
predicted sizes of the fragments would be smaller at 19 and 9kDa. It was also possibly 
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estimating the size of proteins containing polyglutamines. An alternative explanation is 
that the extra bands in the EYFP model were different from the bands Schilling et al. 
(2007) observed. The extra htt bands recognised by Schilling et al. (2007) and in the 
current thesis are also similar in length to those seen by Lunkes et al (2002) between 18 
and 129aa of htt in MT htt expressing cells (Table 6.1).
The presence of the 44 and 34KDa extra htt bands only with lactacystin, in the current 
study, suggested that the bands were possibly present at a low level and proteasome 
inhibition was required for accumulation of these cleavage products. It also suggested that 
the proteins forming these additional bands were processed by the proteasome. The 
absence of these bands in other WT EYFP clones may have been due to variation between 
clones in expression levels, the variation in the integration site of the construct within the 
host SH-SY5Y cells and the variable phenotype within the population of SH-SY5Y cells. 
There are no other reports apart from Schilling et al (2007) and the current thesis of 
processing of WT htt and therefore it remained possible that processing of WT htt was not 
a physiological event and was an artefact of both models. 
There was an additional band at 111kDa in WT clone 23 6 7 following 24 hours treatment 
with 5µM lactacystin (Fig.4.24). This would represent an N-terminal fragment at 
approximately 782aa within the second proposed HEAT sequence (Fig.1.1). A fragment 
of this size has not been described and could represent abnormal transcription/translation 
of the integrated construct or physiological cleavage of WT htt.
Three out of the four EYFP MT htt clones demonstrated an additional band at 36kDa 
following treatment with lactacystin for 24 hours, representing an htt fragment of 11kDa 
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fragment would approximately terminate at the C-terminal end of the polyglutamines 
encoded by the 88 CAGs. An N-terminal fragment terminating within the region of the 
termination of the polyglutamine repeats has not been described previously and may 
represent a novel cleavage product. A MT htt cleavage product of 100aa would be more 
in keeping in size with the htt fragments described by Sieradzan et al (1999), Lunkes et al 
(2002) and Schilling et al (2007) between aa.18 and 129, than the caspase/calpain 
cleavage sites between aa.469-586 (Sun et al 2002, Wellington et al. 1998 and 2002, 
Gafni et al. 2004). 
Cleavage within or close to the C-terminus of the polyglutamine stretch may represent 
one mechanism that distinguishes processing of MT and WT htt, causing an abnormal 
toxic MT N-terminal htt fragment to be cleaved. It is postulated that the expanded 
polyglutamine region alters the confirmation of FL htt at the boundary between the 
polyglutamine sequence and the polyproline region and this enables an otherwise 
unspecified protease to abnormally cleave htt to an N-terminal MT htt fragment. 
The extra htt band in three out of four of the EYFP MT clones were only observed 
following treatment with lactacystin and therefore were probably cleavage products 
formed at a level too low to detect on Western blots in cells with an uninhibited 
proteasome. This would suggest that the extra bands were, at least partially, degraded by 
the chymotrypsin and trypsin-like activities of the proteasome i.e. lactacystin-sensitive 
components, and highlights the importance of the proteasome in the processing of htt. It 
also suggested that the extra bands were not formed by proteasomal processing mitigating 
against a significant role of the proteasome in formation of potentially toxic N-terminal 
htt fragments.
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terminal or FL htt cell models. If processing of MT htt has a significant role in the 
pathogenesis of HD, greater evidence of differences in processing of MT htt in 
comparison to WT htt may have been expected. One explanation would be that 
processing was occurring but at levels too low to detect on the Western blots. Another 
possibility was that mitotic cells do not accumulate N-terminal MT htt fragments as 
efficiently as post-mitotic differentiated cells in vivo. The MT clone (88 1 3) was the only 
MT clone to be differentiated for 4 weeks and was the only MT clone which did not 
demonstrate an extra 36kDa band with lactacystin. It is possible that differentiation of the 
three MT EYFP clones which did demonstrate an extra band with lactacystin may have 
demonstrated an extra band without lactacystin treatment and this would be important 
future work to be performed.
The formation of EYFP htt inclusions occurred in all WT and MT EYFP clones and 
therefore was independent of the formation of the extra band in three out of four of the 
MT clones. This suggested that abnormal processing of htt was not necessary for the 
EYFP inclusions to form. There was also no qualatitative differences in the rate of cell 
death, rate of inclusion formation or the morphology between the MT EYFP clone that 
did not express an extra band from the three that did express an extra 36kDa band 
although this would need to be investigated quantitively. 
Whether processing of FL htt to N-terminal htt fragments is necessary for initiating 
neurodegeneration in HD remains a complex and unanswered question. There are several 
lines of evidence which suggest that processing of FL MT htt occurs but the role of MT 
N-terminal fragments remains unclear. Firstly, transgenic mice that express only N-
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quickly than transgenic mice that express FL htt (Davies et al. 1997, Schilling et al 1999 
and Becher et al 1998). This is suggestive but not conclusive of the requirement for FL htt 
processing in HD. FL htt may be toxic in its own right but less toxic than N-terminal htt. 
Secondly, the HD transgenic mice expressing only N-terminal htt develop a phenotype 
with some similar clinical and pathological features to HD (Davies et al. 1997, Schilling 
et al 1999 and Becher et al 1998). However, ectopically expressed CAG repeats cause 
intranuclear inclusions and a late-onset neurological phenotype in the mouse (Ordway et 
al. 1997) which suggests toxicity is conferred as much by the expanded CAG repeats as it 
is by the protein context. Thirdly, the inclusions formed in FL htt HD transgenic mice are 
formed by N-terminal fragments of MT htt (Reddy et al. 1998, Hodgson et al. 1999 and 
Wheeler 2000), suggesting that processing of FL htt was necessary for htt inclusion 
formation but not necessarily for mediating MT htt toxicity. Lastly,  nuclear and 
cytoplasmic neuronal inclusions in HD post-mortem brain, have been found to be 
immunoreactive with antibodies directed against N-terminal but not C-terminal regions of 
htt (DiFiglia et al. 1997, Gutekunst et al. 1999, and Sieradzan et al. 1999) and N-terminal 
fragments of MT htt have been detected in immunoblots of homogenates from HD brains 
and HD mice (DiFiglia et al. 1997, Zhou et al. 2003 and Tanaka et al. 2006). These 
studies are strongly compelling for the existence of processing of FL MT htt, but do not 
prove that N-terminal htt is the toxic molecule in HD. 
The FL EYFP model also suggested that there were differences in processing between 
WT and MT FL htt. The extra N-terminal MT htt band in three of four MT EYFP clones 
did not appear to cause gross toxic effects on the cells although detailed investigation 
would be needed to clarify this further. The possibility of FL WT htt processing and the 
role of WT N-terminal fragments in the function of htt also remain uninvestigated. 
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expressing N171-18Q formed smaller WT N-terminal htt non-toxic fragments between 90 
and 115aa which suggested that WT htt may also be cleaved physiologically. It is 
postulated that processing of WT htt may be necessary for its nuclear translocation and its 
potential function in nuclear-cytoplasmic trafficking. This may explain why WT htt has 
been detected in the nucleus (Bessert et al. 1995) and how abnormally processed MT N-
terminal htt may form nuclear inclusions as it abnormally accumulates in the nucleus.
6.8. Huntingtin Inclusions
Cytoplasmic and nuclear inclusions are a striking histological feature of HD post-mortem 
brains, HD transgenic mice and some HD cell models (Becher et al 1998, Davies et al 
1997 Lunkes et al 1998). Intracellular inclusions have also been described in organs other 
than the brain such as R6/2 mouse skeletal muscle (Sathasivam et al. 1999, Orth et al. 
2003) and in differentiated HD myotubes (Ciammola et al 2006). The precise role of htt 
inclusions   in   the   pathogenesis   of   HD   may   be   pathological,   protective   or   an 
epiphenomenon (Davies et al 1997, Becher et al. 1998, Hackam 1998 and Lunkes et al 
1998, Hackam 1998, Gutekunst et al 1999, Arrasate et al 2004, Arango et al 2006, Bodner 
et al 2006 and Section 1.7.).
HD cell models 
There was no evidence of intranuclear or cytoplasmic htt inclusions in mitotic or 
differentiating SH-SY5Y cells constitutively expressing WT or MT FL htt, or in the 
inducible HEK293 WT and MT N-terminal htt cell model. Most inducible HD cell 
models in the literature have developed htt inclusions. These models expressed short N-
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al 2001, Wyttenbach et al 2001, Solans et al 2006 and Fukui et al. 2007) and with up to 
150 CAG repeats (Jana et al. 2001). Many of these models were also differentiated 
(Lunkes et al. 1998, Wang et al 1999, Jana et al. 2001, Wyttenbach et al 2001) and 
expressed N-terminal htt for up to 18 days (Lunkes et al. 1998). Table 1.5 summarises the 
characteristics of the inducible cell models and the location of the htt inclusions. The 
HEK 293 cell model described in the current thesis expressed MT N-terminal htt with a 
relatively short CAG repeat length (57 CAGs), the product was expressed for only 48 
hours in mitotic cells and the N-terminal htt fragment was relatively long (176aa in WT). 
Benchoua et al. (2006) described a HD cell model expressing an 171aa htt N-terminal 
fragment with 82 CAGs in a rat primary striatal model, compared to 57 CAGs in 176aa 
N-terminal fragment in the current HEK 293 model. Benchoua et al. (2006) found htt 
aggregate pathology. This suggested that the size of the CAG repeat was possibly an 
important factor in determining htt aggregate formation, as discussed above, although it 
may have also been due to the neuronal primary striatal cells in the Benchoua et al. (2006) 
model, which may be expected to form htt inclusions more readily because of a neuronal 
background. The main factors which therefore influence formation of htt inclusions in 
inducible HD cell models include the length of N-terminal fragment, size of CAG repeat, 
duration of N-terminal htt expression, cell type and differentiation.
There are no constitutively expressing FL htt cell models for direct comparison with the 
EYFP model. The inducible model described by Lunkes et al. (1998) expressed MT FL 
htt with 73 CAG repeats in NG105-15 cells. The cells were differentiated and formed 
predominantly cytoplasmic inclusions which suggested that differentiation may be 
important in the formation of inclusions from FL MT htt. The inducible model described 
by Sugars et al (2004) expressed MT FL htt with 136 CAG repeats and formed htt 
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formation even on the background of FL htt (Table 1.5). In summary, highly expanded 
CAG repeats and/or post-mitotic cells appear to be important determinants of htt 
inclusion formation from FL MT htt. One would therefore have expected the EYFP MT 
htt model to form inclusions spontaneously following two weeks differentiation. The 
absence of inclusions in this model may have been secondary to the EYFP tag at the N-
terminal end of FL htt which could have inhibited N-terminal htt fragment aggregation 
due to the size of the EYFP tag (25kDa). 
Another explanation for the absence of inclusions in the EYFP FL htt model was 
secondary to constitutive expression. The cell models by Li et al. (1999) and Ye et al. 
(2008) constitutively expressed MT htt (exon 1-150Q) in PC12 and differentiated N2a 
cells respectively, and neither formed htt inclusions. Htt inclusions did not form in either 
model in spite of the small N-terminal fragment and high CAG repeat length. Chun et al 
(2001 and 2002) constitutively expressed 63 aa of htt with 82 CAGs and found infrequent 
inclusions. This suggested that aggregate formation was less common in constitutively 
expressing cell models than inducible cell models, possibly due to the toxicity in cells 
forming aggregates during cloning. Several other models lacking inclusion formation 
have been published. Sipione et al. (2002) and Seo et al. (2007) investigated ST14A (rat 
embryonic striatum) cells expressing N-terminal
 548-amino-acid htt fragments with 26, 
67, 105 or 118Q under the control of a doxycycline-regulated promoter. They found early 
changes in gene transcription within 24 hours of induction of MT N-terminal htt in the 
absence of inclusions. This suggested that a relatively long N-terminal fragment can 
inhibit aggregate formation in inducible cell models even when the fragment contains 
118Q. The absence of inclusion formation in HD models has also been described in HD 
mouse models. Shelbourne et al. (1999) have described an HD knock-in mouse model 
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loss or inclusions. These studies further support the hypothesis that neuronal dysfunction 
can occur without inclusion formation.
HD muscle 
In the present thesis, immunocytochemistry with Ab675 or anti-ubiquitin antibody did not 
detect htt positive inclusions in any of the 12 HD muscle biopsies. This was confirmed 
with the absence of intranuclear inclusions on ultrastructural analysis with the exception 
of a severely affected 56 year old patient with a disease duration of 6 years and with the 
highest motor score in the UHDRS (76) and the third lowest cognitive score (126). This 
patient’s   muscle   ultrastructural   studies   demonstrated   electron   dense   intranuclear 
inclusions which suggested that inclusions possibly form in the later stages of HD in 
muscle. Clinically, these inclusions are unlikely to be useful to monitor the disease 
although they do confirm that abnormal MT htt processing does occur outside of the CNS 
and that similar pathological molecular mechanisms may exist in muscle. Htt mRNA 
expression in skeletal muscle (Li S-H et al 1993), cytoplasmic htt in HD muscle fibres 
(Hoogeveen et al. 1993)  and htt inclusion formation in myotubes from HD skeletal 
muscle  (Ciammola et al 2006)  have been described . However, there has been no 
description of htt inclusion formation in skeletal muscle in the literature and this is the 
first description of possible htt inclusions in skeletal muscle from post-mortem tissue. The 
lack of inclusions detected in HD muscle may partially reflect that some of the patients 
were asymptomatic or only mildly symptomatic. Cortical neuropil threads and occasional 
cortical intracellular inclusions have been described in presymptomatic HD brain but 
prominent htt inclusion formation is not a common early feature in post-mortem HD brain 
(DiFiglia et al. 1997; Gutekunst et al. 1999, Gomez-Tortosa et al. 2001). The lack of 
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the brain as demonstrated by the normal routine muscle histology in the majority of 
severely affected HD patients. The molecular processes that relatively spare skeletal 
muscle   from   MT   htt-associated   pathology   will   potentially   be   important   for   our 
understanding of the mechanisms underlying predominantly neuronal degeneration in 
HD.
The early lack of inclusions in the HD brain and skeletal muscle can be compared to HD 
mice where htt aggregate pathology has been described most extensively in mouse 
transgenic models expressing truncated N-terminal fragments of htt with highly expanded 
CAG repeats, such as the R6/2 mouse (Davies et al 1997). HD transgenic mice show a 
more restricted distribution or absence of inclusions in FL htt mouse models (Reddy et al. 
1998 and Shelbourne et al 1999) which suggests that FL htt slows the process of htt 
inclusion formation. In the HD mouse models, the aggregate pathology often occurs 
before the onset of a severe clinical phenotype (Davies et al. 1997, Reddy et al. 1998 and 
Lin et al 2001) and readily occurs in organs outside the CNS, such as skeletal muscle 
(Sathasivam et al 1999). These findings would suggest that aggregate formation occurs 
before the onset of gross clinical dysfunction. However, in some HD mouse models, such 
as the R6/2 mouse, where aggregate pathology starts at 4 weeks in the cortex, subtle 
cognitive and motor dysfunction has been detected at 3.5 and 5 weeks respectively, which 
suggests that early neuronal dysfunction may occur in transgenic HD mice before severe 
aggregate pathology and the method of clinical detection of a neurological phenotype may 
determine the temporal relationship of phenotype to aggregate formation (Carter et al 
1999). 
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a small N-terminal fragment. When the N-terminal fragment contains a highly-expanded 
CAG repeat, htt inclusions form more rapidly. The differentiation of cells may also 
influence aggregate formation. In vitro studies have demonstrated that the threshold for 
htt aggregation is between 32 and 37 polyglutamines when expressed in exon 1 of htt 
(Scherzinger et al 1999). The precise influence of the size of the N-terminal htt fragment 
and the mitotic state of cells on aggregate formation is not clear from the literature. The 
hypothesis generated by Perutz et al. (1994) for the formation of htt inclusions in the 
“polar zipper” model of htt inclusion formation did explain the important influence of 
CAG repeat size on the rate of aggregate formation. One explanation would suggest that 
more highly expanded CAGs would be more likely to form stable triplet repeat “hairpin 
loops” which would more easily aggregate due to greater availability of hydrogen bonds 
between the CAG repeats. Another explanation would suggest that small N-terminal 
fragments could cause less steric hindrance to hairpin loops binding to other hairpin loops 
which would enable htt aggregates to form more easily. Finally, post-mitotic cells could 
enable a cellular environment where accumulating protein aggregates would be less likely 
to be removed during mitosis and promote aggregate formation. There is no data in the 
literature to support these hypotheses and would provide areas of future work. 
The mechanism of aggregate formation is fascinating however the question remains as to 
whether   inclusions   are   pathological,   an   epiphenomenon,   or   protective.   Inclusion 
formation was not a feature of the current HEK 293 and EYFP cell models or in most of 
the HD muscle biopsies. The absence of inclusions is similar to other constitutively 
expressing cell models (Li et al. 1999 and Ye et al. 2008), in some inducible cell models 
(Sipione et al. 2002 and Seo et al. 2007) and in some HD transgenic mice (Shelbourne et 
al 1999). These models and the current HEK 293 and EYFP cell models and HD muscle, 
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muscle), excess free radical production (EYFP model), decreased neuritic outgrowth on 
differentiation (Li et al. 1999, Ye et al. 2008, EYFP model), increased cell death (Li et al. 
1999, Ye et al. 2008), widespread abnormalities in cellular transcription, including 
proteins involved in cell signalling, vesicle trafficking and lipid metabolism (Sipione et 
al. 2002), behavioural abnormalities in HD mice (Shelbourne et al 1999), synaptic 
plasticity (Usdin et al 1999) and reduced proteasome function (Seo et al. 2007, EYFP 
model). These molecular changes occurred in the absence of htt aggregates. This would 
support the role of cellular dysfunction occurring before gross htt aggregate pathology. 
The lack of correlation between inclusion formation and cell death has also been 
described in several animal and cell models of HD (Saudou et al. 1998, Kim et al. 1999, 
Arrasate et al 2004, Arango et al 2006). Based on the cell models and HD skeletal muscle 
investigated in the current thesis, it is postulated that htt aggregates are not responsible for 
the early pathological changes in HD and that MT htt exerts its toxic effect by non-htt 
aggregate-related mechanisms.
6.9. Subcellular localisation of htt
The location of htt may be an important determinant of its function (Section 1.5.3). Most 
studies have used anti-huntingtin antibodies to the N-terminus of htt and therefore it is 
difficult to determine whether cleaved N-terminal fragments or FL htt were detected. 
Endogenous htt has been mostly found in the cytoplasm (Difiglia et al. 1995, Gutekunst et 
al. 1995) but there are several reports of FL and N-terminal htt in the nucleus (Bessert et 
al. 1995, De Rooij et al. 1996 and Sapp et al. 1997) and in a perinuclear location (Sapp et 
al. 1997). Bessert et al. (1995) also described nuclear localisation of WT FL htt in HEK 
293 cells which were the cells used in the N-terminal htt model in this study.  The 
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compartment. FL WT htt has been described in association with the plasma membrane, 
endocytic and autophagic vesicles, endosomal compartments, endoplasmic reticulum, 
Golgi apparatus, mitochondria and microtubules (Atwal et al. 2007, Rockabrand et al. 
2007, Strehlow et al 2007). The widespread distribution of htt does not help in defining 
it’s physiological function but alterations in the subcellular distribution following MT htt 
expression may provide information as to the pathological role of expanded CAGs.
6.9.1. Co-localisation of htt with vesicular markers
The HEK 293 model in the current thesis demonstrated that WT and MT N-terminal htt 
partially co-localised with VAMP and synaptophysin suggesting that htt was associated 
with vesicles. There was no evidence of co-localisation with the Golgi complex or 
lysosomal markers. The association of N-terminal WT and MT htt with synaptophysin is 
in agreement with previous studies (Wood et al. 1996 and Gutekunst et al. 1998) although 
the association of VAMP and htt has not been described. These results suggested that 
VAMP/synaptophysin-associated vesicles may be involved in trafficking of N-terminal 
htt or that N-terminal htt may have a physiological function in vesicle trafficking. The 
presence of intensely staining cells for synaptophysin in some of the pon A-treated MT 
N-terminal htt HEK 293 cells suggested that N-terminal MT htt may cause increased 
expression of synaptophysin, possibly as a compensatory mechanism following failure of 
vesicular function, or MT N-terminal htt may have caused an accumulation of vesicles 
(Figs. 3.17, 3.18, 3.20 and 3.21). There is no previous literature suggesting accumulation 
of synaptophysin in HD. However, there is evidence that expression of MT N-terminal htt 
inhibits movement of vesicles and mitochondria along neuronal projections (Trushina et 
al 2004, McGuire et al 2006, Caviston et al 2007) suggesting that vesicular transport is 
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essential for efficient axonal transport of vesicles containing BDNF (Gauthier et al 2004). 
Therefore, failure of vesicular function may represent one mechanism by which MT htt 
causes neuronal dysfunction and cell death.
6.9.2. Mitochondrial association with huntingtin
There is recent evidence of the association of soluble htt and htt aggregates with 
mitochondria (Panov et al. 2002, Choo et al. 2004, Petrasch-Parwez et al. 2007 and 
Section 1.10.9). MT htt may directly inhibit the mitochondrial respiratory chain although 
there is no data to support this hypothesis. Other pathological roles by MT htt on 
mitochondrial   function   include   impaired   mitochondrial   trafficking   and   distribution 
(Chang et al. 2005, Solans et al. 2006, Orr et al. 2008), altered mitochondrial biogenesis 
(McGill et al 2006 for review), induction of apoptosis (Sawa et al 2003) and impaired 
transient calcium storage (discussed in Section 1.10.).
The association of htt with mitochondria was investigated using subcellular localisation 
studies in the HEK 293 and SH-SY5Y cell models. There was a partial association of 
mitochondria with N-terminal MT and WT htt in the HEK 293 cell model. In some of the 
MT N-terminal htt clones, the association occurred as a perinuclear “aggresome-like” 
inclusion. This suggested that N-terminal htt associated with mitochondria. Panov et al. 
(2002) first demonstrated, by electron microscope, that MT N-terminal htt localised to 
mitochondria in the brain of a HD transgenic model. Subsequently, Choo et al.(2004) 
showed that both WT and MT FL htt were associated with the outer membrane of 
mitochondria isolated from WT and MT mouse striatal cells. The direct association of N-
terminal MT htt with the mitochondria was suggested to affect the respiratory complex 
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on the mitochondrial respiratory chain activities of MT polyQ protein on isolated 
mitochondria, although the poly Qs were not expressed in a htt background (Puranam et 
al 2006). The current HEK 293 cell model would support recent evidence linking the 
association of N-terminal htt with mitochondria although the role of the association is less 
clear and needs further investigation. 
Mitochondria co-localised with the perinuclear EYFP inclusions in the lactacystin-treated 
EYFP WT and MT FL htt clones. The pcDNA3.1. clones also demonstrated a perinuclear 
accumulation of COX1 staining suggesting that the formation of an “aggresome-like” 
perinuclear body was a consequence of proteasomal inhibition, rather than a specific 
accumulation of EYFP htt. However, the association of mitochondria with MT FL htt 
within the aggresome-like inclusions may represent one of the mechanisms that inhibits 
mitochondrial function in HD. It is postulated that MT htt may impair proteasomal 
function and secondarily this leads to the formation of aggresome-like inclusions which 
could   alter   trafficking   and   the   function   of   mitochondria.   Impaired   mitochondrial 
trafficking by MT htt has been described (Trushina et al 2004, Chang et al. 2006). In the 
skeletal muscle of desmin-null mice, failure of locating mitochondria to the correct 
position within the cell impaired mitochondrial function (Milner et al. 2000). Solans et al. 
(2006), in an inducible N-terminal htt cell model, found that misfolded or aggregated htt 
could disturb the network of actin cytoskeleton, which could impair mitochondrial 
distribution and function. Therefore, there is evidence for the association of FL and N-
terminal WT and MT htt as well as htt inclusions with mitochondria but how and if htt 
affects mitochondrial function directly remains to be fully elucidated.
6.9.3. Nuclear and perinuclear localisation of htt
302The nuclear localisation of htt and htt aggregates has been considered to be an important 
step in the pathogenesis of HD (Sections 1.6.1, 1.7.1 and 6.1.3). Nuclear WT htt may 
have a physiological role, but nuclear translocation of MT htt to the nucleus may be an 
important step in causing cell dysfunction/death by aggregate formation or inhibition of 
transcription.
Following the pon A induction of N-terminal htt expression, the nuclear localisation of 
both WT and MT N-terminal htt in the HEK 293 model was observed in all clones. 
Fluorescence microscopy demonstrated nuclear staining as intense fluorescence in the 
centre of the cell (Fig. 3.2). Confocal microscopy confirmed that the nuclei of both WT 
and MT N-terminal htt clones contained several punctate areas of staining with Ab675 
(Fig. 3.16. A and 3.19. A). There was also less intense positive nuclear staining in 
uninduced WT and MT N-terminal htt clones (Fig. 3.16A) in support of the presence of 
physiological nuclear htt in HEK 293 cells.
The first 17 aa of htt, N terminal to the polyglutamine stretch, have been suggested to be 
vital in exporting htt out of the nucleus as a nuclear export signal (NES) (Cornett et al. 
2005, Atwal et al. 2007) The C-terminus may also contain an NES and possibly a nuclear 
localisation signal (NLS) (Xia et al 2003 and Fig. 1.1). The current study would be 
consistent with a NLS in the first 171aa of htt or that truncation of htt to 171aa. was 
associated with the loss of a nuclear export signal (NES) such as that described in the C-
terminal region of htt by Xia et al (2003 and Fig. 1.1.). The inducible cell model by 
Lunkes et al (1998) described nuclear localisation of FL htt with 116 polyQ and not with 
73 or 15 (Table 1.5). This also occurred more quickly with an N-terminal fragment of 
80aa compared to 502aa. Nuclear localisation did not occur with WT htt. This study 
303demonstrated   that   nuclear   htt   immunostaining   increased   with   shorter   N-terminal 
fragments of htt and with longer CAG repeats and suggested that similar factors leading 
to inclusion formation were also associated with translocation of MT htt to the nucleus. 
Most other inducible cell models of HD expressing exon 1 of htt have described nuclear 
and cytoplasmic localisation of htt (Wang et al 1999, Jana et al. 2001, Wyttenbach et al 
2001 and Fukui et al. 2007). The constitutive N-terminal htt models have suggested that 
MT N-terminal htt also localised to the nucleus (Li et al. 1999, Chun et al. 2001, 2002) 
when the N-terminal htt fragment was exon 1 or 63aa (Table 1.5b). This is in contrast to 
Sugars et al. (2004) who expressed FL htt and Sipione et al. (2002) and Seo et al. (2007) 
who expressed 548aa of htt in inducible HD cell models. These authors described 
cytoplasmic htt expression only, in spite of nuclear inclusions forming in the MT cells in 
Sugars et al. (2004). In conjunction with the finding of nuclear N-terminal htt in the HEK 
293 model in the current study, this suggested that between 171aa and 548aa of htt, there 
may be an important nuclear export sequence (NES) that has not been described. This 
region contains a known HEAT repeat sequence and some of the known calpain and 
caspase cleavage sites but not a recognised NES.
In support of the hypothesis that FL htt has to be processed to N-terminal htt fragments in 
order for htt to stay in the nucleus, EYFP FL WT and MT htt SH-SY5Y models did not 
express nuclear fluorescence. This suggested the absence of significant amounts of 
nuclear FL htt which is in agreement with an inducible FL htt cell model (Sugars et al. 
2004). However, htt antibody studies in SH-SY5Y cells (see below) demonstrated 
Ab7667-positive granular staining in the nucleus suggesting that htt up to at least 
aa1844-2131 can physiologically enter the nucleus. 
Nuclear localisation of fluorescence in two of four EYFP WT htt clones investigated, 
following 2 days differentiation, suggested that WT htt was processed in some clones to a 
304fragment which could enter the nucleus or that the nuclear membrane became more 
porous to FL WT htt. Nuclear localisation of FL WT htt has been described by Bessert et 
al. (1995) but not subsequently. Localisation of FL MT htt was not observed in any of the 
four MT EYFP clones following differentiation. The immunocytochemical studies using 
the htt panel of antibodies on the differentiated clones with EYFP nuclear fluorescence, 
demonstrated that the WT htt nuclear staining was positive for all htt antibodies, which 
argued against truncation of the htt product entering the nucleus. It is, however, possible 
that C-terminal cleavage products were also entering the nucleus and being detected, in 
addition to N-terminal htt products. There is no clear explanation for the localisation of 
FL WT MT EYFP htt in two out of four WT clones. A specific effect of the integration of 
the EYFP construct into genomic DNA can not be excluded.
The Abcam (Cambridge, UK) htt antibodies Ab7667 and Ab7668 and to a lesser extent 
Ab7666 demonstrated nuclear punctate staining, which was especially visible in the 
mitotic pcDNA 3.1 clones but also in the mitotic EYFP WT and MT FL htt clones. 
Ab7666, 7667 and 7668 also demonstrated prominent perinuclear accumulations of htt 
which were also more pronounced in pcDNA3.1 than WT or MT htt EYFP clones (Figs. 
4.3. and 4.12-4). This suggested that the Abcam antibodies recognised endogenous htt 
and that endogenous htt localised physiologically to nuclear and perinuclear locations as 
described previously (Bessert et al. 1995, De Rooij et al. 1996, Sapp et al. 1997). The 
relative absence of nuclear staining and strong perinuclear staining in pcDNA 3.1 clones 
developed with Ab7666 suggested that C-terminal region of endogenous htt may be 
processed before htt can enter the nucleus. It also suggested that EYFP may inhibit 
nuclear translocation of htt. The antibodies from Chemicon (EM48, Ab2166 and Ab2168) 
stained endogenous htt poorly in the pcDNA 3.1 clones, including the perinuclear and 
305nuclear   staining   recognised   by   the   Abcam   antibodies.   The   Chemicon   antibodies 
preferentially stained EYFP WT and MT htt (Figs. 4.3 and 4.12-4). 
It remains uncertain why only the Abcam antibodies, and not the Chemicon antibodies, 
should recognise endogenous perinuclear and nuclear htt. The three antibodies used from 
each manufacturer were raised to epitopes across the whole length of htt and therefore 
this effect is unlikely to be due to differences in the site of the antigen. All of the 
antibodies were monoclonal and the same secondary antibody was used throughout all 
experiments. It remains possible that some of the staining with the Abcam antibodies was 
cross-reactivity to non-htt proteins, although this would be unlikely with three unrelated 
antibodies.
In summary, this study demonstrated that N-terminal WT and MT htt can localise to the 
nucleus and that this process is not associated with increased cell death or dysfunction. 
The similar localisation of WT and MT N-terminal htt to the nucleus in the HEK 293 
model suggested that a difference in localisation of N-terminal was unlikely to account 
for the molecular changes described in the MT N-terminal HEK 293 cells. The molecular 
abnormalities in the MT htt EYFP model, such as reduction in complex IV, aconitase and 
proteasomal activities occured in the absence of nuclear translocation of htt which 
suggested that not all MT htt toxicity is mediated by nuclear localisation. The striking 
nuclear staining of all SH-SY5Y cells by two antibodies to internal epitopes (Ab7668 and 
Ab7667) but not to a C-terminal htt antibody (Ab7666) suggested that WT htt probably 
has a physiological role in the nucleus and that it may be cleaved distalt to aa2131 at the 
C-terminus before it enters the nucleus.
6.10. Differentiation and the role of post-mitotic cells in HD
306The   cells   predominantly   affected   in   HD   are   post-mitotic   neurons   (Section   1.4.). 
Eventhough other groups of post-mitotic neurons are relatively spared, such as in the 
cerebellum, there is no evidence that mitotic cells are severely affected in HD which 
suggests that a post-mitotic state is one of the factors important in mediating MT htt 
toxicity. In order to recapitulate the features of post-mitotic neurons, SH-SY5Y cells were 
used to express FL htt in the EYFP model and retinoic acid was used to differentiate the 
SH-SY5Y cells Preis et al. (1998). This enabled the investigation of potential changes in 
subcellular localisation (Section 6.9.3), cellular morphology, possible inclusion formation 
and processing of htt following differentiation. 
Morphology of SH-SY5Y cells following differentiation
Following differentiation for between 2 and 14 days, the SH-SY5Y MT FL htt model 
demonstrated decreased neuritic process formation, less complex neurite patterns of 
development and qualitatively reduced cell numbers compared to WT FL htt cells (Fig. 
4.9-11). MT htt may alter the function of VAMP and other proteins involved in axonal 
transport and neurite formation, such as Hap-1 (Rong, J et al. 2006). It has been shown 
that   htt   interacts   directly,   as   well   as   via   its   binding   partner   Hap-1,   with   the 
dynein/dynactin microtubule-based motor complex responsible for retrograde cellular 
trafficking. Hap-1 may also bind another molecular motor, kinesin, and thus could play a 
role (independently or as part of a complex with htt) in anterograde axonal transport 
(Gauthier et al. 2004 and Caviston et al 2007). This may explain the impaired 
differentiation observed in the EYFP MT htt compared to EYFP WT htt clones as early as 
2 days following treatment with retinoic acid. Decreased neurite formation following 
differentiation and MT htt expression was also observed in the cell models described by 
307Wyttenbach et al (2001) and Ye et al (2008) (Table 1.5). In the cell model described by 
Ye et al (2008), both transiently and stably transfected MT cells developed shorter neurite 
formation following differentiation with 10µM retinoic acid for 48 hours or serum 
deprivation for 24 hours. In summary, MT htt may inhibit neurite formation during 
differentiation of neurons by affecting axonal transport and vesicle trafficking (Yang et al 
2002 and Section 6.9.1.).
Inclusion formation
There was no evidence of inclusion formation on fluorescence microscopy up to two 
weeks post-differentiation in any of the four WT and MT htt EYFP clones or up to four 
weeks in one representative WT and MT clone on fluorescence microscopy and Western 
blotting. A constitutively expressing FL MT htt neuronal cell model has not been 
described previously. However, Ye et al. (2008) published a differentiated N2a transiently 
and  stably  constitutively  expressing  N-terminal htt  cell  model (Table 1.5)  which 
demonstrated predominantly cytoplasmic inclusions in the MT (exon1-150Q) cells 
transiently transfected but not the stably transfected cells. This would be in agreement 
with the EYFP MT htt model and suggested that stable constitutive expression of MT htt 
could have prevented htt inclusion formation. It is speculated that transfected cells which 
formed inclusions may be die during constitutive expression and a population of htt 
expressing cells remained that would not form inclusions.
Several differentiated and inducible neuronal cell models of HD have demonstrated htt 
inclusion formation (Table 1.5). Lunkes et al. (1998) differentiated NG105-15 cells with 
1%   FCS   (from   10%   in   mitotic   cells),   10   mM   forskolin   and   100   mM   IBMX 
(isobutylmethylxanthine) which expressed 80aa, 502aa and FL htt with 73 or 116polyQ. 
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htt with 60 or 150 polyQ with 5mM dcAMP (N6,29-O-dibutyryladenosine-39:59-cyclic 
monophosphate sodium salt). All of these models were associated with htt inclusions in 
differentiated MT cells but the authors did not comment on inclusions in the mitotic cells. 
The   only   inducible   cell   model   to   compare   mitotic   with   differentiated   cells   was 
Wyttenbach et al (2001) using a PC12 cell model. The cells were differentiated for 6 days 
with 1% horse serum and nerve growth factor (NGF) and the authors described increased 
cell death and more htt inclusions following differentiation of MT cells compared to 
mitotic MT cells. It therefore appears that differentiated cells more readily form htt 
inclusions than mitotic cells and that constitutive expression of MT htt prevents survival 
of cells with inclusions or prevents inclusion formation. The mechanism by which 
differentiation promotes htt inclusion formation is not clear but may explain the 
propensity for greater pathological changes to occur in post-mitotic cells in HD brain and 
HD transgenic mice (Becher et al 1998, Davies et al 1997, Sathasivam et al. 1999, Orth et 
al. 2003, Ciammola et al 2006). It is postulated that post-mitotic cells either have reduced 
capacity to remove abnormal or misfolded MT htt, or that processing of MT htt occurs 
more readily to a pathological N-terminal fragment.
Huntingtin processing
Following 4 weeks differentiation, a Western blot of WT htt EYFP clone 23 1 1 
demonstrated a discrete additional band which migrated at approximately 90kDa. This 
was not present in a MT clone (88 1 3) or a pcDNA3.1 clone (Fig. 4.16). This additional 
band would be predicted to be an N-terminal htt fragment of 590 aa. The presence of this 
N-terminal   htt   truncated   cleavage   product   could   have   caused   the  EYFP   nuclear 
fluorescence observed in clone 23 1 1 following differentiation. The putative caspase 6 
309cleavage site is at aa.586 in htt. Caspase 6 cleavage of htt has been found to be necessary 
for neuronal dysfunction and degeneration in an HD mouse model (Graham et al. 2006). 
The absence of a 590aa N-terminal fragment in the MT clone investigated may have been 
due to toxicity of the 590aa N-terminal fragment when it contained MT CAG repeats. 
Alternatively, the failure of the cleavage of the MT htt EYFP clone 88 1 3 to form a 590 
aa fragment may have represented an isolated feature of the clone and further studies 
would assess Western blots of other WT and MT clones.
6.11. Conclusions
6.11.1. Investigating the molecular pathogenesis of HD
The HEK 293 cell model used an inducible system which allowed the analysis of the 
earliest molecular events in response to WT and MT N-terminal htt with undetectable 
background expression of the constructs. The SH-SY5Y model used a constitutive system 
which enabled the investigation of the effects of the FL WT and MT htt expression on a 
neuronal background and the processing of FL htt. Both the HEK 293 and SH-SY5Y cell 
models expressed htt with relatively small pathological CAG expansions in the MT 
clones which was more representative of HD patients. The assessment of the effects of the 
differences between the cell models, such as cell background, size of the htt fragment and 
constitutive compared to inducible expression, enabled comparison of data generated in 
the two cell models, such as mitochondrial and aconitase function. There were drawbacks 
to the cell models. The relatively small sizes of the CAGs may have limited the pathology 
associated with MT htt expression. The inducing agent ponA may have inhibited cell 
division and DMSO caused clumping of the HEK 293 cells. In the SH-SY5Y model, the 
310N-terminal EYFP tag may have inhibited htt from entering the nucleus and prevented 
spontaneous inclusion formation. 
In comparison to the cell models, the biochemical analysis of 12 muscle biopsies from 
HD patients and the assessment of the UHDRS in these patients enabled the correlation of 
clinical parameters and CAG repeats with mitochondrial function in a tissue that was 
relatively easier to study compared to brain. 
6.11.2. FL MT htt cleavage at the polyglutamine/polyproline junction 
The cleavage of FL htt to an N-terminal fragment has been identified in HD brains and 
variably in HD mouse and cell models. The generation of an N-terminal htt fragment may 
have an important role in the pathogenesis of HD although the exact size of the N-
terminal htt fragment, the mechanism of truncation of FL htt and the molecular role of N-
terminal htt remain uncertain. Using the SH-SY5Y model, there was no evidence of WT 
or MT FL htt cleavage under normal growth conditions. A novel N-terminal MT htt 
fragment of approximately 11kDa was described in the majority of EYFP FL MT htt 
expressing clones following treatment with lactacystin. This suggested that the formation 
of the novel MT N-terminal fragment was not a result of processing by chymotrypsin and 
trypsin-like activities of the proteasome which were inhibited by lactacystin. It is unclear 
if the cleaved protein accumulated because it was normally degraded by the proteosome, 
or if lactacystein induced other protease activities which cleaved htt. The absence of the 
11kDa band in the WT clones was consistent with a difference in the processing of WT 
and MT FL htt. The 11kDa fragment was predicted to terminate at the junction between 
the polyglutamines and the first polyproline region. The consensus sequence does not 
311predict a known proteolytic site at this junction and suggested a novel mechanism for 
altered processing of MT htt into a potentially toxic N-terminal fragment. 
In order to assess whether the 11kDa fragment caused cellular dysfunction, future work 
would compare cell death, htt inclusion formation, excess free radicals and mitochondrial 
dysfunction in the MT clones producing the 11kDa fragment with MT and WT clones not 
producing the 11kDa fragment following treatment with lactacystin. Protease inhibitors 
could be used to assess which proteases cleaved MT FL htt to the 11kDa fragment and 
further analysis of the 11kDa band using mass spectroscopy may identify the size of the 
fragment and enable its expression in a cell culture system.
The formation of htt inclusions in lactacystin-treated EYFP FL WT and MT clones 
demonstrated that the breakdown of FL WT and MT htt was dependent on the lactacystin-
sensitive components of the proteasome. The inclusions were also found to contain FL htt 
as evidenced by detection of epitopes across the whole length of htt. Therefore an initial 
important step in the processing of FL htt may be proteasomal cleavage. Htt may be 
cleaved by other proteases as evidenced by the formation of the 11kDa fragment in the 
majority of the MT clones. This suggested a possible mechanism of MT htt toxicity in 
which MT htt impaired proteasome function causing accumulation of FL MT htt. FL MT 
htt subsequently could be cleaved by non-proteasomal proteases which may form toxic N-
terminal products. In support of this was the finding of reduced trypsin-like activity in the 
MT EYFP FL htt clones. The further analysis of proteasomal components for evidence of 
free radical damage, abnormal assembly and co-localisation with MT FL htt would be 
important in the assessment of the mechanism of MT htt inhibition of the proteasome.
6.11.3. The physiological and pathological location of htt
312Using the SH-SY5Y model, endogenous FL htt was found in a predominantly granular 
cytoplasmic location but there were also accumulations of endogenous htt in a perinuclear 
and nuclear distribution, and was in agreement with previous data. A novel finding was 
the reduced nuclear staining with the more C-terminal antibody Ab7666 in comparison to 
the more N-terminal antibodies Ab7667 and Ab 7668 which suggested physiological 
cleavage of FL endogenous htt prior to translocation to the nucleus. These findings also 
supported   previous   evidence   that  endogenous   htt  may   have  a  role  in   regulating 
transcription and be involved in nucleo-cytoplasmic trafficking. This location was not 
affected by WT or MT FL htt expression in the SH-SY5Y model.
The perinuclear inclusions formed in the WT and MT FL htt EYFP clones following 
treatment with lactacystin were “aggresome-like” and formed in a similar location to the 
perinuclear accumulation of endogenous htt. Aggresomes form around the microtubule 
organising centre (MTOC) which suggested that endogenous htt may have a role in 
MTOC/centrosomal function including vesicular transport. MT N-terminal htt expression 
in the HEK 293 cell model was associated with increased synaptophysin staining which 
suggested that MT N-terminal htt may affect vesicular trafficking. Further work would 
investigate the distribution of other proteins involved in vesicular transport, such as 
dynein, to assess if there was a more generalised disruption of vesicle trafficking in 
response to MT htt. N-terminal MT and WT htt expression was mostly cytoplasmic but 
also nuclear. This suggested that expanded CAGs do not cause preferential nuclear 
translocation in comparison to WT CAG repeats. However, physiological processing of 
WT htt to an N-terminal fragment may not occur in vivo but is well established in MT htt. 
Therefore preferential processing of FL MT htt, in vivo, to an N-terminal htt fragment 
313which translocates to the nucleus can not be ruled out as a potential mechanism of MT htt 
toxicity.
6.11.4. The determinants of mitochondrial dysfunction in HD
There was no evidence of a reduction in MRC activities following N-terminal htt 
expression in the HEK 293 cell model in comparison to several published cell models. 
Comparison of published cell models with the HEK 293 model suggested that MT N-
terminal htt may cause a reduction in complex II/III activity with greater than 72 CAG 
repeats and that the size of the N-terminal fragment is less important. The finding of 
reduced complex IV activity in the SH-SY5Y model and not in the HEK 293 model 
initially suggested that FL htt was required to inhibit complex IV. This would be 
consistent with the data from HD post-mortem brain but is in contrast to the reduction in 
complex IV in the R6/2 mouse. It was therefore postulated that complex IV inhibition 
occurred following prolonged expression of MT htt, as has been found in the SH-SY5Y 
model, HD brain and R6/2 mouse and not by the size of the htt fragment. It is possible 
that cleavage of MT FL htt to a toxic MT N-terminal htt fragment causes complex II/III 
dysfunction possibly in association with cytoplasmic htt inclusions. This would provide 
an explanation for prominent complex II/III defects in HD post-mortem brain and N-
terminal cell models but not in the R6/2 mouse and the SH-SH5Y model where 
cytoplasmic htt inclusions are less common or do not occur.
MRC dysfunction may be caused by a direct effect of htt on the MRC, altered 
mitochondrial biogenesis by MT htt-induced transcriptional dysregulation or due to 
disrupted mitochondrial trafficking by htt inclusions or transcriptional dysregulation. The 
temporal relation of mitochondrial dysfunction and excess free radical formation in HD 
314remains unanswered. Future work would include treatment of the EYFP clones with anti-
oxidants to determine if this protected the MT clones from complex IV dysfunction.
6.11.5. Cellular Dysfunction in the absence of htt inclusion formation 
The EYFP model is the first stably-transfected constitutively expressing FL htt cell model 
to be characterised. MT FL htt expression was associated with mitochondrial dysfunction, 
free  radical   production   and   proteasomal   dysfunction   in   the  absence  of   inclusion 
formation. The N-terminal htt HEK 293 cell model demonstrated increased sensitivity to 
lactacystin, malonate and paraquat in association with MT N-terminal htt expression also 
in the absence of inclusion formation or cell death. Htt inclusions may independently be 
toxic however data from the current thesis suggested that early molecular defects in 
response to MT htt can occur prior to inclusion formation. It remains possible that if 
inclusion formation had occurred, the toxic effects of MT htt expression may have been 
greater. This study does not definitively answer the question of the role of htt aggregates 
in the pathogenesis of HD. However, htt inclusions are not a prominent early pathological 
feature in presymptomatic HD brain and the EYFP FL htt model would mimic these 
conditions more closely than most HD cell models and transgenic mice. The finding of 
molecular abnormalities described above would favour significant MT htt-induced 
cellular dysfunction prior to inclusion formation.
6.11.6. A molecular cascade leading to cell death and dysfunction in HD
A hypothesis is postulated using data from the current thesis and previous studies for the 
sequence of molecular events leading to cell dysfunction and death in HD. This 
hypothesis suggests that an early event in the pathogenesis of HD is inhibition of complex 
315IV and/or increased free radical production which leads to a chronic reduction in ATP 
causing a reduction in proteasome activity, inhibition of vesicular transport, impairment 
of transcriptional activity and excitotoxicity. Abnormal processing and accumulation of 
MT htt, possibly in association with impaired proteasomal function, would cause the 
formation of toxic N-terminal MT htt fragments. The N-terminal fragments and increased 
free radicals may cause inhibition of complex II/III, leading to further reductions in ATP 
levels. N-terminal htt aggregation may occur as a later event and cause cellular toxicity by 
sequestration   of   key   cellular   proteins,   proteasomal   dysfunction   and   inhibition   of 
intracellular transport mechanisms. The relative roles of FL MT htt compared to N-
terminal MT htt in causing toxicity has not been substantiated. HD transgenic mice 
expressing MT N-terminal htt have a phenotype similar to HD which has been suggested 
to imply that N-terminal htt may be more important for cellular toxicity than FL MT htt. 
However, the phenotype of these transgenic models differ from human HD and a 
neurological  phenotype  similar  to  HD has been  demonstrated in  transgenic mice 
expressing expanded CAGs in the hprt gene (Ordway et al 1997). It is postulated that 
eventhough MT N-terminal htt may form aggregates and be independently neurotoxic, it 
may not represent the initial toxic species in vivo. Fig. 6.1. summarises the molecular 
mechanisms in the pathogenesis of HD related to the findings in the current thesis. In the 
16 years since the discovery of the HD gene, major advances have been made in our 
understanding of the neurobiology of HD. In spite of this, HD remains an incurable 
disease with a grave prognosis. Symptomatic and supportive treatments remain the 
mainstay of current management of HD. A greater understanding of the molecular 
pathogenesis of HD will enable the development of better rational therapeutic strategies 
in the future.
Fig. 6.1.
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390Appendix
1.1. The standard PCR reaction conditions using G49 and G50:
“Denaturation”  94
0C  4min 1cycle
“Denaturation”  94
0C  1min
“Primer annealing”  54
0C  1min       25 cycles
“Primer extension”  72
0C  1min  
“Extension”  72
0C  10 min 1 cycle   
1.2. Sequencing the 5’ junction 
The standard conditions for sequencing the 5’ junction between the EYFP sequence and 
the 5’ end of full-length huntingtin sequence in SHSY5Y cells, using the EYFPfor and 
RS2:
“Denaturation”  94
0C  2min 1cycle
“Denaturation”  94
0C  30 secs
“Primer annealing”  64
0C  45 secs      35 cycles
“Primer extension”  72
0C  60 secs 
“Extension”  72
0C  10 min 1 cycle   
1.3. Sequencing the 3’ junction 
391The standard conditions for sequencing the 3’ junction between EYFP-C1 plasmid and 
the 3’ end of full-length huntingtin sequence in SHSY5Y cells, using the R2 and F3:
“Denaturation”  94
0C  2min 1cycle
“Denaturation”  94
0C  30 secs
“Primer annealing”  58
0C  45 secs      35 cycles
“Primer extension”  72
0C  60 secs 
“Extension”  72
0C  10 min 1 cycle   
1.4. Buffers
TE
For one litre
10mM Tris. Cl (pH8.0)(1.2114g)
1mM EDTA (pH8.0) (2mls from the 0.5M stock)
Make up to 1 litre.
0.5M EDTA (pH8.0)
186.1gdisodium ehtylenediaminetetra-acetate.2H2O
Make up to 800ml with H2O
Adjust pH with NaOH (approx. 20g of pellets)
Make up to 1 litre.
50XTAE
For one litre
242g Tris Base
39257.1ml Glacial Acetic Acid
100ml 0.5M EDTA pH8.0
Homogenisation buffer (pH 7.4) made up as below;
Reagent 500ml
ddH20 made up to 500ml
10mM Tris (MW 121.1) 0.606g
1mM K2EDTA (MW 404.5) 0.202g
0.25M Sucrose (MW342.3) 42.79g
Dissociation Buffer for Western blotting 
1) 0.1% SDS
2) 62.5 mM Tris HCl pH6.9
3) Protease inhibitors (pepstatin A 1mg/ml, leupeptin 1mg/ml, aprotinin1 
mg/ml, PMSF 2µg/ml)
4x NuPAGE Sample buffer (pH 8.5)
Glycerol (40%) 4g
Tris Base (564mM) 0.682g
Tris HCl (424mM) 0.666g
LDS (8%) 0.8g
EDTA (2.04mM) 0.006g
Serva Blue G250 (0.88mM) 0.0075g
Phenol Red (0.7mM) 0.0025g
Made up to 10ml with ddH20
NuPAGE Running Buffer x20 500ml (TRIS-Acetate SDS) pH 8.25
Tricine (1M) 89.5g
Tris Base (1M)60.5g
393SDS (2%) 10g
Made up to 500ml with ddH20
NuPAGE Running Buffer (MOPS pH 7.7/MES pH7.3)
MOPS (1M)  104.6g
or MES (1M)  97.6g 
Tris Base (1M)60.6g
SDS (69.3mM) 10g
EDTA (20.5mM) 3g
Made up to 500ml with ddH20
1.5. HEK 293 clone sequencing: Standard Curve
Standard curve for known DNA markers and distance from well.
Base pairs ln base pair
Distance from 
well (mm)
250 5.52 102
500 6.21 88
750 6.62 76
1000 6.91 68
1500 7.31 55
2000 7.60 48
2500 7.82 42
3000 8.00 38
4000 8.29 33
5000 8.52 29
394Normal curve for DNA ladder relating ln (base pair) versus distance from well
1.6. Unified Huntington’s Disease Rating Scale (UHDRS)
1) MOTOR ASSESSMENT
OCULAR PURSUIT (horizontal and vertical)
0=complete (normal) 1=jerky movement 2=interrupted pursuits/full range 3=incomplete range 4=cannot pursue
SACCADE INITIATION (horizontal and vertical)
0=normal 1=increased latency only 2=suppressible blinks or head movements 3=insuppressible head 
movements 4=cannot initiate saccades
SACCADE VELOCITY (horizontal and vertical)
0=normal 1=mild slowing 2=moderate slowing 3=severely slow, full range 4=incomplete range
DYSARTHRIA
0=normal
1=unclear, no need to repeat 2=must repeat to be understood 3=mostly incomprehensible 4=mute
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 TONGUE PROTRUSION
0=can hold tongue fully protruded for 10 seconds 1=cannot keep fully protruded for 10 seconds 2=cannot keep 
fully protruded for 5 seconds 3=cannot fully protrude tongue 4=cannot protrude tongue beyond lips
MAXIMAL DYSTONIA (trunk and extremities)
0=absent
1=slight/intermittent 2=mild/common or moderate/intermittent 3=moderate/common 4=marked/prolonged
MAXIMAL CHOREA (face, mouth, trunk and extremities)
0=absent
1=slight/intermittent 2=mild/common or moderate/intermittent 3=moderate/common 4=marked/prolonged
RETROPULSION PULL TEST
0=normal 1=recovers spontaneously 2=would fall if not caught 3=tends to fall spontaneously 4=cannot stand
FINGER TAPS (right and left)
0=Normal
1=Mild slowing and or reduction in amplitude 2=Moderately impaired. Definite and early amplitude fatiguing 
May have occasional arrests in movement 3=Severely impaired. Frequent hesitation in initiating movements or 
arrests in ongoing movements 4=Can barely perform the task.
PRONATE/SUPINATE-HANDS (right and left)
0=normal
1=mild slowing and/or irregular 2=moderate slowing and irregular 3=severe slowing and irregular 4=cannot 
perform
LURIA (fist-hand-palm test)
0=3 4 in 10 seconds, no cue 1=<4 in 10 seconds, no cue 2=2 4 in 10 seconds, with cues 3=<4 in 10 seconds with 
cues 4=cannot perform
RIGIDITY -ARMS (right and left)
0=absent 1 = slight or present only with activation 2=mild to moderate 3=severe, full range of motion 4=severe 
with limited range
396BRADY KINESIA-BODY
0=normal
1=minimally slow 2=mildly but clearly slow 3=moderately slow, some hesitation 4=markedly slow, long delays 
in initiation
GAIT
0=normal gait, narrow base 1=wide base and/or slow 2=wide base and walks with difficulty 3=walks only with 
assistance 4=cannot attempt
TANDEM WALKING
0=normal for 10 steps 1=1 to 3 deviations from straight line 2=>3 deviations 3=cannot complete 4=cannot 
attempt
2) COGNITIVE ASSESSMENT
VERBAL FLUENCY TEST (raw score)
SYMBOL DIGIT MODALITIES TEST (raw score)
STROOP INTERFERENCE TEST Color Naming (number correct) Word Reading (number correct) 
Interference (number correct)
3) BEHAVIORAL ASSESSMENT
Rate the severity and frequency of the following using the scale below:
Severity 0=absent 1=slight, questionable 2=mild 3=moderate 4=severe
Frequency 0=almost never 1=seldom 2=sometimes 3=frequently 4=almost always
Sad/Mood: feeling sad, sad voice/expression, tearfulness, inability to enjoy anything.
Low Self-Esteem/Guilt: self blame, self deprecation including feelings of being a bad or unworthy person, 
feelings of failure.
Anxiety: worries, anticipation of the worst, fearful anticipation.
Suicidal Thoughts: feels life not worth living, has suicidal thoughts, active suicidal intent, preparation for the 
act. behavior, physical violence, verbal outbursts, threatening, foul, or abusive language.
397Disruptive or Aggressive Behavior: threatening behavior, physical violence, verbal outbursts,
threatening, foul, or abusive language.
Irritable Behavior: impatient, demanding, inflexible, driven and impulsive, uncooperative.
Obsessions: recurrent and persistent ideas, thoughts or images
Compulsions: repetitive, purposeful, and intentional behaviors.
Delusions: Fixed false beliefs, not culturally shared
Hallucinations: a perception without physical stimulus:
Auditory, Visual. Tactile, Gustatory and Olfactory
Does the investigator believe the subject is confused? Yes or No
Does the investigator believe the subject is demented? Yes or No
Does the investigator believe the subject is depressed? Yes or No
Does the subject require pharmacotherapy for depression? Yes or No
4) FUNCTIONAL ASSESSMENT Yes or No
Could subject engage in gainful employment in his/her accustomed work?
Could subject engage in any kind of gainful employment?
Could subject engage in any kind of volunteer or non-gainful work?
Could subject manage his/her finances (monthly) without help?
Could subject shop for groceries without help?
Could subject handle money as a purchaser in a simple cash transaction?
Could subject supervise children without help?
Could subject operate an automobile safely and independently?
Could subject do his/her own housework without help?
Could subject do his/her own laundry (wash/dry) without help?
Could subject prepare his/her own meals without help?
Could subject use the telephone without help?
Could subject take his/her own medications without help?
Could subject feed himself/herself without help?
Could subject dress himself/herself without help?
Could subject bathe himself/herself without help?
Could subject use public transportation to get places without help?
Could subject walk to places in his/her neighborhood without help?
Could subject walk without falling?
398Could subject walk without help?
Could subject comb hair without help?
Could subject transfer between chairs without help?
Could subject get in and out of bed without help?
Could subject use toilet/commode without help?
Could subject’s care still be provided at home?
5) INDEPENDENCE SCALE
Please indicate the most accurate current level of subject’s independence (only 0 or 5 selections are acceptable)
100: No special care needed
090: No physical care needed if difficult tasks are avoided
080: Pre-disease level of employment changes or ends; cannot perform household chores to pre-disease level, 
may need help with finances
070: Self-care maintained for bathing, limited household duties (cooking and use of knives), driving 
terminates; unable to manage finances
060: Needs minor assistance in dressing, toileting, bathing; food must be cut for patient
050: 24-hour supervision appropriate; assistance required for bathing; eating, toileting
040: Chronic care facility needed; limited self feeding, liquefied diet
030: Patient provides minimal assistance in own feeding, bathing, toileting
020: No speech, must be fed
010: Tube fed, total bed care
6) FUNCTIONAL CAPACITY
OCCUPATION
0=unable 1=marginal work only 2=reduced capacity for usual job 3=normal
FINANCES
0=unable 1=major assistance 2=slight assistance 3=normal
DOMESTIC CHORES
0=unable 1=impaired 2=normal
ADL
0=total care 1=gross tasks only 2=minimal impairment 3=normal
CARE LEVEL
0=full time skilled nursing 1=home or chronic care 2=home
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